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Abstract 
Progressive retinal atrophy (PRA) in dogs is characterised by the degeneration of the 
photoreceptor cells of the retina, resulting in vision loss and eventually complete 
blindness.  The condition affects more than 100 breeds, and is known to be genetically 
heterogeneous between breeds.  Fourteen genes have been identified that are associated 
with PRA in at least 45 breeds, but for the majority of breeds the mutation(s) 
responsible have yet to be identified.  This project utilised a genome-wide association 
mapping approach followed by sequencing of candidate genes or associated loci to 
characterise the molecular basis of PRA in three breeds: Golden Retrievers (GR), 
Gordon Setters (GoS) and Tibetan Spaniels (TS). Homozygous recessive mutations in 
four genes were identified as disease causing: SLC4A3c.2601_2602insC and TTC8c.669delA in 
GRs (PRA-1 and PRA-2 respectively), C2ORF71c.3149_3150insC in GoSs (RCD4) and 
FAM161Ac.1758-15_1758-16ins238 in TSs (PRA-3). SLC4A3 is a novel retinal atrophy gene. 
Canine isoforms of each of the genes identified were confirmed by sequencing retinal 
messenger RNA.  DNA genotyping tests for each of the mutations were used to 
determine disease allele frequencies in the affected breeds.  PRA-1 and PRA-2 were 
found to be mainly restricted to the GR breed, with allele frequencies of 0.04 and 0.01 
respectively.  RCD4 and PRA-3, with allele frequencies of 0.36 and 0.15 respectively, 
were also identified as the cause of PRA in at least one other breed.  While none of the 
SLC4A3 variants identified in DNA from 200 human patients with autosomal recessive 
retinal degeneration were considered to be disease-causing mutations, the gene remains 
a plausible candidate for rare forms of retinal degeneration in humans.  This research 
has identified four new potential models for human retinal degeneration and has resulted 
in the development of diagnostic DNA tests for each of the canine diseases, which will 
facilitate the elimination of PRA from affected breeds. 
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Chapter 1  Introduction 
1.1 The Eye 
The eye is an organ, in most animals, which responds to light and thereby provides 
arguably the most important of the five human senses, vision. The human eye is made 
up of many different parts that are all required for optimal vision. The canine eye is very 
similar to the human eye in size, shape and anatomical features (Figure 1), with four 
main differences (discussed in more detail in section 1.2.5): 
1) Dogs and other animals have layers of additional cells directly behind the retina, 
termed the tapetum lucidum (tapetal fundus) or tapetum nigrum (non-tapetal 
fundus). The former is a semi-circular, reflective area in the upper posterior part of 
the eye, while the latter is dark brown and occupies the rest of the fundus
1
.  
2) Human eyes have a tiny, cone-rich area in the centre of the retina, termed the fovea, 
which forms the sharpest image. This is surrounded by a photoreceptor-dense area 
called the macula. Dogs do not have a fovea or macula, although they do have a 
functionally similar visual streak or area centralis. 
3) Humans have three different types of cone photoreceptor cells enabling 
trichromatic vision. Dogs only have two and therefore have dichromatic vision. 
4) Many animals have a third eyelid, known as a nictitating membrane. Humans only 
have what is thought to be a tiny remnant of a third eyelid in the inside corner of the 
eye.  
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Figure 1. Cross section of the canine eye. 
The canine eye and human eye are very similar in size, shape and anatomical features, 
but a few structures are unique to the canine eye: the 3
rd
 eyelid, the gland of the 3
rd
 
eyelid (not shown), the tapetum lucidum and the tapetum nigrum (labelled in red). 
Image has been modified from www.biographixmedia.com 
1.2 The Retina 
The retina is the innermost layer of the eye, the main function of which is to convert 
captured light into neural signals to be transmitted to the brain for interpretation as 
vision. The retina is a complex, highly organised tissue that is composed of two main 
layers: the outer retinal pigment epithelium (RPE) and the inner neurosensory retina 
(Figure 2).  
1.2.1 Retinal Pigment Epithelium 
The RPE is a single layer of epithelial cells that separates the photoreceptor outer 
segments from the choroid. Microvilli of the RPE surround approximately one third of 
the photoreceptor cell outer segments and the RPE thereby maintains and supports the 
functions of the photoreceptor cells. Pigment granules containing melanin are found in 
the cytoplasm of the RPE. Their function is to prevent scattered light or light coming 
through the sclera from reaching the photoreceptors by absorbing it. In addition these 
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pigments protect the retina by scavenging free radicals. The main functions of the RPE 
are the formation of a barrier between the retina and blood circulation of the choroid, 
the transportation between the retina and choroid of ions, metabolites and water and 
phagocytosis of outer segments shed by photoreceptor cells. The RPE also participates 
in the retinoid cycle. 
1.2.2 The Neurosensory Retina 
The neurosensory retina is organised into two main layers: The outer nuclear layer 
(ONL), containing photoreceptor cells, makes up the sensory retina and is the site of 
phototransduction; the ganglion cell layer (GCL) and inner nuclear layer (INL), 
containing the remaining cell types, make up the neural retina in which the visual 
processing steps take place (Figure 2). The neurosensory retina is made up of six major 
classes of neuronal cells: rod and cone photoreceptor, bipolar, horizontal, ganglion and 
amacrine cells. These cells are responsible for the complex processing of signals from 
the photoreceptor cells to the optic nerve, which is formed by the axons of the ganglion 
cells. A number of non-neuronal, or glial, cells are also present: Müller cells, astrocytes 
and microglia. Müller cells are the predominant glia whose cell bodies occupy the INL 
and processes span all three layers. They are responsible for maintaining the structure 
and function of the retina. 
 
Figure 2. Cross section of the canine retina. 
The direction from which light enters the retina is indicated by the yellow arrow.  RPE – 
Retinal pigment epithelium; ONL – Outer nuclear layer; INL – Inner nuclear layer; 
GCL – Ganglion cell layer. Image has been modified from Smith et al.2. 
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1.2.2.1 Photoreceptors 
In humans there are approximately 120 million rod photoreceptor cells that are 
responsible for scotopic (low light) vision and 6 million cone photoreceptor cells that 
are responsible for photopic (bright light) vision
3
. Photoreceptor cells are most densely 
packed in the foveal region of humans and the visual streak or area centralis of dogs, 
and this is therefore where the ONL is thickest. In contrast, photoreceptor cells are 
absent from the optic nerve, resulting in a blind spot.  
The photoreceptor cells consist of four main parts: an outer segment (OS), an inner 
segment (IS), a cell body and a synaptic terminal (Figure 3). The OS is made up of disks 
formed through folding of the photoreceptor cell membrane and that contain the 
photopigments, which are responsible for photon absorption. The rods have a long, 
cylindrical OS made up of discrete discs that are unattached to the plasma membrane. 
The cones have an OS made up of a short series of invaginations that are continuously 
connected to the membrane and that tapers distally. Photoreceptor outer segments are 
damaged by the light they absorb, they continuously shed their tips for phagocytosis by 
the RPE and new discs are formed at the base of the OS. The inner and outer segments 
are connected through the connecting cilium (CC). 
The IS contains the basal body from which the CC originates, and other cellular 
organelles including mitochondria, endoplasmic reticulum, ribosomes and the Golgi 
apparatus. Components such as replacement proteins that are required for the renewal of 
outer segments are synthesized in the inner segments and transported through the 
cilium. In addition the energy required for phototransduction is provided by inner 
segment mitochondria. The cell body contains the photoreceptor nucleus and the 
synaptic terminal is made up of synaptic vesicles that store the chemical transmitters 
required for neural communication (Figure 3). 
The photopigments of the photoreceptors are made up of an opsin protein that is 
covalently bound to a light-absorbing chromophore, 11-cis-retinal. The opsin varies 
between different cell types and makes them functionally distinguishable. Rods have 
only a single type of photopigment known as rhodopsin. In cones the opsin component 
varies and each opsin is sensitive to specific ranges of the light spectrum. In humans 
there are three cone types, each of which contains an opsin that absorbs light at a 
specific wavelength (Table 1).   
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Figure 3. Photoreceptor cells 
Schematic of the rod and cone photoreceptor cells. Image has been modified from 
Wright et al.
4
.  
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Table 1. Photopigments in humans 
1.2.2.2 Connecting Cilium 
Cilia are evolutionary conserved organelles that are essential for the development and 
maintenance of many cell types, tissues and organs. They are composed of a 
microtubule axoneme that stems from a basal body (Figure 4). The basal body is 
composed of nine microtubule triplets and the axoneme of nine microtubule doublets 
arranged in a circle. Based on their structure and ability to move cilia can be classified 
as two main types: motile cilia or non-motile/primary cilia. In general, motile cilia have 
a “9 + 2” configuration, with an additional pair of microtubules at the centre of the 
axoneme, while primary cilia lack the central microtubule pair and have a “9 + 0” 
configuration. The photoreceptor cell OS of the retina are essentially highly specialised 
primary cilia, other cell types and tissues with primary cilia include the kidneys, thyroid 
gland, liver, pancreas and endothelial cells. 
In photoreceptor cells the axoneme forms the structural backbone of the OS and this 
together with the CC and basal body make up a highly specialised sensory cilium. The 
structural and functional components of the cilia, including proteins required for 
phototransduction, are synthesized in the IS cytoplasm, but are concentrated in the OS. 
The CC is effectively a bottleneck and regulatory site, as all movement of molecules 
between the IS and OS must proceed through this structurally complex and narrow 
space. The CC mediates the bidirectional transport between the IS and OS by means of 
intraflagellar transport (IFT). IFT is a specialised system responsible for the movement 
of cargo (IFT particles) into (anterograde transport) or out of (retrograde transport) the 
cilium using the molecular motors Kinesin-II and Dynein respectively (Figure 4). 
However, given the high metabolic rate of the photoreceptor cells, the number of 
molecules moving into the OS in light conditions would be extraordinary and probably 
saturate the motor-driven mechanism of IFT. It is therefore likely that movement 
between segments is accomplished by additional means, including simple diffusion of 
Photoreceptor type Wavelength λmax Light colour 
S-cones Short 420nm Blue 
M-cones Medium 535nm Green 
L-cones Long 560nm Red 
Rods  498nm  
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soluble proteins and other facilitated mechanisms. For example, it is thought that 
rhodopsin trafficking involves myosin VIIa
5
. 
 
  
Figure 4. Connecting cilium and intraflagellar transport 
The connecting cilium extends from the basal body into the OS of the photoreceptor. 
Transportation of particles between the IS and OS is indicated by arrows. IFT – 
intraflagellar transport. Image has been modified from Wright et al.
4
. 
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1.2.3 The Phototransduction Cascade 
External information in the form of photons is captured by the photoreceptor cells, 
which convert it into a change in membrane resistance through the phototransduction 
cascade (Figure 5).  Rod phototransduction is the most well characterised of all sensory 
transduction pathways. In the dark there is a steady current of cations, known as the 
“dark current”, through channels in the photoreceptor OS membrane which are kept 
open by the presence of cyclic guanosine monophosphate (cGMP) in the cytoplasm
6
. 
This results in depolarised photoreceptor cells that continuously release glutamate, a 
neurotransmitter, onto postsynaptic cells. Photon absorption by the photopigment 
(rhodopsin and 11-cis-retinal in rods) results in the isomerisation of 11-cis-retinal to all-
trans-retinal, and this drives a conformational change in rhodopsin, activating the 
protein (RHO*). RHO* catalyses the activation of a G-protein, transducin, a process 
that includes the exchange of guanosine diphosphate (GDP) for guanosine triphosphate 
(GTP) with the release of the α-subunit of transducin6. The GTP-linked α-subunit of 
transducin drives the activation of cGMP phosphodiesterase (PDE), which in turn is 
responsible for the hydrolysis of cGMP to guanosine monophosphate (GMP). This 
reduction in cGMP concentration in the cytoplasm results in the closure of cGMP-gated 
channels in the plasma membrane and therefore the localised reduction in cation influx 
into the OS. This results in hyperpolarisation of the membrane and closure of synaptic 
glutamate-releasing calcium channels and therefore reduction or termination of 
glutamate release
6
.  
In order to prevent further transducin activation RHO* is inactivated. Phosphorylation 
of RHO* allows binding of arrestin, preventing further interaction with transducin. 
Transducin and PDE are inactivated through the hydrolysis of GTP to GDP
6
. The 
falling calcium concentration in the OS results in the activation of membrane-bound 
retinal guanylate cyclase (GC), which in turn catalyses the regeneration of cGMP. The 
resulting increase in cGMP concentration results in the re-opening of cGMP-gated 
channels and the return of the photoreceptor to its depolarised state
6
. 
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Figure 5. Phototransduction cascade 
Summary of the phototransduction cascade resulting in the closure of cGMP-gated 
channels, followed by the inactivation of the cascade resulting in the re-opening of the 
channels. R – rhodopsin, R* – activated rhodopsin, G – transducin, PDE – 
phosphodiesterase, cGMP – cyclic guanosine monophosphate, GC – retinal guanylate 
cyclase, RK – rhodopsin kinase, Arr – arrestin. Modified from Burns et al.6.  
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1.2.4 The Visual Cycle 
The visual cycle (Figure 6) is the process whereby the chromophore, 11-cis-retinal, is 
regenerated after photon absorption by rhodopsin. Upon activation rhodopsin releases 
all-trans-retinal, which is transported to the cytoplasm of the OS by ATP-binding 
cassette, subfamily A, member 4 (ABCA4). Here retinol dehydrogenase (RDH12) 
modifies it to all-trans-retinol (vitamin A). This is then transported by interstitial 
retinol-binding protein (IRBP) to the RPE where it undergoes a series of reactions. First, 
lecithin-retinol acyltransferase (LRAT) esterifies all-trans-retinol, followed by trans-
isomerisation and further modification through the actions of RPE-specific 
isomerohydrolase (RPE65) and 11-cis-retinol dehydrogenase (RDH5) respectively to 
form 11-cis-retinal
4
. This is finally transported back to the photoreceptor cell OS. 
It has been suggested that the processing of isomerised retinoid from cone cells occurs 
in Müller cells as well as in the RPE, although evidence is conflicting
7,8
. 
 
Figure 6. Visual cycle 
Chromophore, 11-cis-retinal, is regenerated from spent all-trans-retinal through a 
number of reactions in the photoreceptor cells and RPE. PR – photoreceptor, RHO – 
rhodopsin, RHO* - activated rhodopsin, IRBP – interstitial retinol-binding protein, 
LRAT – lecithin retinol acyltransferase, RPE65 - Retinal pigment epithelium-specific 
65 kDa protein, RDH5 – 11-cis-retinol dehydrogenase. Image has been modified from 
Wright et al.
4
. 
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1.2.5 The Canine Retina 
As stated previously, the canine and human eye differs anatomically by only four major 
aspects, three of which involve the retina. Firstly, the canine eye has 9-20 additional 
layers of cells, adjacent to the RPE, called the tapetum lucidum and tapetum nigrum 
(Figure 1). The former is made up of reflective cells that line the top half of the retina. 
They receive light mostly from the darker ground and reflect light back through the 
retina, thereby improving scotopic vision. In lemurs (which also have these extra layers) 
it has been suggested that tapetal riboflavin absorbs shorter wavelengths of light (in the 
region of 260nm, 370nm and 450nm) and converts it to longer wavelengths (520nm) to 
which rhodopsin is more sensitive
9
. This may in effect brighten the appearance of a 
black or blue evening and also enhance the contrast between the background sky and 
objects in the environment. The tapetum nigrum is made up of darkly pigmented, non-
reflective cells that line the bottom half of the retina. They receive light mostly from the 
brighter sky and may reduce the light scattering in the retina
10
.  
Secondly, in the human eye the macula lutea is a region at the back of the eye that 
contains the highest concentration of pigments, which protect the retinal neurons against 
oxidative stress
11
. At the centre of the macula is a single point made up entirely of 
densely packed cones and ganglion cells, called the fovea. It is this point that produces 
the sharpest image. Dog eyes do not have a macula or fovea, but similarly to other 
animals they do have an oval region located just above the optic nerve, termed the 
visual streak, enclosing a smaller circular region termed the area centralis. Similar to the 
fovea, the visual streak and area centralis is the region with the highest concentration of 
photoreceptor and ganglion cells, although only 10% are cone photoreceptor cells
10,12
. 
The area centralis, found particularly in mammals with frontalised eyes, is specialised 
for binocular, high-resolution vision
13
. Grey wolves, from which domestic dogs are 
thought to have descended, have a pronounced visual streak that is thought to favour 
animals that live in open terrain and for which the horizon is an important feature of the 
field of view
12
.  Interestingly the distribution and density of ganglion cells varies 
between dog breeds and is correlated with skull shape. In general, traditional working 
breeds, such as those bred for hunting or herding and which would benefit from good 
peripheral vision, are mesocephalic. These dogs have retinas with a weak visual streak 
and more obvious area centralis or a pronounced visual streak and no obvious area 
centralis
14
. Conversely, many of the smaller breeds, such as Pugs and others bred almost 
exclusively as pets and which benefit from the ability to focus intently on a particular 
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object (such as a person), are brachycephalic. These dog breeds have a pronounced area 
centralis and virtually no visual streak
14
. The variation seen in dogs is most likely a 
result of morphological and functional trait selection and the lack of specific 
environmental pressures during domestication.    
Finally, humans have three types of cone photoreceptors and therefore have trichromatic 
vision and can distinguish millions of colours. The canine retina on the other hand has 
only two types of cone photoreceptors, sensitive to light with wavelengths in the range 
of 429nm and 555nm, which appear violet and yellow-green respectively to humans. 
Dogs consequently have dichromatic colour vision, and light with a wavelength 
between 475-485nm, which appears green to humans, probably appears white or grey to 
dogs
15,16
. Therefore, dogs probably see colours in a similar way to people with 
deuteranopia i.e. unable to discriminate between the colours red and green. 
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1.3 Canine Genetics 
The domestic dog (Canis lupus familiaris) is an increasingly popular subject for the 
study of hereditary traits such as disease susceptibility, behavioural traits and 
morphological features due to its economic and social importance and unique history 
and population structure. The development of numerous genetic resources for the dog 
has resulted in considerable progress in the understanding of canine hereditary diseases 
and the development of DNA tests for monogenic traits. In addition the dog has recently 
become a prominent model species for the study of human disease.  
1.3.1 History of Canine Breeds 
The unique patterns of genetic variation between and within dog breeds can be 
attributed to their unique history and development through two major bottlenecks. The 
first was an ancient bottleneck that occurred when dogs were originally domesticated 
from the grey wolf approximately 15,000-100,000 years ago
17,18
. The second occurred 
during more recent breed formation, approximately 200 years ago, when dogs were 
selectively bred for herding and hunting abilities, obedience and desired physical 
characteristics such as size, shape and coat colour. In the cases of some breeds there 
have been further bottlenecks associated with fluctuations in popularity, excessive use 
of show champion sires (the popular sire effect), geographic restrictions and 
catastrophic events such as world wars and economic depression. As a result there are 
approximately 400 distinct dog breeds worldwide. The development of breeding 
standards regulated by bodies such as the Kennel Club, and controlled breeding within 
these breeds has resulted in closed breeding populations with high levels of inbreeding 
and homogeneous genetic pools.  
1.3.2 Canine Genetic Resources 
The dog is an increasingly popular subject of scientific study for a number of reasons: 
1) extensive medical surveillance and modern diagnosis and treatment options are 
second only to humans; 2) physical similarities with humans, such as body and organ 
sizes, physiology and phenotype as well as environmental exposure; 3) lifespans 
conducive to scientific study; 4) phenotypic homogeneity within breeds and 5) 
phenotypic heterogeneity between breeds. It has only been in recent years that genetic 
resources available for the dog have enabled extensive genetic study of the species. 
Linkage maps
19,20
, a high quality radiation hybrid map
21
, and the 1.5x Poodle 
sequence
22
 were once valuable tools, but have recently been superseded by more 
sophisticated tools. The first high-quality (7.5x) draft sequence of the dog (a Boxer) was 
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made available in 2004 (CanFam1.0), and the updated assembly (CanFam2.0) in 2006
23
. 
The assembly was updated again in 2012 (CanFam3.1), albeit only after much of this 
PhD project had been completed. The publication of the dog genome sequence has led 
to the development of a single nucleotide polymorphism (SNP) map containing >2.5 
million SNPs
23
, medium and high density whole genome SNP marker arrays and 
messenger RNA (mRNA) sequencing (RNA-seq) data from a variety of canine tissues, 
all accessible with the Ensembl genome browser (www.ensembl.org/Canis_familiaris).  
1.3.3 The Canine Genome 
The canine genome is approximately 2.4 gigabases (Gb) in size with approximately 
19,000 genes
23
. In a genetic study of 85 breeds it was found that dogs have similar 
levels of overall nucleotide diversity – 8x10-4 nucleotide substitutions per base/pair 
between random pairs of genomes – to humans. However, the variation between dog 
breeds is 27.5% compared with 5.4% between human populations, while the 
homogeneity of 94.6% within individual dog breeds is greater than that of humans 
(72.5%)
24
. This contributes to dogs having unique patterns of linkage disequilibrium 
(LD), extending over several megabases (Mb) within breeds (10-100 fold further than in 
humans), but only tens of kilobases (kb) between breeds
23
. LD patterns vary 
enormously from breed to breed, with the general trend of greater LD seen in 
numerically smaller breeds that have experienced significant population bottlenecks, 
while reduced LD is seen in numerically larger breeds such as Golden Retrievers
25
.  
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1.4 Canine Hereditary Disease 
The stringent breeding of dogs within closed breeding populations and population 
bottlenecks has resulted in elevated levels of inbreeding. This in turn has led to the 
emergence of hereditary diseases specific to or at higher prevalence in certain breeds, 
including heart disease, blindness, cancers and epilepsy
26
. Most of these diseases occur 
in human populations, and clinical manifestations are often similar between the two 
species
27
. Some monogenic conditions are shared by multiple breeds, but most are 
confined to very few breeds, while complex conditions tend to affect multiple breeds. 
To date more than 600 genetic traits, mostly disease traits, and 280 breeds are listed in 
the Inherited Diseases In Dogs (IDID) database
27
 with a total of 1,552 entries when 
considering traits found in multiple breeds (http://www.vet.cam.ac.uk/idid, accessed on 
13/11/2012). Similarly there are 583 entries for the dog in the Online Mendelian 
Inheritance in Animals (OMIA) database (http://omia.angis.org.au/home/, accessed on 
13/11/2012), representing the largest number of known naturally occurring genetic 
diseases in any non-human species. Canine genetic disorders affect a wide variety of 
physiological systems including blood, cardiovascular, endocrine, ocular, 
gastrointestinal, immune, musculoskeletal, nervous system, respiratory, urinary and 
reproductive disorders as listed in the Canine Inherited Disorders Database (CIDD) 
(http://www.upei.ca/~cidd, accessed 21/06/2011). Of these inherited diseases it is 
thought that more than half closely resemble human diseases in terms of laboratory and 
clinical abnormalities
26
. 
1.4.1 Canine Retinopathies 
The canine retinal dystrophies, a common cause of blindness in purebred dogs, are 
fairly well characterised, albeit not as well as in humans, and often based only on 
ophthalmoscopic findings. However, our understanding of the genetic and phenotypic 
characteristics of each condition, and their correlation, is continuously improving and as 
such their characterisation and classification is ever-changing. Causal mutations have 
been found for some forms of retinal diseases, but many remain undefined and novel 
reports of the condition being observed in breeds for the first time are commonplace.  
Various methods are employed for the classification of canine retinopathies, one of 
which is based on three main factors (Figure 7 and Table 2): 
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Developmental versus degenerative – abnormal development of the retina results in 
developmental disease, while degeneration of a normally developed retina results in 
degenerative disease. 
Stationary versus progressive – retinopathies in which the clinical effects remain 
relatively constant are described as stationary, whereas those in which the clinical 
effects become more severe over time are progressive. 
Rod-led versus cone-led – in progressive retinal atrophy (PRA) the rod 
photoreceptor cells are affected first while in the cone rod dystrophy (CRD) the cone 
photoreceptor cells are affected first.  
PRA and CRD are two groups of ocular diseases in dogs and other animals 
characterised by progressive retinal degeneration resulting in loss of vision. In typical 
PRA rod photoreceptor responses are lost first followed by cone photoreceptor 
responses. Therefore dogs experience nyctalopia (night blindness) followed by 
deterioration of daytime vision, culminating in complete blindness
28
. In CRD cone 
responses are typically lost first and rod responses are affected later or to a lesser extent. 
Usually the ophthalmoscopic findings of PRA and CRD are similar, especially late in 
the progression of the disease
29
. The only method of distinguishing between cone- or 
rod-led degeneration is by electroretinogram (ERG) testing in the early stages of 
disease. Because an ERG is not frequently performed on a canine patient as part of a 
routine consultation due to the expense and the necessary sedation in patients, 
ophthalmoscopically similar conditions such as CRD are often misdiagnosed as PRA. 
Numerous forms of PRA and CRD have been documented in more than 100 dog breeds 
and whilst they exhibit similar clinical signs, the aetiology, age at onset and rate of 
progression vary between and within breeds. Typically the later onset forms of the 
disease progress slower than the early onset forms. Most forms have an autosomal 
recessive (aR) mode of inhertiance
30,31
, although an autosomal dominant (aD)
32
 and two 
X-linked
33
 forms have been reported. 
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Figure 7. Classification of the canine retinopathies 
Each of the canine retinopathies for which a genetic mutation has been identified is 
shown. Figure has been modified from Mellersh
34
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Table 2. Classification and known mutations of canine retinopathies 
Gene Form of disease Mutation 
CanFam2 
Coordinates
*
 
Mutation 
Type 
Breeds Ref. Orthologous Human Disease 
Gene 
OMIM no.
†
 
Developmental retinal disorders 
NHEJ1 
Collie eye anomaly 
(CEA) 
7.8kb deletion  
CFA37:28697542
–28705340 
Binding 
domain 
deletion 
8 breeds
‡
 
35
 
SCID (Severe combined 
immunodeficiency) 
611290 
COL9A3 
Oculoskeletal 
dysplasia 1 
(osd1/drd1) 
1 bp insertion 
(A) 
CFA24:49699847
-49699850 
Frame-shift Labrador Retriever 
36
 Multiple Epiphyseal dysplasia 120270 
COL9A2 
Oculoskeletal 
dysplasia 2 
(osd2/drd2) 
1,267 bp 
deletion  
CFA15:5649586-
Unknown 
Exon loss Samoyed 
36
 
Multiple Epiphyseal dysplasia  
Stickler syndrome, type V 
120260 
Stationary retinal disorders 
CNGB3 Achromatopsia 140kb deletion Unknown Gene loss Alaskan Malamute 
37
 
Achromatopsia-3  
Juvenile macular degeneration 
605080 
CNGB3 Achromatopsia G->A CFA29:35840555 Missense 
German 
Shorthaired Pointer 
37
 
BEST1 
Canine multifocal 
retinopathy (cmr1) 
C->T CFA18:57508040 Nonsense 3 breeds
§
 
38
 
Retinitis pigmentosa 50 
Retinitis pigmentosa, concentric  
Vitelliform macular dystrophy  
Best macular dystrophy  
Bestrophinopathy  
Microcornea, rod-cone dystrophy, 
cataract and posterior staphyloma  
Vitreoretinochoroidopathy 
Maculopathy, bull's-eye 
607854 
BEST1 
Canine multifocal 
retinopathy (cmr2) 
G->A CFA18:57505416 Missense Coton de Tulear 
38
 
BEST1 
Canine multifocal 
retinopathy (cmr3) 
1 bp deletion (C) 
& G->T 
CFA18:57499959 
& 57499881 
Frame-shift Lapponian Herder 
39
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Gene Form of disease Mutation 
CanFam2 
Coordinates
*
 
Mutation 
Type 
Breeds Ref. Orthologous Human Disease 
Gene 
OMIM no.
†
 
Progressive retinal disorders: Cone-rod dystrophies (CRDs) 
RPGRIP1 
Cone-rod dystrophy 
1 (cord1) 
44bp insertion 
(A29GGAAGCA
ACAGGATG) 
CFA15:21338814
-21338815 
Frame-shift 4 breeds
**
 
30
 
Cone-rod dystrophy 13  
Leber congenital amaurosis 6 
605446 
NPHP4 Cone-rod dystrophy 180bp deletion 
CFA5:62913591-
62913770 
Exon skipping 
Standard Wire-
haired Dachshund 
40
 
Nephronophthisis 4  
Senior-Loken syndrome 4 
607215 
ADAM9 
Cone-rod dystrophy 
3 
24.7kb deletion 
CFA16:29.400-
29.423Mb 
Exon skipping 
Glen of Imaal 
Terrier 
41,42
 Cone-rod dystrophy 9 602713 
Progressive retinal disorders: Progressive retinal atrophies (PRAs) 
RPE65 Canine LCA (cLCA)  
4bp deletion  
(AAGA) 
CFA6:79959789-
79959792 
Frame-shift Briard 
43
 
Leber Congenital Amaurosis 2  
Retinitis pigmentosa 20 
180069 
RHO 
Autosomal dominant 
PRA 
C->G CFA20:8641456 Missense 
English Mastiff; 
Bull Mastiff 
32,44
 
Night blindness, congenital stationery, 
autosomal dominant 1  
Retinitis pigmentosa 4, autosomal 
dominant or recessive  
Retinitis punctata albescens  
180380 
STK38L 
Early retinal 
degeneration (erd) 
SINE insertion 
CFA27:23459892-
23459893 
Exon skipping 
Norwegian 
Elkhound 
45
   
CCDC66 Generalised PRA 
1bp insertion 
(A) 
CFA20:36742856-
36742857 
Frame-shift Schapendoes 
46
   
PRCD 
Progressive rod-cone 
degeneration (prcd) 
G->A CFA9:7186710 Missense 29 breeds
††
 
47
 Retinitis pigmentosa 36  610598 
PDE6A 
Rod-cone dystrophy 
3 (rcd3) 
1bp deletion (A) CFA4:62348897 Frame-shift 
Cardigan Welsh 
Corgi 
31
 Retinitis pigmentosa 43  180071 
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Mutation 
Type 
Breeds Ref. Orthologous Human Disease 
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†
 
PDE6B 
Rod-cone dystrophy 
1 (rcd1) 
G->A CFA3:94574275 Missense Irish setter 
48
 Night blindness, congenital stationary, 
autosomal dominant 2  
Retinitis pigmentosa 40  
180072 
PDE6B 
Rod-cone dystrophy 
1 (rcd1a) 
8bp insertion 
(TGAAGTCC) 
CFA3:94574247-
94574248 
Frame-shift Sloughi 
49
 
RD3 
Rod-cone dystrophy 
2 (rcd2) 
22bp insertion 
(gcccgcccccgccc
ccgccccc) 
CFA7:12832684-
12834235  
Frame-shift 
Rough and smooth 
collies 
50
 Leber congenital amaurosis 12 180040 
PDC Type-A PRA C->G CFA7:22463847 Missense 
Miniature 
Schnauzer 
51
  171490 
RPGR X-linked PRA 1  
5bp deletion 
(GAGAA)  
CFAX:Unknown
‡‡
 Frame-shift 
Samoyed and 
Siberian Husky 
52
 
Cone-rod dystrophy-1  
Macular degeneration, X-linked 
atrophic  
Retinitis pigmentosa 3  
Retinitis pigmentosa, X-linked, and 
sinorespiratory infections, with or 
without deafness  
312610 
RPGR X-linked PRA 2 
2bp deletion 
(GA)  
CFAX:Unknown
‡‡
 Frame-shift 
Mongrel (Mixed 
breed) 
52
 
 
* Unknown = precise coordinates or boundaries unknown due to missing from CanFam2 assembly or insufficient information in literature. 
† Online Mendelian Inheritance in Man database (http://www.ncbi.nlm.nih.gov/omim) 
‡ Australian Shepherd, Border Collie, Lancashire Heeler, Nova Scotia Duck Tolling Retriever, Rough Collie, Shetland Sheepdog, Smooth Collie, Long haired Whippet 
§ Great Pyrenees, English Mastiff, Bullmastiff 
** Miniature Long, Short and Wire Haired Dachshunds, English Springer Spaniel 
†† American Cocker Spaniel, American Eskimo Dog, Australian Cattle Dog, Australian Shepherd, Australian Shepherd (Miniature), Australian Stumpy Tail Cattle Dog, Chesapeake Bay Retriever, 
Chinese Crested, Cockapoos, Dwarf Poodle, English Cocker Spaniel, Entelbucher Mountain Dog, Finnish Lapphund, Golden Retriever, Golden Doodle, Karelian Bear Dog, Kuvasz, Labradoodle, 
Labrador Retriever, Lapponian Herder, Markiesje, Moyen Poodle, Norwegian Elkhound, Nova Scotia Duck Tolling Retriever, Poodle Miniature and Toy, Portuguese Water Dog, Spanish Water Dog, 
Swedish Lapphund, Yorkshire Terrier. 
‡‡ Exact coordinates unknown, but somewhere between 33,026,823 and 33,027,678 bp. 
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1.4.2 Progressive Retinal Atrophy 
1.4.2.1 Ophthalmoscopic and Clinical Signs of PRA 
Disease progression is bilateral and usually symmetrical. Initially the tapetal periphery 
takes on a granular appearance, and with loss of thickness of the retina the tapetum 
becomes increasingly reflective (known as tapetal hyper-reflectivity). Some dogs do not 
have a tapetum, in which case the identification of retinal thinning is difficult. Further 
disease progression, however, results in depigmentation and pigment clumping of the 
non-tapetal fundus
53
. Another typical sign of PRA is attenuation of the blood vessels. 
However caution must be taken as smaller dogs tend to have small vessels and can thus 
be misdiagnosed on the basis of their retinal vasculature. Finally, in advanced PRA, the 
loss of ganglion cell axons that form the optic nerve results in atrophy of the optic nerve 
head, giving it a flatter, grey appearance
28
. 
1.4.2.2 Diagnosis of PRA 
Accurate diagnosis requires ophthalmoscopic examination at the very least and 
preferably also an ERG. Retinal abnormalities can be detected by ERG before 
ophthalmoscopic signs appear or if the view of the retina is impeded by secondary 
cataracts which often accompany PRA
54
. An ERG is a measure of the response of the 
retina to a light stimulus. The retina is stimulated by a flash of light and the electrical 
response at the corneal surface is recorded. A detailed ERG can provide information 
about the retinal dysfunction including the order in which rods and cones are affected, if 
both are affected, and the age of onset of retinal dysfunction. ERGs tend to be most 
informative when carried out very early in the development of PRA, often prior to the 
onset of ophthalmoscopic signs
28
.  
The BVA/KC/ISDS (British Veterinary Association/Kennel Club/International Sheep 
Dog Society) Eye Scheme in the UK and other similar international schemes offer dog 
breeders the opportunity to have their dogs screened by veterinary ophthalmologists for 
the presence of hereditary eye disease, including PRA. The clinical data pertaining to 
dogs obtained through such schemes is well-documented, and as it is collected by 
clinical specialists, robust, albeit usually limited to ophthalmoscopic signs. 
Other methods employed to assist diagnosis, usually only obtained for the purposes of 
research and requiring dogs bred specifically for the purpose of research, include 
histopathology and biochemistry. The former can identify the cell type involved in 
disease and also determine whether the cells involved develop normally before 
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degeneration, or never reach maturity at all
28
. Biochemical assays can potentially 
identify any abnormalities in the cell biochemistry. For example, with certain rod-cone 
dystrophies elevated levels of cGMP is seen within the process of rod 
phototransduction
55
. 
The presence of phenocopies, i.e. non-hereditary retinal degenerations that mimic the 
effects of hereditary retinal dystrophies, complicates the accurate diagnosis of PRA. In 
sudden acquired retinal degeneration (SARD), as reviewed by Petersen-Jones, 
ophthalmoscopic signs of retinal degeneration only appear many weeks after a sudden 
loss of visual function, and these dogs can therefore be identified based on their 
history
28
. However, it is prudent to bear in mind the possibility of misdiagnosis of PRA 
during any molecular or clinical investigations.  
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1.5 Human Retinal Degenerations 
The degeneration of photoreceptor cells and/or the RPE results in retinal dystrophies, 
which are the major cause of familial blindness in the western world, and are incurable. 
Similarly to dogs, human retinal dystrophies can be characterised by which cells are 
affected and in which order they degenerate during disease progression e.g. cone, rod-
cone etc.. Despite these classifications there is still a great deal of genetic and clinical 
overlap of the retinal dystrophies. In addition, retinal dystrophies present along with 
other symptoms in a number of syndromic conditions. The past two decades has seen an 
explosion in the numbers of retinal disease loci mapped and mutations found. 
According to the Retinal Information System (RetNet; 
http://www.sph.uth.tmc.edu/Retnet/; accessed 13/11/2012), 185 of 225 genes causing 
retinal disease have been identified. Incredibly, approximately one third of these genes 
localise to the CC or basal body of photoreceptor cells
56
, and diseases caused by 
mutated ciliary genes are known as ciliopathies. Canine PRA has not been described as 
part of a syndrome in any of the breeds under investigation, and I will therefore be 
focusing mainly on the non-syndromic retinal dystrophies for the purposes of this 
project.  Of 153 genes causing non-syndromic retinal disease in humans, 122 have been 
identified. A number of these genes have also been implicated in canine retinal disease 
(Table 2). Despite this success, a large number of mutations have yet to be identified in 
humans. It is estimated that the genes identified thus far account for approximately 65% 
of inherited autosomal recessive retinal dystrophies
57
. 
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1.5.1 Retinitis Pigmentosa 
PRA is considered the veterinary equivalent of Retinitis pigmentosa (RP) in humans 
and has already proved to be a valuable model for various forms of human retinal 
degenerations. RP is the name given to a group of common inherited retinal diseases in 
humans which affects 1 in 3500 to 4500 people
58
. Photoreceptor cells predominantly 
affected are the rods and therefore clinical symptoms typically include night blindness 
(nyctalopia) and loss of peripheral vision. With disease progression the cones also 
degenerate resulting in central vision loss and eventually possibly complete blindness
59
. 
While this heterogeneous group of diseases is highly variable with regard to age of 
onset, retinal appearance, progression and visual outcome, there are hallmark 
characteristics secondary to photoreceptor degeneration. These include “bone spicules” 
caused by pigment granule migration from the RPE and retinal arteriole and vein 
attenuation
59
. 
1.5.2 Other Non-syndromic Retinal Dystrophies 
While RP is the most common of the hereditary retinal degenerations, there are a 
number of other diseases that exhibit degeneration of the retina: 
Leber congenital amaurosis (LCA) is clinically similar to RP, but more severe. 
Patients are impaired visually from birth and present with nystagmus (involuntary eye 
movements). Pigmentation and arteriole attenuation can vary from mild to severe, and 
an electroretinogram is usually non-detectable within the first year of life. LCA is 
relatively rare, with a worldwide incidence of approximately 1 in 30,000 and most cases 
show aR inheritance
60
.   
Startgardt Disease Type 1 (STGD1), with a worldwide incidence of 1 in 10,000, is the 
most common juvenile macular dystrophy. Patients typically experience loss of visual 
acuity in early childhood or early adolescence. Progressive retinal and macular changes 
result from lipofuscin accumulation
61
. 
Cone-rod dystrophy (CRD) is a disorder predominantly characterised by a loss of 
cone function, with patients experiencing photoaversion (intolerance of light), and 
defective colour vision in adolescence or early adult life. Mild thinning of the retinal 
vessels is observed, but bone spicules are usually absent
62
. 
Achromatopsia (ACHM) is a stationary, congenital aR cone disorder, where 
diminished cone ERG responses are observed, but rod ERG responses are normal. 
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Patients generally experience low visual acuity, photophobia (pain caused by light 
exposure), nystagmus and severe defects in colour vision
63
. 
Cone dystrophy (CD) is a progressive condition in which cone function is initially 
normal. However patients experience progressive loss of visual acuity, colour vision 
disruption and increasing photophobia. Cone ERG responses begin to diminish within 
the first two decades of life and by the fourth decade of life visual acuity worsens to the 
point of legal blindness
63
. 
1.5.3 Syndromic Disorders: Bardet-Biedl Syndrome 
A number of syndromes (Senior-Løken syndrome, Alström syndrome, Joubert 
syndrome, Bardet-Biedl syndrome and Usher syndrome), all of which are ciliopathies, 
have been described in which a broad range of clinical manifestations are observed, 
including retinal degeneration. Bardet-Biedl Syndrome (BBS) is probably the best 
characterised of the syndromes. Patients display some or all of the features common to 
ciliopathies including, but not limited to, RP, cystic kidneys, polydactyly, obesity, situs 
inversus (left-right reversal of organ distribution), gonadal malformations/ 
hypogenetalism, heart disease, liver dysfunction and mental retardation. Seventeen 
genes to date have been implicated in the disease (RetNet; 
http://www.sph.uth.tmc.edu/Retnet/; accessed 16/11/2012 and Online Mendelian 
Inheritance in Man (OMIM) database; OMIM number 209900; 
http://www.ncbi.nlm.nih.gov/omim; accessed 16/11/2012). Most forms of BBS have an 
aR mode of inheritance, although triallelic inheritance has also been reported
64,65
. 
Clinical symptoms tend to progress in a similar way in most BBS patients: Postaxial 
polydactyly and hypogenetalism are present at birth. Within a few years children begin 
to gain weight and eventually become obese. By eight years of age visual problems 
begin with night-blindness, which progresses to complete blindness by the age of 15-20 
years. During childhood patients also develop kidney cysts. Many patients eventually 
develop chronic kidney disease and end-stage renal failure is the most common cause of 
premature death. 
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1.6 Canine Models for Human Genetic Disease 
The study of genetic disease in model organisms is potentially highly beneficial to 
humans and the identification of certain disease genes in dogs has already facilitated 
progress in studies of equivalent human disease. For example, autosomal recessive 
congenital ichthyosis (ARCI) in humans is associated with mutations in various genes 
that affect skin barrier function. However, in the canine equivalent (a lamellar 
ichthyosis in Golden Retrievers) mutations were identified in the patatin-like 
phospholipase domain containing 1 (PNPLA1) gene. This discovery led scientists to the 
human homologue, in which mutations were identified in six affected individuals from 
two families
66
. Human populations with limited genetic variation, such as the Bedouins, 
Finns and Icelanders, have been successfully used in disease-mapping studies
67,68
. 
However, most human populations have a great deal of genetic variation and as a result 
mapping of most disease traits that segregate in them is far more difficult. Canine 
breeds, with their limited genetic variation, are analogous to the former, inbred human 
populations. In addition, the development of canine genetic resources and the disease 
similarities of humans and dogs suggest that genes involved in disease may be more 
quickly and easily found in dogs than in humans. The dog is therefore an ideal species 
in which to study complex and simple genetic diseases. The prevalence and 
heterogeneity of canine retinal degenerations has resulted in the identification of 
numerous canine models for human retinal degenerations (Table 2). Due to the recent 
and continuing development of sophisticated resources for the dog, the rate at which 
novel disease- and trait-associated genes are identified is expected to increase.  
1.6.1 Canine Models for Retinal Gene Therapy Studies 
Animal models for human disease have also proved useful in gene therapy studies. The 
mouse is the most commonly used model for human retinal degenerations with 
spontaneous or man-made models available for many of the genes implicated in 
nonsyndromic retinal dystrophies. However, a disadvantage of the mouse as a model is 
that the size and anatomy of the mouse eye differs from that of the human, and as a 
result gene delivery requires different surgical techniques. In addition, due to the short 
lifespan of the mouse it has limited relevance to human disease. 
Large animal models such as dogs are increasingly being used for gene therapy studies. 
Anatomically, the eyes of dogs are far more similar to humans than those of mice. 
While only primates have maculas, dogs do have the ganglion-enriched areas known as 
a visual streak or area centralis, which are functionally similar to the human macula. In 
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addition, the size of the eye in dogs is similar to humans, allowing the use of the same 
surgical approaches for gene delivery. 
1.6.1.1 LCA and RPE65 
Canine leber congenital amaurosis (cLCA) in Briards, previously known as congenital 
stationary night blindness, is an autosomal recessive retinopathy caused by 
dysfunctional rods and cones. The fundus appears ophthalmoscopically normal for up to 
three years before subtle clinical signs appear and photoreceptor cells only begin to 
change late in the progression of the disease
69
. RPE65 plays an important role in the 
visual cycle (Figure 6) and a mutation in the gene that is associated with cLCA has been 
described
43
. Aberrant RPE65 also accounts for approximately 6% of LCA in humans 
(LCA2)
60
. The phenotype is similar to that of cLCA in that, initially, retinal architecture 
is normal and patients have useful visual acuity. Vision becomes severely impaired by 
the third decade due to progressive deterioration in photoreceptor morphology and 
visual function. A mouse model for LCA2 is available, but is a sub-optimal system for 
development of therapies for humans due to phenotypic differences between the two 
species:  the knockout mice retain cone function, whereas human patients exhibit rod 
and cone dysfunction
70
.  
Canine LCA is proving to be an extraordinarily valuable model for gene therapy studies 
involving LCA2 in humans
71
. Retinal degeneration in affected dogs is slow and as a 
result the window of opportunity for administering treatment is relatively large. In 
addition, as the mutation results in a lack of gene product an appropriate treatment is 
simply to administer a functional product into the subretinal space, carried by a vector. 
RPE65
-/-
 dogs have been used to test the efficacy of gene therapy using an adeno-
associated virus (AAV) vector carrying wildtype RPE65, and visual function was 
restored and improvements were maintained for more than three years
72,73
. As a result, 
to assess the safety and efficacy of similar therapy in humans, three phase I/II clinical 
trials have been undertaken in LCA2 patients in which no serious adverse effects were 
reported. In addition, improvements in rod-mediated visual function were also 
reported
2,71,74-76
.  
1.6.1.2 X-linked Retinal Dystrophy and RPGR 
The two forms of X-linked PRA are both caused by mutations in the retinitis 
pigmentosa GTPase regulator (RPGR) gene, specifically in open reading frame 15 
(ORF15), but they are clinically distinct. Type 1, found in the closely related Siberian 
Husky and Samoyed breeds, manifests after normal photoreceptor morphogenesis. 
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Affected dogs display electroretinographic abnormalities from six months of age and 
retinal degeneration is led by the rods. By four years of age the blood vessels are 
severely attenuated and the tapetum displays advanced hyper-reflectivity. Type 2, found 
in a mixed breed, is more severe and manifests during retinal development. Affected 
dogs display electroretinographic abnormalities from six weeks of age and advanced 
PRA by two years of age
52
. RPGR is a component of the connecting cilium and is 
thought to be involved in microtubule organisation and intracellular trafficking
77
. 
Aberrant RPGR is the most common cause of retinal dystrophy in humans and more 
than 240 mutations have been identified in the gene, as reviewed by Shu et al.
78
. Of 
these, 95% cause X-linked RP (XLRP), 3% X-linked cone or cone-rod dystrophy 
(XLCRD) and 2% cause atrophic macular dystrophy. A mutational hotspot, ORF15, 
contains more than half of the reported mutations
78,79
. XLRP-affected males typically 
develop nyctalopia by the age of 10 years and are legally blind by the third decade of 
life. They have generalised rod and cone dysfunction, but due to normal visual acuity 
during childhood the window of opportunity for gene therapy is longer than LCA
80
. An 
Rpgr knockout mouse has slow retinal degeneration, and cone and rod photoreceptor 
abnormalities, but the small amount of residual protein that remains suggests some 
residual function
77,81
. Mutations that result in retention of partial function in humans are 
associated with XLCRD
82
. The knockout mouse therefore represents a better model for 
human XLCRD than XLRP. A second, transgenic, mouse model expressing truncated 
RPGR
ORF15
 had a more severe gain-of-function phenotype
83
.  
Recently Beltran et al. described the use of gene augmentation therapy in the canine 
XLPRA1 and XLPRA2 models. RPGR
-/-
 dogs given subretinal injections of AAV 
vectored with human RPGR proved the efficacy of the treatment with improvements 
seen in treated eyes only compared with untreated eyes: inner and outer segments were 
preserved, rod and cone photoreceptor function was greater, photoreceptor structure was 
normal and opsin mislocalisation was reversed
84
. While this suggests that gene 
augmentation therapy is a viable option for the treatment of RPGR-associated 
retinopathies, the broad range of phenotypes observed and the effect of modifiers on 
RPGR expression may be a potential obstacle in selecting suitable recipients
85,86
.  
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1.7 Identifying Variants Associated With Canine Genetic 
Traits 
A number of approaches have been used to successfully map and identify canine genetic 
mutations, including a candidate gene approach, family-based linkage analyses and 
case-control association studies. The two latter approaches essentially compare the 
segregation of genetic markers among affected and non-affected individuals to identify 
loci potentially containing the mutation. The long LD within breeds makes it possible to 
map simple traits efficiently using few samples and a relatively sparse marker set 
compared with human studies
23
. 
1.7.1 Genetic Markers 
Microsatellite markers are short repetitive DNA units, usually 2-4 base pairs, scattered 
throughout the genome. The number of repeat units is highly variable and each marker 
could have multiple alleles, making microsatellites very useful genetic markers. 
Minimal Screening Set 2
87
 and Minimal Screening Set 3
88
, containing 325 and 507 
microsatellite markers respectively, were developed for use in mapping studies, but 
have become obsolete. Markers within these sets are separated by an average physical 
spacing of 9 Mb and 5 Mb respectively. As a result, both sets lack the density of 
markers required when studying traits in the majority of breeds as LD seldom extends 
>3 Mb
89
. 
SNP markers are defined as the change at a specific genomic position from one 
nucleotide to another. SNPs are usually bi-allelic and therefore less informative than 
microsatellite markers, but genotyping is easier to automate as a result. Despite this they 
have a far higher density across the canine genome with an average spacing of 
approximately 1 kb between SNPs, making them very useful for whole genome 
mapping approaches
23
.  
1.7.2 Candidate Gene Approach 
Candidate genes are genes that have been identified based on their function, expression 
patterns and/or association with similar diseases or traits in other species. In the case of 
ocular disease the number of candidate genes could be extremely high and screening all 
of them for variants would be labour-intensive, time-consuming and costly. Therefore 
polymorphic markers within close proximity to the candidate genes are identified and 
co-segregation of marker alleles with the disease examined and confirmed prior to 
undertaking more thorough investigations. Mutations are identified by searching for 
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differences in the genes between affected and unaffected dogs. Prior to the development 
of dense SNP maps, this strategy was frequently used as an easy way to interrogate the 
whole genome. However, this approach has proved to be inefficient with only 3.4% of 
published studies reporting probable retinal disease-causing mutations in dogs
90
, and as 
a result is seldom used nowadays. 
1.7.3 Linkage Analysis 
Family-based linkage studies examine the transmission of marker alleles through 
multiple generations of families in which a genetic disease or trait segregates. 
Previously microsatellite markers were most often used for linkage studies, but SNP 
markers can also be used. Using statistical methods, marker alleles that segregate with 
the trait more often than is expected at random are identified
90
. To reduce and define the 
size of the trait-linked locus identified, additional markers are often genotyped, 
followed by the analysis of candidate genes within the defined locus. A number of 
disease loci have been mapped by linkage analysis including canine progressive rod 
cone degeneration, and the mutation has since been identified
47,91,92
. A disadvantage of 
linkage studies is the requirement of complete data and samples from large families. 
Apart from the difficulty of obtaining sufficient samples and complete datasets, limited 
recombination within families often results in the identification of linked regions too 
large to follow up methodically and economically. 
1.7.4 Case-Control Association Analysis 
Association studies are similar to linkage studies in that the segregation of marker 
alleles with a genetic trait are compared in affected (case) and unaffected (control) 
cohorts, and statistical methods are used to ascertain whether this occurs more often 
than is expected if a random occurrence. The main difference from linkage studies is 
that unrelated dogs are used, making sample collection far easier. However, a much 
denser set of markers is required. Due to increased recombination within a population 
compared with within families, associated loci tend to be relatively small. 
Genetic association studies are commonly used to identify loci associated with certain 
traits or disease in many species. The difficulty in human studies is that, with the 
exception of relatively few closed breeding populations, the average LD in human 
populations, while highly variable, tends to be short. As a result at least 500,000 SNP 
markers
93
 and usually hundreds or even thousands of samples are required to conduct 
successful association studies. Currently arrays containing approximately one million 
SNPs are used routinely and arrays containing more than four million SNPs are 
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available.  However, the problem of adequate sample number remains the limiting 
factor for the detection of alleles without a very large effect on a multifactorial trait, or 
very rare alleles involved in a simple mendelian trait. For example, in order to detect an 
allele with a twofold increased risk (odds ratio = 2) with 90% power, 1,000 samples are 
required if the allele frequency is 0.3 and 6,000 if the frequency is 0.03
94
. In the case of 
heterogeneous diseases such as RP where it is difficult, if not impossible, to distinguish 
between diseases caused by different mutations at the ophthalmoscopic or clinical level 
and many of which are thought to be sporadic cases, association studies are not a 
feasible option for identifying mutations. In contrast, while PRA in dogs is 
heterogeneous between breeds, it is largely homogeneous within individual breeds. For 
the study of PRA in dogs therefore, genome wide association (GWA) mapping is 
particularly well suited.  
Since the assembly of the 7.5x canine reference sequence, the development of the 2.5 
million SNP map and the subsequent development of SNP arrays for the dog, case-
control association studies have become the method of choice for mapping canine 
genetic traits. Based on the unique LD patterns seen in dogs Lindblad-Toh et al. 
predicted that canine GWA studies could require as few as 15,000 evenly spaced SNP 
markers
23
. Karlsson et al. mapped the ridgeless allele in Rhodesian Ridgebacks to a 750 
kb region on chromosome 18 using only 9 ridgeless (case) and 12 ridged (control) dogs 
and approximately 27,000 markers
95
. The first arrays developed, which contained 
22,362 SNPs (CanineSNP20 BeadChip, Illumina) and 26,578 SNPs (Version 1 Canine 
array, Affymetrix), have both been discontinued and replaced by denser chips 
containing 49,663 SNPs (50K Version 2 Canine array, Affymetrix) and 173,662 SNPs 
(CanineHD BeadChip, Illumina). The number of samples required depends on the 
inheritance patterns of the trait under investigation: 20 each of cases and controls are 
recommended for simple Mendelian recessive traits with full penetrance, and 50 each of 
cases and controls for dominant traits. For complex traits a fivefold risk allele can be 
detected with 100 each of cases and controls, while a twofold risk allele requires 
approximately 500 each of cases and controls
96
. This is significantly less than the 1,000-
6,000 samples required to detect a twofold risk allele in human studies
94
.  
Due to the relatively long LD in dogs, loci identified through GWA studies can be large, 
up to 10 Mb. Cross-breed comparison of disease-associated loci could significantly 
benefit fine-structure mapping if the trait is shared by two or more breeds, provided they 
share the same genetic background
23
. By combining the SNP genotyping data from two 
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breeds, Boxers and Bull Terriers, in which the major white spotting S locus segregates, 
Karlsson et al. reduced the associated region to 102 kb, compared with 800 kb identified 
using boxers only, and a mutation in microphthalmia-associated transcription factor 
(MITF) was identified
95
. However, in the case of rare alleles segregating in only one 
breed or heterogeneous conditions such as PRA this across-breed strategy is usually not 
possible, and it may therefore not be possible to reduce trait-associated loci to an easily 
managed size. 
1.7.5 DNA Testing 
Upon identification of a causal mutation or markers associated with a disease, a DNA 
test can be developed. In the case of simple recessive, dominant and X-linked 
conditions, the availability of DNA tests to identify carriers of disease will allow 
breeders to make more informed decisions regarding the use of their breeding dogs. The 
hope is that by carefully selecting against a disease allele, the mutant gene can 
eventually be eliminated from a breed without adversely affecting the genetic diversity 
of the breed, as has been the case with canine leukocyte adhesion deficiency (CLAD) in 
the Irish Setter (IrS) breed. 
CLAD is a fatal immunodeficiency disease with an aR mode of inheritance. Kijas et al. 
identified a single missense mutation in the Integrin beta (ITGB2) gene
97
. This led to the 
development of a DNA test to identify dogs that carry or are affected with CLAD i.e. 
ITGB2
+/-
 or ITGB2
-/-
 respectively. The Animal Health Trust Genetic Services 
department (www.aht.org.uk/genetics_tests.html) has been testing IrSs for this mutation 
since 1999 and offers advice on breeding with carrier dogs. Over the years the 
proportion of mutant alleles in tested IrS populations from all over the world has 
decreased steadily (Figure 8). Since 2005 the Kennel Club has only registered IrSs that 
are genetically clear of CLAD implying that the disease has, in theory at least, been 
eliminated from the purebred IrS breeding population in the UK, or from the vast 
majority of the population at the very least. 
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Figure 8. CLAD alleles in the IrS population.  
DNA testing results for CLAD since 1999. The proportion of samples from dogs tested 
that have 1 or 2 copies of the ITGB2 mutation, calculated from the figures in the table, 
has shown a decreasing trend. The sharp decline seen since 2005 coincides with the 
removal of carrier dogs from UK breeding stock by many breeders. 
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1.8 Breeds Under Investigation 
Many dog breeds are prone to hereditary disease of some description, and more than 
100 breeds are affected by PRA. For this project, three main breeds, the Golden 
Retriever (GR), Tibetan Spaniel (TS) and Gordon Setter (GoS) breeds, were selected for 
initial investigation. Follow-up studies were conducted in other breeds considered likely 
to share any mutations with the GR, TS or GoS.  
1.9 Aims and Objectives 
This study was conceived with three main aims: 
1) Investigate the molecular basis underlying PRA.  
2) Establish a diagnostic DNA test to be commercially and publically available. 
3) Assess the relevance of findings to human retinal degenerations. 
The primary aim of this project (comprising points 1 and 2) was to investigate the 
molecular basis of canine PRA in three dog breeds, GRs, TSs and GoSs. This was done 
initially by mapping mutation-harbouring loci and then identifying probable PRA-
causing mutations in these breeds with PRA of unknown aetiology. Follow up studies 
such as population screening and investigation of the functional effects of each mutation 
were conducted where possible. Population screening allowed the determination of the 
prevalence of the mutation, which is required to offer suitable advice for breeding 
strategies. This is of particular benefit to the individual breeds as PRA could, in theory, 
be eliminated from each breed while avoiding significant loss of genetic diversity. 
Functional studies, while of limited benefit to the breeders or their dogs, may allow 
confirmation of whether probable disease causing mutations are certainly disease-
causing. Functional investigations could also reveal information about previously 
unknown or little understood genes or pathways. 
The secondary aim was to determine if any of the PRAs investigated are suitable 
models for equivalent human retinopathies. While not within the scope of the current 
project, PRA affected dogs could form the foundation of research colonies to be used 
for gene therapy investigations. Alternatively the results of the canine studies could 
provide novel candidate genes for unknown human retinopathies such as RP or LCA.  
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Chapter 2 Materials and Methods 
2.1 Canine DNA Sample Collection 
2.1.1 PRA Diagnosis and Sample Identification 
The diagnosis of individual dogs was determined by veterinary ophthalmologists. Many 
dogs were examined through the BVA/KC/ISDS Eye Scheme in the UK, the Swedish 
Kennel Club Eye Scheme in Sweden, or the Canine Eye Registry Foundation (CERF) in 
the USA, while others were independently examined. Cases were defined as dogs 
diagnosed as affected with PRA on the basis that they displayed ophthalmoscopic signs 
consistent with PRA including tapetal hyper-reflectivity, vascular attenuation and 
pigmentary changes in the non-tapetal fundus. Controls for the GWA studies were dogs 
free of inherited eye disease of any kind, and of a predetermined age or older at the time 
of examination (see section 2.3 and Table 3), depending on the breed under 
investigation. In subsequent investigations “unaffected” dogs were simply those of any 
age that had not been diagnosed with PRA. 
2.1.1.1 Exclusion of Known PRA Mutations 
PRA cases were screened for mutations known to cause PRA, if any were known, in the 
breed under investigation. DNA from 80 PRA-affected GRs and 46 PRA-affected LRs 
were screened for the prcd (progressive rod cone degeneration) mutation using the 
TaqMan® Allelic Discrimination (AD) technique (section 2.6.1.2). DNA from six IrS 
dogs affected with late-onset PRA were screened for the rod cone degeneration (rcd1) 
mutation using the Sanger sequencing method (section 2.6.1.3). For additional 
information regarding these techniques see sections 2.4.1.3-2.4.1.8 and 2.6.   
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2.1.1.2 Ophthalmoscopic Examination 
A number of dogs had retrospective ophthalmoscopic and other examinations on the 
basis of their affected genotypes at PRA loci. These included fundus examination, pupil 
reflexes in response to light, the ability to navigate obstacles in the dark and retinal 
function by ERG. ERGs were conducted in a darkened room, without dark adaptation or 
sedation, and responses to 12 flashes were measured for each eye to mitigate for muscle 
artefacts. 
2.1.2 Sample Collection 
2.1.2.1 Samples for DNA extraction 
All DNA samples were collected from privately owned pet dogs with the owners’ 
consent and where possible with copies of eye examination certificates and 5-generation 
pedigrees. All information pertaining to samples was used to establish relationships 
between individuals and draw pedigrees using the software package Progeny Lab 
(Progeny Software, LLC). Samples collected by the Animal Health Trust (AHT) were 
received in the form of residual blood samples (drawn for the purposes of a veterinary 
procedure) collected into EDTA tubes or cheek cells collected with buccal swabs, and 
were stored at -20°C until DNA was extracted. Samples collected from collaborators 
were received in the form of DNA in solution and were stored at -20°C. 
2.1.2.2 Samples for mRNA extraction 
A retinal tissue sample from a dog of unknown breed that was free of PRA was taken 
post mortem, with the owner’s consent. The retina was immersed in RNAlater 
(Ambion) to prevent RNA degradation, and stored at -20°C. 
Two blood samples, one from a Tibetan Spaniel with PRA and one from a healthy dog 
(breed unknown), were collected into EDTA tubes, kept at room temperature while in 
transit, and processed immediately upon receipt to extract RNA.  
2.1.3 DNA and RNA Extraction 
2.1.3.1 DNA Extraction from Blood 
Genomic DNA (gDNA) was extracted from whole blood using a protocol based on the 
Nucleon BACC2 Genomic DNA Extraction Kit (Tepnel Life Sciences). Briefly, 
Nucleon Reagent A (section 2.9) was added to up to 5 mL whole blood in a 50 mL 
conical tube (Falcon) to a total volume of 25 mL, and mixed by inversion for four 
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minutes to lyse the red blood cells. White blood cells were collected by centrifugation at 
4,300 x g for ten minutes, discarding the supernatant. To lyse the white blood cells, 2 
mL Nucleon Reagent B (section 2.9) was added to the pellet, which was then 
fragmented by vortexing and incubated at 37°C overnight. The solution was transferred 
to a 15 mL conical tube (Falcon) and protein precipitation was achieved by adding 800 
μL 5M sodium perchlorate and mixing by inversion. This was followed by the addition 
of 2 mL chloroform and mixing by inversion for 4 minutes. Centrifugation at 4,300 x g 
for 5 minutes facilitated the separation of the fluid phases to form three distinct layers, 
chloroform at the bottom, a layer of precipitated proteins in the middle and solution 
containing the DNA at the top. The DNA-containing aqueous phase was transferred to a 
new 15 mL tube and the protein precipitation stages (addition of chloroform and 
centrifugation) repeated. The top aqueous phase was again transferred to the new tube, 5 
mL ice cold absolute ethanol was added to precipitate the DNA, and the solution was 
slowly inverted until precipitated DNA became visible. Finally, a sealed glass hook was 
used to hook out the precipitated DNA, which was allowed to air dry and then washed 
off into a microcentrifuge tube with 300 μL 1X TE buffer (section 2.9).  
2.1.3.2 DNA Extraction of Buccal Mouth Swabs 
For samples collected as buccal mouth swabs, DNA was extracted using a QIAmp
®
 
DNA Blood Midi Kit (Qiagen) and an optimised protocol. Briefly, buccal cells were 
lysed by suspending up to four buccal swabs from a single donor in a solution of 1 mL 
phosphate buffered saline, 1 mL Lysis Buffer and 50 µL 20 mg/mL Proteinase K, in a 
15 mL conical tube (Falcon). The solution was incubated at 56°C for 20 minutes, during 
which time it was mixed by inversion briefly every 5 minutes. DNA was then 
precipitated by adding 1,000 µL absolute ethanol and mixing by vortexing. Precipitated 
DNA was collected by passing the solution through the filter units supplied in the kit by 
centrifuging at 1,500 x g for 5 minutes. DNA on the filter was then purified with two 
wash steps using wash buffers AW1 and AW2, each followed by centrifugation at 4,300 
x g for 1 minute and 15 minutes respectively. Finally the DNA on the filter was eluted 
by adding 150 µL Elution Buffer and centrifuged at 4,300 x g for 1 minute. The elution 
step was repeated twice, resulting in a final volume of approximately 450 µL. All 
extracted DNA samples were stored at -20°C. 
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2.1.3.3 Messenger RNA Extraction from Retina 
RNA was extracted from retinal tissue using an RNeasy Protect Mini Kit (Qiagen) 
according to the manufacturer’s instructions. Briefly, 15-20 mg RNAlater stabilised 
tissue was disrupted using a mortar and pestle, transferred to a new microcentrifuge tube 
and 600 µL Buffer RLT was added. The lysate was transferred to a QIAshredder spin 
column (Qiagen) in a 2 mL collection tube for homogenisation. After centrifugation at 
16,000 x g for 3 minutes the supernatant of the flow-through was transferred to a new 
microcentrifuge tube, without disturbing the pellet. 600 µL 70% ethanol was added to 
the lysate, mixed and 700 µL sample was transferred to an RNeasy spin column placed 
in a 2 mL collection tube. After centrifugation at 16,000 x g for 15 seconds the flow-
through was discarded, and the process repeated with the remaining sample solution. 
RNA on the spin column membrane was washed by adding 700 µL Buffer RW1 and 
centrifuging at 16,000 x g for 15 s. This was repeated a further two times using 500 µL 
Buffer RPE, centrifuging first for 15 seconds and then for 2 minutes. The RNeasy spin 
column was then transferred to a new 1.5 mL collection tube, and 50 µL ultrapure 
filtered water added to the membrane (Ultra Clear™ RO/EDI Water Purification 
System, hereafter termed UFWater) before centrifuging 16,000 x g for 1 minute to elute 
the RNA. Extracted RNA was stored at -20°C. 
2.1.3.4 Messenger RNA Extraction from Blood 
RNA was extracted from EDTA-stabilised whole blood using the PerfectPure RNA 
Blood Kit (5 Prime) according to the manufacturer’s instructions. Briefly, up to 3 mL 
whole blood was incubated with 3 volumes RBC Lysis Solution to facilitate red blood 
cell (RBC) lysis, followed by centrifugation at 2,000 x g for 2 minutes and removal of 
the supernatant to collect the white blood cells. White blood cells were then lysed by the 
addition of Lysis Solution and detergent tris(2-carboxyethyl)phosphine (TCEP). Nucleic 
acids were extracted by passing the lysate through a Purification Column at 16,000 x g 
for 2 minutes, and further purified through a number of wash steps, including the 
removal of DNA with the addition of DNase Wash Solution. Each wash step included 
centrifugation at 16,000 x g for 1 or 2 minutes. Finally RNA was eluted in 50 µL 
Elution Solution and collected by centrifugation at 16,000 x g for 1 minute.    
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2.1.4 DNA Normalisation 
DNA concentration and purity was determined by a NanoDrop 1000 spectrophotometer 
(Thermo Scientific) and/or a Qubit® Fluorometer with the Qubit® dsDNA BR Assay 
Kit (Invitrogen), and normalised to the required concentrations. Samples required for 
GWA mapping were normalised to a final concentration of 75 ng/µL and a final volume 
of 50 µL. Samples for target-capture and next-generation sequencing were normalised 
in 1X TE buffer to a final concentration of 25 ng/µL and a final volume of 120 µL. For 
“in-house” investigations such as mutation screening, microsatellite genotyping and 
Sanger sequencing, aliquots of DNA diluted with UFWater to concentrations of 
approximately 20 ng/µL were used. Samples with low concentrations were precipitated 
using MultiScreenHTS PCR filter plates or Amicon Ultra-0.5 mL Centrifugal Filters 
(Millipore) and resuspended in UFWater. 
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2.2 Polymerase Chain Reaction 
The polymerase chain reaction (PCR) is the targeted amplification of a specific section 
of DNA, and is used in a wide variety of applications. The basic principle of PCR 
involves 3 steps that are repeated approximately 30 to 40 times in sequence: 
1) Denaturation of the double-stranded DNA template at approximately 95°C. 
2) Annealing of the primers to complementary sequence on the denatured DNA at 
temperatures that are dependent on the melting temperature (Tm) of the primers, 
usually between 55°C and 60°C. 
3) Extension of the complementary strand from the 3’-end of the annealed primers, 
at approximately 72°C. 
2.2.1 Primers  
All primers for microsatellite genotyping (section 2.3.3), Sanger sequencing from 
gDNA or complimentary DNA (cDNA) (section 2.4.1 and 2.6.1.3), mutation screening 
by AD (section 2.6.1.2) or Amplified Fragment Length Polymorphism (AFLP; section 
2.6.1.1) analysis and quantitative PCR (qPCR; section 2.5), were designed with Primer3 
(Appendix II)
98
 to meet the following criteria:  
Size:   16-24 base pairs (bp), with an optimum length of 21 bp  
GC content:  40-60%, or 20-80% in GC-rich regions  
Tm:  57°C - 63°C, with an optimum of 60°C and a difference of no more than 
2°C between each primer pair.  
The sequence of each primer pair was blasted against the canine reference sequence, 
CanFam2.0, i.e. aligned with the reference sequence using BLAST, and pairs that 
produced more than 100 alignments were discarded. For primers intended for 
microsatellite genotyping an 18 bp tail (5’- TGACCGGCAGCAAAATTG -3’) was 
added to the 5’-end of each left/forward primer. A primer complementary to the tail was 
labelled with a fluorescent molecule, FAM or VIC (with blue and green fluorescence 
respectively) e.g. 5’-FAM-CAATTTTGCTGCCGGTCA-3’. One primer of each pair 
intended for AFLP was labelled with a fluorescent molecule, FAM. All primers with 
and without fluorescent tags, including PrimeTime Dual-Labelled Probes for AD, were 
purchased from Integrated DNA Technologies (IDT). 
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2.2.2 Thermal Cycling Reactions 
PCR reaction mixes varied between applications, and the reaction mixes and reagents 
used are listed in Appendix III. Amplitaq Gold® DNA Polymerase (Applied 
Biosystems) was used for all microsatellite genotyping reactions. HotStarTaq Plus DNA 
Polymerase (Qiagen) was used for most other PCR reactions. In the case of difficult to 
amplify templates, such as those with a particularly high GC content, an additive, Q 
solution, was also added. For a small number of amplicons amplification with 
HotStarTaq Plus was unsuccessful and either AmpliTaq Gold
®
 360 DNA Polymerase 
(Applied Biosystems) or Herculase II Fusion DNA Polymerase (Agilent Technologies) 
was used with 360 GC Enhancer and DMSO respectively added for GC-rich templates. 
All thermal cycling was performed with a MJ Research PTC-225 gradient cycler or a 
Bio-Rad T100™ thermal cycler.  
2.2.3 Thermal Cycling Parameters 
Each standard PCR reaction starts with an extended denaturation to ensure the genomic 
double-stranded DNA is completely denatured, followed by cycles of denaturation, 
annealing and extension, and finally an extended annealing period to ensure that all 
fragments in the mixture are completely amplified and identical. Variations of the 
standard reaction were used for some applications and protocols are listed in Appendix 
IV. The standard cycling protocol was used for AFLP and amplification for Sanger 
sequencing. An additional step at the end of the standard cycling protocol was added for 
AD to measure the fluorescent emissions in the reaction (allelic reads). Finally, PCR 
amplification for microsatellite genotyping made use of two sets of three-step cycles, 
one for amplification from the tailed-forward primer and reverse primer and another, at 
a lower annealing temperature, for amplification from the reverse primer and the tail-
complementary fluorescent primer.  
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2.3 Genome-Wide Association Mapping 
2.3.1 SNP Genotyping 
CanineSNP20 BeadChips or CanineHD BeadChips (Illumina Inc.) were used to obtain 
genotype calls for 22,362 and 173,662 SNPs respectively, using DNA from PRA cases 
and controls from four separate PRA cohorts (Table 3). Each BeadChip is a silica slide 
approximately the size of a standard microscope slide and contains millions of three 
micron beads. Each bead is covalently linked to hundreds of thousands of copies of a 
single locus-specific 50-mer oligo. Single-base, allele-specific extension of the oligo, 
and subsequent fluorescent staining of the extension enable identification of the allele at 
that locus. 
This genotyping was conducted externally by service laboratories (Wellcome Trust 
Sanger Institute in the UK; The Centre National de Génotypage (CNG) in France and; 
Cambridge Genomic Services in the UK), but briefly the procedure involved whole 
genome amplification of 750 ng genomic DNA followed by enzymatic fragmentation. 
Fragmented DNA was then ethanol precipitated, resuspended and hybridised to the 
oligos on the BeadChip. Each oligo was extended by a single base, determining the SNP 
allele, and fluorescently stained. An Illumina BeadArray Reader determined the 
fluorescence intensities.  
2.3.2 SNP Genotyping Data Analysis 
Processing of SNP genotyping data was almost identical for all four cohorts, regardless 
of service laboratory or SNP array used, with the exception of genotype calling for the 
GoS_PRA cohort. This data was processed through the LUPA consortium
99
, and 
therefore raw signal intensities were not released and genotype calls were made by the 
service laboratory (CNG). For the three remaining cohorts genotyping fluorescence 
signals were clustered and SNP alleles called automatically using GenomeStudio 
(Illumina). The resulting genotypes were imported into Progeny and assigned to the 
relevant samples and pedigrees. A GWA analysis was conducted using the software 
package PLINK
100
. SNPs with a minor allele frequency <0.05 or missing genotype calls 
>0.1 within each cohort were removed from the analysis. This significantly reduced the 
number of SNPs used in downstream analyses (Table 3) although it did improve the 
overall quality, as indicated by overall genotyping rates > 99% for each cohort. All 
samples had >90% of SNP genotypes called, with the exception of a single case from 
the GR_PRA2 study for which 80-90% of SNP genotypes were called. Many of the 
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dogs used in each cohort were known to be related through established pedigrees and 
therefore the presence of population stratification was expected. The extent of 
population stratification, represented by the inflation factor (λ) was calculated based on 
median χ2 values using the following process: 
χ2observed values were sorted from largest to smallest, and assigned a “rank” from 1 to 
the number of SNPs analysed (n). 
pexpected = (rank – 0.5)/n 
χ2expected was calculated using the pexpected and 1 degree of freedom 
λ = (Median χ2observed)/(Median χ
2
expected)  
For additional visualisation of population stratification, χ2observed and χ
2
expected values 
were used to create quantile-quantile (Q-Q) plots and multidimensional scaling (MDS) 
analysis of the 2x2 matrix of identity-by-state (IBS) pairwise distances was performed 
(Appendix I). Population stratification was corrected by IBS clustering based on the 
SNP genotypes, analysed for association within individual clusters and the results 
combined with a Cochran-Mantel-Haenszel (CMH) meta-analysis. As a correction for 
multiple testing, the GWA analysis was repeated using the Max(T) permutation 
procedure in PLINK (100,000 permutations). praw denotes p-values that have not been 
corrected for multiple testing, while pgenome denotes p-values that have. In the event of 
weak or insignificant association, an additional analysis, using a mixed model algorithm 
to correct for population stratification, was also conducted with Fast Mixed Model 
(FMM)
101
. For the purposes of plotting graphs using CMH- and FMM-generated data, 
the Bonferroni correction was applied to the significance level of 0.05: 
α = 0.05/n 
Where n is the number of SNPs remaining after filtering (Table 3). 
Finally, visual examination of SNP genotypes for homozygosity was performed to 
narrow and define critical regions. For the GR_PRA2 and TS_PRA cohorts PHASE was 
used for haplotype reconstruction
102
. 
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Table 3. SNP genotyping summary 
Cohort* SNP Array Cases Controls 
Age of 
Controls 
(years) 
Before filtering After filtering 
SNP 
genotypes 
Overall 
Genotyping 
Rate 
SNP 
genotypes 
Overall 
Genotyping 
Rate 
GR_ 
PRA1 
SNP20 
BeadChip 
27 19 8 22,362 0.9929 14,389 0.9984 
GR_ 
PRA2 
CanineHD 
Genotyping 
BeadChip 
10 16 7† 173,662 0.9842 103,264 0.9904 
TS_   
PRA 
SNP20 
BeadChip 
22 10 4 22,362 0.9903 15,674 0.9991 
GoS_ 
PRA 
CanineHD 
Genotyping 
BeadChip 
16 22 9 173,662 0.9895 107,982 0.9901 
 
* GR_PRA1 and TS_PRA were processed by the Wellcome Trust Sanger Institute in Cambridge, GR_PRA2 by 
Cambridge Genomic Services in Cambridge and GoS_PRA by The Centre National de Génotypage (CNG) in Paris. 
† 2 of the controls were younger than 7 years of age due to sample availability constraints. 
 
2.3.3 Microsatellite Genotyping 
Microsatellite markers within the targeted loci were identified by searching the 
reference sequence (CanFam2.0) for dinucleotide repeats with a total length of at least 
twenty nucleotides. Primers flanking each marker were designed as discussed in section 
2.2.1, and so that the resulting products would be between 200 and 400 base pairs in 
size. After amplification with the third, fluorescent primer complementary to the tail 
(sections 2.2.2 and 2.2.3), the products were separated by size on a 3100 or 3130xl 
Genetic Analyzer (Applied Biosystems) and the data analysed and alleles assigned to 
each sample with the GeneMapper software package (Applied Biosystems). 
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2.4 Sequencing of Loci and Candidate Genes 
2.4.1 Sanger Sequencing 
If functional candidate genes could be identified in the associated loci, as was the case 
in the GR_PRA1 (SLC4A3) and GoS_PRA (C2ORF71) cohorts, the gene sequence was 
compared between PRA-affected and unaffected dogs. Sanger sequencing of candidate 
genes was carried out on gDNA from six dogs of the breed under investigation that 
were included in the GWA study and made up of two PRA cases and four controls. For 
the GR_PRA1 cohort two out of four controls were obligate carriers i.e. dogs that are 
known to have produced PRA-affected offspring. DNA from one Miniature Long-
Laired Dachshund and one Border Collie were included as additional controls.  
In the GR_PRA1 cohort two variants in SLC4A3 that were considered potentially 
disease-causing were sequenced in 25 dogs, comprising 19 PRA cases and 6 controls.In 
the GR_PRA2 cohort a potentially disease-causing variant in TTC8 was sequenced in 
26 dogs, comprising 10 PRA cases and 16 controls. In the GoS_PRA cohort one variant 
in C2ORF71 that was considered potentially disease-causing was sequenced in 38 dogs, 
comprising 16 PRA cases and 22 controls. In the TS_PRA cohort two variants in exon 1 
of FAM161A were sequenced in 43 TSs and 76 dogs comprising 31 breeds. In addition, 
one potentially disease-causing variant in intron 4 was sequenced in 80 TS dogs, 
comprising 29 PRA cases, 10 obligate carriers and 41 unaffected dogs.  
Candidate genes in retinal and blood mRNA were also sequenced using the Sanger 
method. Amplification and sequencing protocols were identical to those of gDNA, with 
the exception that 2 µL cDNA was used as template DNA instead of gDNA. 
2.4.1.1 Canine Gene Annotation 
When genes annotated in CanFam2.0 are compared with orthologous genes in other 
species such as the human and mouse it is often found that potential exons are not 
identified or intron-exon boundaries are inconsistent between the dog and other species. 
For each gene identified an alignment was produced using the Ensembl predicted canine 
transcript and available known mouse and human Ensembl transcripts (Table 4). Exons 
to target through sequencing of gDNA and cDNA were defined based on a combination 
of CanFam2.0 annotation and a ClustalW
103
 alignment with orthologous genes. In 
addition, RNA-Seq data obtained from brain tissue (sequenced by Oliver Forman) was 
useful for confirmation of intron-exon boundaries of candidate genes.  
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Table 4. Ensembl gene identification numbers for alignment 
2.4.1.2 Complimentary DNA First Strand Synthesis 
Reverse transcriptase PCR was used to create and amplify double-stranded DNA from 
single-stranded retinal and blood mRNA. SuperScript®II Reverse Transcriptase 
(Invitrogen) was used for first-strand synthesis of cDNA. Briefly, 2 µL RNA (1 ng – 5 
µg), 1 µL Oligo(dT)15 Primer (500 µg/mL, Promega), 1 µL 10 mM dNTP mix (from 
100mM stock, Thermo Scientific) and 8 µL UFWater were mixed in a 200 µL tube, 
incubated at 65°C for 5 minutes on a thermal cycler and cooled to 4°C on ice. Added to 
this was 4 µL 5X First Strand Buffer, 2 µL 0.1 M Dithiothreitol (DTT) and 1 µL 
RNaseOUT™, followed by incubation at 42°C for 2 minutes on a thermal cycler. 
Finally 1 µL SuperScript™ II Reverse Transcriptase was added and the solution was 
incubated at 42°C for 50 minutes and then heated to 70°C for 15 minutes on a thermal 
cycler, and cDNA products were stored at -20 °C. 
2.4.1.3 Primers and Amplification 
All primers (Appendix II) were designed according to the criteria discussed in section 
2.2.1. Primers for the amplification of exons in gDNA were designed in the introns, 
flanking the exons. Primers for the amplification of cDNA were designed in the exons, 
flanking splice sites. In both cases the fragments were amplified by the standard PCR 
protocol. Reagents and thermal cycling conditions (sections 2.2.2 and 2.2.3) are listed in 
appendices II, III and IV. 
2.4.1.4 Agarose Gel Electrophoresis 
Prior to Sanger sequencing the success of PCR amplification was determined through 
agarose gel electrophoresis. Molecular grade agarose (Bioline) gels of 2% were used 
(e.g. 2 g agarose in 100 mL 1X TAE buffer, section 2.9). 3 µL ethidium bromide was 
added to the gel solution prior to casting. Once the gel had set it was completely 
submerged in 1X TAE buffer in the electrophoresis tank (PerfectBlue™ Gel System 
 Dog Gene Human Gene Mouse Gene 
SLC4A3 ENSCAFG00000015723 ENSG00000114923 ENSMUSG00000006576 
C2ORF71 ENSCAFG00000023626 ENSG00000179270 ENSMUSG00000044375 
SPATA7 ENSCAFG00000017354 ENSG00000042317 ENSMUSG00000021007 
TTC8 ENSCAFG00000017478 ENSG00000165533 ENSMUSG00000021013 
FAM161A ENSCAFG00000003079 ENSG00000170264 ENSMUSG00000049811 
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Mini L, PeqLab). 2 µL of each PCR product mixed with 5 µL STOP (section 2.9) was 
loaded into each lane in the agarose gel. As a size control 5 µL 2-Log DNA Ladder 
(New England Biolabs, section 2.9) was also loaded in one of the empty lanes. 
Electrophoresis was performed at 100-120 V for approximately 30 minutes, and gels 
were analysed using a FluorChem™ 5500 Imager (Alpha Innotech). Samples for which 
a single band of the expected size was visible were considered suitable for purification 
and sequencing. 
2.4.1.5 Purification of PCR Products 
Successful amplification was followed by purification of the PCR products to remove 
excess primers and PCR reagents. PCR products were purified using 96-well 
MultiScreenHTS PCR filter plates (Millipore) according to the manufacturer’s 
instructions. Briefly, 100 µL UFWater was added to the PCR product and this was then 
loaded into a well on the filter plate. The filter plate and vacuum manifold were 
assembled, and a vacuum of approximately 15 inches Hg was applied for 30 minutes, or 
until the wells appeared empty. The plate was then removed from the manifold, 20 µL 
UFWater was added to each well containing DNA, and samples were mixed on a 
rocking table (Luckham Ltd) for 20 minutes to allow full resuspension of the PCR 
products. Purified products were transferred to 96-well PCR plates for storage and 
further use. 
In some instances, individual PCR products were excised and purified directly from the 
agarose gel, using the QIAquick Gel Extraction Kit (Qiagen), according to the 
manufacturer’s instructions. Briefly, the DNA fragment was excised from the gel using 
a scalpel, weighed and added to Buffer QC. The agarose was solubilised by incubating 
at 50°C for 10 minutes, after which 100% isopropanol was added to precipitate the 
DNA fragments. The solution was applied to a QIAquick filter column and subjected to 
a series of washing steps. These comprised the addition of wash buffers, followed by 
centrifugation at 17,000 x g for 1 minute. Finally, the purified DNA was eluted in 30 μl 
Buffer EB for storage and further use. 
2.4.1.6 Sequencing Reaction 
For most exons or amplicons, the primers that were used for PCR amplification were 
also used for Sanger sequencing. For amplicons that were larger than approximately 600 
bp additional internal primers (Appendix II) were also used for Sanger sequencing to 
ensure complete coverage of the forward and reverse strands of the amplicon. 
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Amplification products were then sequenced using 2 µL purified PCR product, 0.5 µL 
BigDye Terminator v3.1 (Applied Biosystems), 1 µL SBDD buffer (section 2.9) and 1.5 
µL UFWater on a thermal cycler.  
2.4.1.7 Isopropanol Precipitation 
Excess reagents were removed from the sequenced product by precipitation. Briefly 50 
µL 80% isopropanol was added to each reaction in a 96-well plate, precipitating the 
DNA. DNA was collected at the bottom of the well by centrifugation at 2,600 x g for 30 
minutes. The supernatant was discarded by turning the plate upside down and allowing 
the liquid to drain out. This was followed by the addition of 100 µL 60% isopropanol to 
further purify the DNA, centrifugation at 2,600 x g for 10 minutes to collect the DNA 
and removal of the supernatant by draining upside down. The plate was then placed 
upside down on tissue, centrifuged at 160 x g for one minute and then dried at 37°C to 
remove all traces of isopropanol, thereby ensuring the purity of the pellet. The pellet 
was resuspended in 10 µL Hi-Di Formamide (Applied Biosystems) and analysed on a 
3100 or 3130xl Genetic Analyzer (Applied Biosystems), which generated raw sequence 
data for further analysis.  
2.4.1.8 Sequence Data Analysis 
Sequence traces were assembled, analysed and compared using Pregap4 and Gap4 in 
the Staden Package
104
. Raw sequencing data was processed through Pregap4 to 
determine where sequence quality was too low for alignment and convert the data 
format from ABI to ZTR, and create experiment files. Gap4 (Genome Assembly 
Program) is a graphical interface that was used to assemble and compare sequence 
reads, align and compare them to a reference sequence and view the sequence traces. 
2.4.2 Targeted Next Generation Sequencing 
Functional candidate genes could not be identified in a PRA-associated locus identified 
in the TS_PRA cohort at the time of experiment design. Multiple critical regions and 
candidate genes were identified in the GR_PRA2 cohort. For both of these cohorts 
therefore, the entire PRA-associated locus was sequenced in 10 samples, made up of 
PRA-affected and unaffected dogs. The TS_PRA cohort was made up of four PRA 
affected dogs and six unaffected dogs, including two obligate carriers. The GR_PRA2 
cohort was made up of five PRA cases and five unaffected dogs, including two obligate 
carriers. The loci chosen for sequencing in these cohorts were large (5 Mb for TS_PRA 
and 3.8 Mb for GR_PRA2) and next generation sequencing (NGS) was therefore the 
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most affordable and convenient method to do this. NGS with the Genome Analyzer II or 
HiSeq 2000 (Illumina), which uses sequencing-by-synthesis (SBS) technology (Figure 
9), enables massively paralleled sequencing and the process is made up of three parts: 
library preparation, cluster generation and sequencing. The library preparation was 
performed in-house, except where specified otherwise, but library samples were then 
sent to the High Throughput Genomics (HTG) group at The Wellcome Trust Centre for 
Human Genetics, University of Oxford, for cluster generation and sequencing on a 
HiSeq2000 platform (Illumina), in 51 bp paired end runs. 
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Figure 9. Next-generation sequencing using sequencing by synthesis technology. 
A) DNA library is prepared by fragmenting genomic DNA and adding adaptors. B) 
Cluster generation to amplify each DNA fragment. C) Sequencing one base at a time 
using fluorescently-labelled, reversibly-terminated nucleotides. Modified from 
http://www.illumina.com/documents/products/techspotlights/techspotlight_sequencing.
pdf  
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2.4.2.1 Library Preparation – RNA Baits 
A DNA library was prepared from each DNA sample (Figure 9A) using the 
SureSelectXT Custom MP4 Kits (Agilent Technologies), for the enrichment of targets 
between 1.5 Mb and 2.99 Mb. Each kit contained a custom Capture Library of 
biotinylated RNA baits, designed based on the CanFam2.0 reference sequence across 
the associated loci, using Agilent Technologies’ eArray tool 
(https://earray.chem.agilent.com/earray/). The following Optimised Parameters were 
selected for the Design Options: Centred design strategy (baits are designed from the 
centre of a region outwards), baits 120 bp in length, a 2x bait tiling frequency and a 20 
bp overlap into avoided regions. For the TS_PRA cohort baits were designed for a 5 Mb 
region on CFA10, from 63 to 68 Mb. For the GR_PRA2 cohort baits were designed for 
two regions on CFA8, one from 62.046 to 64.373 Mb (2.237 Mb) and the other from 
71.147 to 72.634 Mb (1.487 Mb), covering a total of 3.813 Mb. Repeating elements 
identified with the RepeatMasker program (www.repeatmasker.org) were avoided, 
resulting in baits covering 2.7 Mb for TS_PRA and 2.3 Mb for GR_PRA2. 
2.4.2.2 Library Preparation – Target Enrichment 
Target enrichment was performed according to the manufacturer’s instructions. Briefly, 
3 µg genomic DNA was prepared by shearing it to an optimum size of 150-200 bp using 
a Covaris S220 (Covaris; performed by the Eastern Sequence and Informatics Hub 
(EASIH), Cambridge). The fragmented DNA ends were repaired to create blunt-ended 
fragments with 5’-phosphorylated ends, a 3’-dA overhang added, followed by the 
ligation of indexing-specific paired-end adaptors and amplification of the adapter-
ligated library. After each step the samples were purified using Agencourt AMPure XP 
beads and a DynaMag™-2 Magnetic Particle Concentrator (Invitrogen). The quality and 
quantity of the amplified library was assessed with a NanoDrop. Half of the amplified 
library was then hybridised to the Capture Library (RNA baits), and hybrids selected 
using Dynabeads® M-280 Streptavidin (Invitrogen) magnetic beads and purified using 
the AMPure beads, both with the magnetic concentrator. Finally, unique Illumina index 
tags were added to each capture library by amplification and purified using the AMPure 
beads. The quality of the captured library was assessed with a 2100 Bioanalyzer 
(Agilent Technologies; performed by the Eastern Sequence and Informatics Hub 
(EASIH), Cambridge). The quantity of the captured library was assessed by qPCR using 
the KAPA Library Quantification Kit for the Illumina Genome Analyzer Platform 
(KAPA Biosystems), according to the manufacturer’s instructions. Briefly, a 20 µL 
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reaction volume was used, made up of 10 µL 2X KAPA SYBR® FAST Universal 
qPCR Master Mix, 2 µL 10X Illumina Genome Analyzer Primer Premix, 4 µL 
UFWater and 4 µL library DNA (diluted 1:1,000 with Library Dilution Buffer, section 
2.9) or 4 µL  DNA standard. Reactions were performed in triplicate, on an Eco Real-
Time PCR System (Illumina) (Table 5). 
Table 5. Quantitative PCR thermal cycling conditions 
Average concentrations (pM) determined through qPCR were adjusted to account for 
differences in the average length of the DNA library and the length of the standards 
(452 bp) with the formula: 
     
   
 
   
Where C is the adjusted concentration, A is the average concentration (pM) determined 
by qPCR, S is the average size of the fragments (bp) as determined by Bioanalyzer 
analysis and D is the dilution factor (1,000 in this project) used during qPCR. 
Finally, all ten captured libraries were then pooled in equimolar amounts for 
multiplexed sequencing using the formula 
 i = 
 f   Cf
n   C
 
Where Vi is the initial volume of sample required, Vf is the final volume required (20 
μL), Cf is the final concentration required (10 nM), n is the number of samples in the 
pool (10) and C is the size-adjusted concentration calculated above, and converted from 
pM to nM. The final volume, if less than 20 μL, was adjusted with 1X TE buffer to 20 
µL at 10 nM. 
2.4.2.3 Cluster Generation 
During cluster generation (Figure 9B) individual molecules of the prepared, pooled 
library are amplified in a flow-cell in preparation for sequencing. The adaptors to which 
the single-stranded library fragments are ligated bind to a lawn of oligos on the surface 
of the flow-cell. Bound fragments are extended to form double-stranded molecules and 
Step Description Temp Duration 
Initial activation / denaturation 95 °C 5 minutes 
Denaturation 95 °C 30 sec 
X35 
Annealing / extension / data acquisition 60 °C 45 sec 
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the adapter on the unattached end also binds covalently to the flow-cell surface, forming 
a bridge. Through a series of expansions, bridge amplifications and denaturation each 
library fragment is clonally amplified, creating millions of unique clusters of DNA 
fragments. The reverse strands are removed, leaving only single-stranded DNA 
molecules attached to the flow-cell at one end. Finally the free ends are blocked and 
sequencing primers are hybridised to the DNA templates. 
2.4.2.4 Next Generation Sequencing 
The Illumina systems utilise SBS technology (Figure 9C), which means that DNA 
templates are sequenced in parallel on a base-by-base basis. Four fluorescently-labelled 
nucleotides compete to bind to the template. These bases are also reversibly-terminated 
so that in each round of synthesis extension by only a single base is possible. After each 
round clusters are excited by a laser, resulting in the emission of a colour that is unique 
to the newly bound base. Following laser excitation the blocking molecule and 
fluorescent label are cleaved from bound nucleotides, allowing the addition of the next 
base. The first 51 bases of each fragment, from both ends of the fragment were 
sequenced, resulting in 51 bp paired-end reads. The resulting data was subjected to the 
HTG group’s standard analysis pipeline: Illumina base-calling pipeline; Illumina index 
tag identification and subsequent separation of generated data into ten batches, one for 
each sample; alignment to the CanFam2 reference genome using Stampy
105
 and quality 
control.  
2.4.2.5 NGS Data Analysis 
Sequence data was received from the HTG group in the form of raw FASTQ files 
containing millions of sequence reads 51 bp in lengths and BAM files containing reads 
already aligned to CanFam2.0. These were run through an analysis pipeline created by 
PhD candidate Oliver Forman at the AHT, made up of various analysis tools (Figure 
10), discussed below. I created a second analysis pipeline to assess target capture 
efficiency using the sequencing data. Both pipelines were written using the Perl 
programming language and the code, demonstration video clips and relevant files can be 
found on the CD in Appendix VI. 
The BWA (Burrows-Wheeler-Alignment) tool aligns short sequences to the reference 
sequence (CanFam2.0) by assigning chromosomal coordinates to each read, creating a 
read file in the SAM (Sequence Alignment/Map) format
106. The “short” algorithm was 
used as reads were <200 bp in length. This algorithm has a low error rate (<3%), 
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supports paired-end reads and is one of the fastest available. SAMtools enables 
manipulation of SAM and BAM (Binary Alignment/Map) files
107
. It was used to 
remove PCR duplicate reads, by retaining from multiple read pairs with identical 
chromosomal coordinates only the pair with the highest mapping quality. It was also 
used to index the reference FASTA and read BAM files. Picard 
(http://picard.sourceforge.net) is a java interface comprising a number of utilities that 
manipulate SAM files to create BAM files in which the reads were sorted by their 
chromosomal coordinates. The “CalculateHSMetrics” function of Picard was used in 
the Target Capture Efficiency pipeline to measure metrics for each sample, including 
total number of reads generated, average read depth and efficiency of target capture. 
GATK (Genome Analysis Toolkit) provides a Java programming framework for 
writing tools for the analysis of next generation sequencing
108
. A number of built-in 
analysis tools were used in the analysis pipeline, including base quality score 
recalibration to improve the accuracy of base quality scores, identification of indels and 
SNPs, and depth of coverage calculations. The Variant Effect Predictor from Ensembl 
predicts the effects of variants on transcripts and regulatory regions annotated in 
Ensembl
109
. Pindel
110
 identifies large deletions (1 bp – 10 kb) and medium insertions (1 
-16 bp), and their breakpoints. However, in our experience Pindel proved extremely 
unreliable and seldom produced any results at all. The Integrative Genomics Viewer 
(IGV) is a visualisation tool for large datasets, and was used to visually explore and 
examine NGS data
111,112
. This included visual inspection for larger changes not 
identified by any tools in the analysis pipeline. 
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Figure 10. Next generation sequencing analysis pipeline.  
The steps, tools and specific commands with tools used in the pipeline are indicated. 
Either two or three input files are required for the analysis of paired-end reads: a 
reference file in FASTA format and either two read files in FASTQ format or one read 
file in BAM format. 
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2.5 Quantification of mRNA transcripts 
Quantitative real time PCR (qPCR) was performed using KAPA SYBR
®
 FAST 
Universal 2x qPCR Master Mix (Kapa Biosystems, Appendix III) on an Eco Real-Time 
PCR System (Illumina, Appendix IV). Target primers (Appendix II) were designed 
based on sequence determined through sequencing of mRNA. For each target a standard 
curve was established using a 1:2 dilution series of retinal cDNA, from which the 
amplification efficiency (E) of each reaction was determined. Melt-curve analysis was 
conducted using target primers to identify the generation of primer-dimers. Expression 
levels of the targets were ascertained using the comparative cycle threshold (Ct) 
method, where two technical replicates were averaged. Due to variable E between 
targets, relative expression (RQ) levels were normalised to two housekeeping genes
113
, 
ACTB (β-Actin) and TBP (TATA box binding protein), using the Pfaffl method, i.e. 
based on E and Ct
114
, according to the formula: 
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2.6 Variant Screening 
2.6.1 Variant Screening Methods 
The method employed to detect previously known mutations or to create DNA tests for 
mutations identified during the course of this project were largely dependent on the type 
of mutation, as well as the cost and equipment available. For descriptions of primers 
and thermal cycling see section 2.2. 
2.6.1.1 Amplified Fragment Length Polymorphism Analysis 
AFLP analysis was preferred when the mutation was an insertion or deletion (indel) that 
resulted in a change in the size of an amplicon. A pair of primers, one of which is 
fluorescently-labelled, was used to amplify by PCR the region containing the mutation. 
In this way, products that differed by as little as a single base-pair in size could be 
separated and accurately identified using a 3100 or 3130xl Genetic Analyzer and 
GeneMapper software (Applied Biosystems).  
2.6.1.2 TaqMan® Allelic Discrimination 
AD analysis provided a convenient method to identify SNPs  that do not affect the size 
of an amplicon. This method makes use of allele-specific fluorescently labelled probes 
to determine which alleles are present. Each probe is labelled with a unique fluorescent 
reporter on the 5’-end and a quencher on the 3’-end. As long as the reporter and 
quencher are in close proximity, as they are when attached to the same probe, the 
quencher absorbs the energy emitted by the reporter dye. However, when the primer 
hybridises to a complementary DNA template in a PCR reaction the quencher is cleaved 
by the 5’- to 3’-exonuclease activity of polymerase. The resulting spatial separation of 
the reporter and quencher increases the fluorescence of the reporter dye. By determining 
which reporter dye is fluorescing, the allele-specific primer that is hybridizing with the 
DNA template, and therefore the allele, can be identified. Briefly, the region containing 
the mutation was amplified using a pair of primers and at the same time allele-specific 
PrimeTime Dual-Labelled Probes, labelled with 6-FAM or HEX reporters and Black 
Hole Quencher® 1, were hybridised to the mutation. PCR amplification and AD plate 
read and analysis were carried out on a Techne Quantica Real Time Thermal Cycler 
with the Quansoft software (Bibby Scientific). 
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2.6.1.3 Sanger Sequencing 
Sanger sequencing (sections 2.4.1.3-2.4.1.8) is preferred to screen small numbers of 
samples for indels or SNP mutations. The same primers are used to amplify and 
sequence the region containing the mutation.  
2.6.2 Population Screening of Variants 
An appropriate screening method (as discussed in section 2.6.1) was selected for rapid 
and cost-effective mutation screening. In the case of all four mutations identified in this 
project an AFLP assay was designed and optimised for each. Population screening of 
disease-causing mutations was done in two stages for each cohort. 
2.6.2.1 Sample Cohorts Collected for Research 
As many samples as possible from the breed under investigation and samples from 
related breeds, with known PRA clinical statuses and submitted to the AHT for research 
purposes, were screened (Table 6). 
Table 6. Research samples screened for each mutation
*
 
PRA-1 PRA-2 PRA-3 RCD4 
709 GR 
(80 A, 39 C, 590 U) 
475 GR 
(33 A, 5 C, 437 U) 
247 TS 
(35 A, 16 C, 196 U) 
126 GoS 
(22 A, 104 U) 
132 LR 
(16 A, 116 U) 
70 LR 
(17 A, 53 U) 
76 TT 
(12 A, 64 U) 
19 IRWS 
(3 A, 16 U) 
49 CBR 
(2 A, 47 U) 
48 CBR 
(2 A, 46 U) 
23 LA 
(9 A, 7 C, 7 U) 
72 IrS 
(10 A, 62 U) 
92 FCR 
(92 U) 
59 FCR 
(59 U) 
 
56 ES 
(6 A, 5 C, 45 U) 
   
98 TT 
(17 A, 81 U) 
   
92 SP 
(1 A, 91 U) 
 
* PRA clinical status: A = Affected, C = Obligate Carrier, U = Unaffected, LR =Labrador Retriever, CBR = 
Chesapeake Bay Retriever, FCR = Flat Coat Retriever, TT = Tibetan Terrier, LA = Lhasa Apso, IRWS = Irish Red 
and White Setter, IrS = Irish Setter, SP = Standard Poodle. 
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2.6.2.2 Genetic Services Testing Data 
Genetic Services at the AHT offer DNA tests to the public for three of the four variants 
identified, PRA-1, PRA-2 and RCD4, using the same AFLP assays described above. 
The second stage of population screening made use of data obtained by Genetic 
Services over time for allele frequency calculations (Table 7). χ2 statistics and p-values 
were calculated to test the hypothesis that the observed genotypes conform to Hardy 
Weinberg Equilibrium (HWE; P = 0.05, degrees of freedom = 1).  
Table 7. Samples screened for each mutation through the AHT Genetic Services* 
PRA-1 PRA-2 RCD4 
855 GR (26 months) 425 GR (6 months) 1,788 GoS (24months) 
  2,249 IrS (18 months) 
  60 TT (3 months) 
 
* The duration for which the test has been available for each breed is indicated in brackets 
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2.7 Human Variant Identification 
2.7.1 Sample Identification and Collection 
Variant screening of SLC4A3 in samples from 200 unrelated patients with retinal 
degeneration was performed. These included samples from 192 sporadic cases of aRRP, 
as well as samples from eight individuals with familial recessive retinal degenerations 
(five aRRP, one rod monochromasy, one retinal dystrophy and one cone-rod 
dystrophy). For all eight familial samples a locus containing SLC4A3 had previously 
been identified through autozygosity mapping. Samples were identified at Moorfields 
Eye Hospital using standard techniques, and were of mixed ethnic origin. In adherence 
with the Declaration of Helsinki informed consent for genetic studies was obtained. 
Samples were normalised to 20 ng/µL in ultrapure Milli-Q filtered water (Millipore), 
hereafter termed MQ. 
2.7.2 Sanger Sequencing of SLC4A3 
The process of Sanger sequencing of human samples, from primer design through to 
trace analysis with Staden, was largely similar to that of canine samples (sections 
2.4.1.3-2.4.1.8). Instances where slightly different protocols were used are described 
here. 
2.7.2.1 Purification of PCR Products 
PCR products were purified using Multiscreen PCRµ96 filter plates (Millipore) 
according to the manufacturer’s instructions. Briefly, 75 µL MQ was added to the PCR 
product and this was then loaded into a well on the filter plate. The filter plate and 
vacuum manifold were assembled, and a vacuum of approximately 20 inches Hg was 
applied until the wells appeared empty (approximately 10 minutes). An additional 50 
µL MQ was added to each well and the vacuum applied until wells appeared empty. 
The plate was then removed from the manifold, 20 µL MQ was added to each well 
containing DNA, and samples were mixed on a Vortex-Genie 2 at low speed (Scientific 
Industries, Inc.) for 10 minutes to allow full resuspension of the PCR products. Purified 
products were transferred to 96-well PCR plates for storage and further use. 
2.7.2.2 Sequencing Product Clean-up 
Excess reagents were removed from sequenced products using the Montage SEQ96 
Cleanup Kit (Millipore), according to the manufacturer’s instructions. Briefly, 25 µL 
Injection Solution was added to the sequencing product and this was then loaded into a 
well on the filter plate. The filter plate and vacuum manifold were assembled, and a 
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vacuum of approximately 20 inches Hg was applied until the wells appeared empty 
(approximately 10 minutes). An additional 25 µL Injection Solution was added to each 
well and the vacuum applied until wells appeared empty. The plate was then removed 
from the manifold, 20 µL Injection Solution was added to each well containing DNA, 
and samples were mixed on a Vortex-Genie 2 at low speed (Scientific Industries, Inc.) 
for 10 minutes to allow full resuspension of the sequencing products. Purified products 
were transferred to 96-well PCR plates and then run on a 3730 Genetic Analyzer 
(Applied Biosystems).  
2.7.2.3 Variant Pathogenicity Analysis 
The potential pathogenicity of variants identified were assessed with various 
bioinformatics tools, described in section 2.8. This included novelty of the variants and 
their predicted effect on exon splicing, amino acid sequence and protein function. 
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2.8 Bioinformatics Tools 
The Ensembl genome browser (www.ensembl.org) was used for examining the canine 
(CanFam2.0), human (GRCh37) and mouse (GRCm38) assemblies. BLAST (Basic 
Local Alignment Search Tool) and BLAT (BLAST-Like Alignment Tool) on the 
Ensembl genome browser (http://www.ensembl.org/Multi/blastview) were used to 
assess primer quality and identify the exact genomic location of all variants. ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) is a multiple sequence alignment tool, 
suitable for DNA and protein sequence alignment, and was used mainly to compare 
orthologous DNA sequences. A Splice site prediction tool, NNSPLICE0.9
115
 
(http://www.fruitfly.org/seq_tools/splice.html), was used to identify any variants that 
may affect intron splicing. The Single Nucleotide Polymorphism database, dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/), the 1000 Genomes browser 
(http://browser.1000genomes.org/index.html) and the Exome Variant Server (EVS; 
http://evs.gs.washington.edu/EVS/) were used to determine whether any of the human 
variants discovered were novel and to determine allele frequencies of those SNPs 
previously identified through the 1000 Genomes Project and the NHLBI GO Exome 
Sequencing Project. Three tools were used to assess potentially pathogenic SNP 
variants. Firstly, SIFT (Sorting Intolerant From Tolerant - http://sift.jcvi.org/) predicts 
whether amino acid substitutions are likely to affect protein function based on the 
degree of conservation of amino acid residues
116
. Secondly, PolyPhen (Polymorphism 
Phenotyping - http://genetics.bwh.harvard.edu/pph/) predicts the possible impact of an 
amino acid substitution on the function and structure of a protein, using physical and 
comparative considerations
117
. Finally, PMut (http://mmb2.pcb.ub.es:8080/PMut/) 
predicts the pathological character of amino acid mutations  based on the use of neural 
networks trained with a large database of neutral and pathological mutations
118
. The 
ExPaSy Bioinformatics Resource Portal (http://expasy.org) is a database of 
bioinformatics tools
119
, two of which were used: The Translate tool translates DNA 
sequence into amino acid sequence and the Compute pI/Mw tool calculates the 
theoretical isoelectric point and molecular weight of a protein. 
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2.9 Buffers and Solutions 
Nucleon Reagent A: 6.304 g Tris Hydrochloride, 438.12 g Sucrose, 4.066 g MgCl2, 40 
mL Triton X-100, Make up to 4 L with UFWater, Adjust to pH 8.0 with 40 % NaOH. 
Nucleon Reagent B: 63 g Tris Hydrochloride, 22.3 g EDTA, 8.8 g NaCl, 800 mL 
UFWater, Adjust to pH 8.0 with 2M NaOH, Adjust to 1 litre with UFWater and then 
add 10 g Sodium Dodecyl Sulphate (SDS). 
1X TE Buffer (10mM Tris-HCL, 0.1mM EDTA): 10 mL  1 M Tris-hydrochloride, 2 
mL 500 mM EDTA, Add UFWater to 1 L, Adjust to pH 8.0. 
STOP: 10 mL Glycerol, 4 mL 500 mM EDTA, 1 mL 1M Tris, 1 mL Bromophenol blue. 
Diluted 1:5 with 1X TAE Buffer. 
50X TAE Buffer: 242 g Tris base, 57.1 mL Glacial acetic acid, 37.2 g EDTA, Add 
double-distilled water to 1 L, Adjust to pH 8.0. 
2-Log DNA ladder: 120 µL  STOP, 240 µL 1X TAE Buffer, 40 µL 500 µg/mL 2-Log 
DNA ladder. 
SBDD Buffer: 160 mL 1M Tris base, 3 mL 1 M MgCl2, 50 mL 
Tetramethylenesulphone, 290 mL UFWater. 
Library Dilution Buffer (LDB): 200 µL 1M Tris (10 mM Tris), 10 µL Tween (0.05% 
Tween), 19.79 mL UFWater. 
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Chapter 3 Golden Retrievers 
3.1 Introduction and background 
The GR breed is one of the most popular and recognisable breeds worldwide. As with 
many traditional “working” breeds, GRs can broadly be split into two groups based on 
whether they come from working or non-working breeding lines, with the latter 
consisting mostly of pets, but also show dogs. These dogs are easy to train due to their 
extraordinary intelligence and affable nature and are therefore very well suited to be 
working dogs in a wide variety of areas. While still used in their traditional role as gun 
dogs to retrieve game, the breed are now used in a variety of other areas including guide 
dogs for the blind and deaf, rescue dogs, and therapy for the physically and mentally 
disabled. The GR breed is one of the more genetically heterogeneous breeds and has a 
relatively short LD (D’=0.5 at 400-700kb) in comparison with breeds such as the Akita 
(D’=0.5 at 2.4 Mb)89. Due to the popularity of the breed there is little importing and 
exporting of dogs for breeding, relative to the size of the breeding population. As such, 
dogs from different continents in particular tend to form distinct genetic populations
120
, 
an important factor to consider when undertaking genetic mapping studies. GRs are 
prone to a large number of hereditary diseases including hip and elbow dysplasia, PRA, 
epilepsy, cataracts and muscular dystrophy
121
. The origin of the GR breed can be traced 
back to a mating of an ancestor of the modern day Flat-Coated Retriever (FCR) to a 
Tweed Water Spaniel (now extinct) in the mid-19
th
 century. The FCR in turn, along 
with Labrador Retriever (LR) and Chesapeake Bay Retriever (CBR), can be traced back 
to the St Johns Water dogs from the St Johns region of Newfoundland, Canada, also in 
the 19
th
 century
122
. All four breeds are also known to be affected by PRA and due to 
their common ancestors they could share PRA mutations(s). In the case of the LR breed 
the main form of PRA has been identified as prcd
47
, but there is at least one additional, 
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unknown form of PRA in the breed. A very small number of GRs in the USA also have 
PRA caused by the prcd mutation, but it does not account for most PRA cases, and none 
of the European dogs tested (OptiGen®; http://www.optigen.com). It is therefore 
thought that there is at least one other form of PRA in this breed. This chapter describes 
the identification of the causal mutations for two additional forms of PRA in the breed, 
termed PRA-1 and PRA-2. 
3.2 Diagnoses and Clinical Findings 
PRA in the GR is ophthalmoscopically indistinct from most other forms of PRA. 
Typical ophthalmoscopic signs include tapetal hyper-reflectivity, attenuated blood 
vessels and optic nerve atrophy (Figure 11). The average age at diagnosis in our sample 
cohort, which is indicative of age of onset, is 6.02 years, but ranges from 1 to 11 years 
of age.  
 
Figure 11. Fundus changes observed in typical PRA in GRs. 
A) The fundus of a healthy GR. B) The fundus of a GR displaying signs typical of PRA. 
Due to the advanced stage of disease, the tapetum has gone dark (after a period of 
hyper-reflectivity), the blood vessels are attenuated and the optic disc is pale. The 
photos were taken on the same day from littermates that were 6 years old. 
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3.3 Prcd Variant Screening 
DNA samples were collected from 80 GRs with PRA, of which 50 were from Sweden, 
and the remainder from the UK (n=9), France (n=8), Finland (n=3), Canada (n=3) and 
the USA (n=7). To exclude the possibility that the PRA-affected GRs were positive for 
the mutation already known to cause prcd, all 80 of our GR cases were investigated for 
the previously described, aR prcd mutation
47
 (as described in sections 2.2 and 2.6.1.2). 
None of the affected GRs tested in this study was found to be homozygous for the prcd 
mutation. A single individual was heterozygous (G/A) while the remaining 79 were 
homozygous for the wild type (normal) allele (G/G). 
3.4 SNP Genotyping 
3.4.1 Genome Wide Association Mapping 
GWA analysis of genotyping data from 46 GR dogs, (27 cases and 19 controls) 
genotyped with 14,389 SNPs (section 2.3) revealed a genome-wide significant 
association on chromosome 37 (CFA37; praw = 1.14x10
-11
, pgenome = 1.0x10
-5
). IBS 
clustering using genome-wide SNP marker data confirmed the presence of population 
stratification with a genomic inflation factor > 1 (λ = 1.44) and MDS analysis revealed a 
similar distribution of cases and controls (Appendix I). The signal on CFA37 remained 
strong (praw = 1.94x10
-10
) after correction for this by analysing for association with a 
CMH meta-analysis (Figure 12A). However, the inflation factor was increased (λ = 
1.46), indicating that population stratification had not been corrected for. The signal 
remained significant after correction for multiple testing using permutations (pgenome = 
1.0x10
-5
). Before and after CMH-correction, the strongest statistically associated SNP 
was BICF2G630131493 at 29.277 Mb. Alternative analysis of the data using FMM to 
correct for population stratification revealed similar results, with the strongest signal on 
CFA37 (praw = 4.13x10
-11
; Figure 12B) and a reduced inflation factor (λ = 0.96). After 
FMM-correction the strongest statistically associated SNP was BICF2S23032414 at 
29.252 Mb. A number of weaker signals were seen on other chromosomes including 7, 
19, 24 and 29, but none reached the level of significance (pgenome = 0.05). The 
statistically associated region on CFA37, defined as the region encompassing permuted 
SNPs statistically associated with PRA, extended from 28.331 to 29.847 Mb (data not 
shown) with the strongest statistically associated SNPs indicated (Figure 12C).  
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Figure 12. Genome-wide association mapping of PRA in GRs 
-Log10 of p-values after correction for population stratification. The red lines indicate 
the Bonferroni-corrected 5% significance level based on 14,389 SNPs. A) The CMH 
meta-analysis approach shows a statistically significant signal on CFA37 (praw = 
1.94x10
-10
, pgenome = 1.00x10
-5
). B) The FMM approach also shows a statistically 
significant signal on CFA37 (praw = 4.13x10
-11
). C) Statistically associated SNPs span a 
1.64 Mb region from 28.331 Mb to 29.847 Mb on CFA37. 
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3.4.2 Homozygosity Analysis 
Visual examination of SNP genotypes revealed two overlapping homozygous regions 
on CFA37 from 27.813 to 29.277 Mb and 28.633 to 29.878 Mb (Figure 13A) and most 
of the PRA cases (23/27) analysed were homozygous for one or both of these regions. 
These homozygous regions overlap from 28.633 to 29.277 Mb on CFA37 (Shared 
Block in Figure 13A) and this 644 kb region was defined as the PRA critical region. It 
is likely that the four dogs that do not carry the haplotype associated with the critical 
region are affected with a form of PRA that is genetically distinct from that addressed 
here. The average age at diagnosis of the 27 cases used in the GWA study was 6.41 
years. When these four cases were excluded the average age at diagnosis in the 
remaining 23 cases increased to 6.78 years, ranging from four to 11 years of age. These 
four dogs had a lower age at diagnosis (4.25, ranging from three to five years) than the 
rest of the dogs in the cohort. This is consistent with a different form of PRA 
segregating in these four dogs.  
There are 27 genes within the PRA critical region, of which 25 have orthologous genes 
in humans (Figure 13B and Appendix V).  Nonhomologous end-joining factor 1 
(NHEJ1) has been associated with Collie Eye Anomaly, an ocular condition clinically 
distinct from PRA
35
. It is therefore unlikely, although not impossible, that this gene is 
harbouring any PRA-causing mutations. None of the remaining 24 genes had previously 
been associated specifically with ocular function or retinal degeneration in humans, 
however a solute carrier anion exchanger gene (SLC4A3) located within this region was 
identified as a strong candidate based on function and its association with retinal 
degeneration in mice. SLC4A3 mediates Cl
-
/HCO3
-
 exchange across cellular 
membranes
123
 and is expressed in various tissues including the Müller and horizontal 
cells of the retina
124
. The effect of SLC4A3-deficiency has been described in a knockout 
mouse model showing that a selective inner retina defect is followed by photoreceptor 
degeneration
125
, similar to the retinal degeneration seen in many forms of PRA and RP. 
SLC4A3 was therefore considered an excellent candidate gene for further investigation. 
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Figure 13. Homozygosity analysis of GRs with PRA 
A) SNP genotypes for 27 PRA cases and 19 PRA controls, encompassing the 1.6 Mb 
region identified during the GWA study. Fifteen of the cases share a homozygous 
haplotype of eight SNPs (Left Block) and 15 cases share another homozygous 
haplotype of nine SNPs (Right Block). These two homozygous blocks overlap by just 
one SNP (Shared Block), defining a critical region of 644 kb between 28.633 Mb and 
29.277 Mb on CFA37. Four of the cases do not share any haplotypes with the other 23 
cases, but do share haplotypes with the controls. The strongest statistically associated 
SNPs are indicated by arrows (↓). B) There are 27 genes found within the critical 
region, as annotated on CanFam2.0. 
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3.5 Sequencing of Candidate Gene SLC4A3 
3.5.1 Characterising SLC4A3 Retinal Transcripts in Dog Retina 
SLC4A3 occurs in two main isoforms, full-length (SLC4A3fl) and cardiac (SLC4A3c), 
formed by alternative splicing of the N-terminal exons (Figure 14)
124,126
. Alignment of 
canine, human and mouse genomic and coding sequences revealed several 
inconsistencies and possible errors in the prediction of intron-exon boundaries of canine 
SLC4A3 (Figure 14A-C). These included missing exons that are probably due to gaps in 
the reference sequence, perhaps due to extremely high GC content in these regions.  All 
of the coding sequence of the SLC4A3 retinal transcripts, from both the main isoforms 
(SLC4A3fl and SLC4A3c), was successfully amplified and sequenced in a healthy dog 
(sections 2.2 and 2.4.1) revealing that both isoforms are transcribed in the canine retina. 
In addition, intron-exon boundaries were confirmed to be identical to those of the 
human and mouse, which is in conflict with the boundaries predicted by Ensembl 
genebuild for the canine gene (Figure 14D). Alternative splicing of exon 5 of the full-
length isoform results in two “full-length” isoforms that differ by the presence 
(SLC4A3fl1) or absence (SLC4A3fl2) of 27 nucleotides at the 5’ end. Amplification of the 
full 5’ and 3’ untranslated regions (UTR) for any isoform was unsuccessful. Sequencing 
of the retinal mRNA transcripts of all three isoforms revealed that canine SLC4A3fl1 
(Genbank accession no HQ379706) contains 1237 amino acids, SLC4A3fl2 (Genbank 
accession no HQ379707) contains 1228 amino acids and SLC4A3c (Genbank accession 
no HQ379708) contains 1030 amino acids, with predicted molecular weights of 
136kDa, 135kDa and 114kDa respectively. SLC4A3fl1 is considered the reference 
transcript for the remainder of this document; the terms SLC4A3fl and SLC4A3fl1 are 
therefore interchangeable. 
3.5.2 Sanger Sequencing of SLC4A3 
Primers for the sequencing of gDNA were designed to ensure sequencing coverage of 
the known exons as well as the probable 5’- and 3’-UTRs for both full-length and 
cardiac isoforms of SLC4A3 (sections 2.2 and 2.4.1).  To identify possible causal 
variants in SLC4A3, 20 of the 23 SLC4A3 exons and splice sites were sequenced in 
gDNA from six GRs and two non-GR dogs (a Border Collie and a Miniature Long Hair 
Dachshund). The GRs comprised two PRA-affected dogs that were homozygous for the 
“affected haplotype” at the critical region, two obligate carriers that were heterozygous 
for the “affected haplotype” and two unaffected dogs that were homozygous for a 
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wildtype haplotype. The CanFam2.0 reference sequence and annotation for SLC4A3 
was incomplete and includes two gaps that cover exons 1, 2 and 7 of the gene (Figure 
14D). All attempts at sequencing across the two gaps (including combinations of 
various thermal cycling parameters, primers based on canine and human reference 
sequence, and Taq polymerases) were unsuccessful and these three exons were therefore 
not sequenced. Comparison of the sequence data with the canine reference genome 
sequence revealed 50 sequence variants. Five of the sequence variants showed perfect 
segregation with PRA within the eight samples sequenced, and of these two were 
exonic (Figure 14D). Splice-site predictions (section 2.8), when taking the variants into 
consideration, revealed neither the introduction of novel splice sites nor the eradication 
of existing splice sites, although the prediction scores for splice sites involving two of 
the intronic variants were altered slightly (data not shown). Two of the five variants are 
exonic and non-synonymous. An A to C transversion at position 44 (c.A44C; 
CFA37:29,141,439) that results in a nonsynonymous substitution (p.Q15P) was found 
in the first exon of the cardiac specific isoform, but did not affect the full-length isoform 
(Figure 15B). The second exonic change was a frame shift caused by the insertion of a 
single cytosine in exon 16 of the full-length isoform (c.2601_2602insC; 
CFA37:29,147,633). It is predicted to cause a premature stop codon in exon 18 
(p.E868RfsX104) possibly resulting in degradation of the mRNA by nonsense-mediated 
decay (NMD) or a truncated protein product (Figure 15B). Exon 16 is included in both 
the cardiac specific isoform and the full-length isoform of SLC4A3
124
. 
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Figure 14. Graphical comparison of intron-exon boundaries of SLC4A3. 
A) Mouse (Mus muscularis) SLC4A3. B) Human (Homo sapiens) SLC4A3. C) Canine 
(Canis familiaris) SLC4A3 as predicted by Ensembl genebuild. Sixteen of the genebuild 
exons predicted are identical to the mouse and human exons (black), but the intron-exon 
boundaries of exons 1, 4, 5 and 7 (grey) are inconsistent. Exon 6 (grey) shows no 
sequence similarity to its human and murine equivalents and is probably incorrect. D) 
Canine SLC4A3 exons confirmed by sequencing the retinal mRNA transcript. The 
locations of the five fully-segregating sequence variants are indicated.  
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Figure 15. Effect of SLC4A3c.A44C and SLC4A3c.2601_2602insC on the SLC4A3 protein. 
A) The wildtype full-length 1 and 2, and cardiac isoforms are encoded by 1,237, 1,228 
and 1,030 amino acids respectively. The proteins differ only at the N-terminus with 280 
amino acids unique to the full-length isoform 1, and 73 unique to the cardiac isoform. 
The remainder of the protein is identical in all isoforms. The C-terminal cytoplasmic 
domain is represented by “C”. B) The cardiac isoform alone is affected by the c.A44C 
SNP variant (p.Q15P). All isoforms are affected by the c.2601_2602insC variant. 867 
amino acids at the N-terminus of the full-length mutant protein and 660 of the cardiac 
isoform are unaffected. However the insertion causes a shift in the reading frame 
introducing 104 amino acids, leading to a premature termination codon. This results in a 
truncated protein product, lacking 266 residues of the C-terminus of both isoforms, if 
expressed. 
3.5.3 SLC4A3c.2601_2602insC Variant Validation 
A total of 25 GR dogs (19 cases and 6 controls present in the GWA data set) were then 
screened (section 2.4.1) for the two coding variants, SLC4A3c.A44C and 
SLC4A3c.2601_2602insC, to investigate the association of both these variants with PRA and 
compare them with the most highly associated SNP, BICF2G630131493. The 
genotypes of the two variants i.e. homozygous for the reference allele, heterozygous or 
homozygous for the rare variant were concordant in all but two dogs (data not shown), 
indicating the two variants are in very close linkage disequilibrium. SLC4A3c.2601_2602insC 
was more strongly associated (praw = 4.1x10
-6
) than SLC4A3c.A44C or 
BICF2G630131493 (praw = 1.2x10
-5
 and praw = 9.5x10
-5
 respectively). Neither variant 
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shows complete concordance with PRA, but SLC4A3c.2601_2602insC has a stronger 
likelihood of a deleterious effect on the protein i.e. it affects both transcripts shown to 
be present in dog retina and is a frame-shift rather than missense. SLC4A3c.A44C was also 
predicted to be benign by PolyPhen and PMut. A comparison among 33 eutherian 
mammals (data not shown) showed that the position is not well conserved, indicating 
that the missense sequence variant may not be functionally important. This variant was 
therefore considered to be non-pathogenic and discarded from further analysis. Analysis 
of the segregation of SLC4A3c.2601_2602insC with PRA in a family of Swedish ancestry 
(Figure 16) indicates that the form of PRA associated with this mutation, known 
hereafter as PRA-1, is recessive and fully penetrant. Fifty-six percent of the GR PRA 
cases in our sample cohort were homozygous for SLC4A3c.2601_2602insC (SLC4A3
-/-
), while 
eight were heterozygous (SLC4A3
+/-
) and 27 were homozygous for the wildtype allele 
(SLC4A3
+/+
, section 3.8.1). PRA-1 and prcd therefore, do not account for 35/80 PRA 
cases in our cohort. A second study was subsequently undertaken to identify the third 
form of PRA in the breed, known hereafter as PRA-2, using these 35 cases (see section 
3.6). The average age at diagnosis in this sample cohort is 5.27, but ranges from 2 to 11 
years of age. 
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Figure 16. Segregation of PRA-1 in a GR pedigree. 
The segregation of PRA-1 is consistent with an autosomal recessive mode of 
inheritance. The PRA-1 mutant allele (SLC4A3c.2601_2602insC) is represented by “-“ and 
the wildtype allele by “+”. A single dog (#29) that is homozygous for the PRA-1 mutant 
allele (-/-), had not been diagnosed with PRA, but did show ophthalmoscopic signs 
consistent with the early stages of PRA at the age of 6 years. Clinical information 
pertaining to and DNA samples from individuals 1-4 and 22 were unavailable. Samples 
used in the GWA study are indicated (*). 
  
91 
Chapter 3 – Golden Retrievers 
3.6 SNP Genotyping (PRA-2) 
3.6.1 Genome Wide Association Mapping 
GWA analysis of genotyping data from 26 GR dogs (10 cases that are not PRA-1 or 
prcd, and 16 controls) genotyped with 103,264 SNPs (sections 2.3.1 and 2.3.2) revealed 
a genome-wide significant association, using permutations, on chromosome 8 (CFA8; 
praw = 1.30x10
-6
, pgenome = 0.036). IBS clustering using genome-wide SNP marker data 
confirmed the presence of population stratification with a genomic inflation factor > 1 
(λ = 1.32). MDS analysis revealed an uneven distribution of cases and controls 
(Appendix I), but this could be due to the low number of samples used, and could 
therefore not be corrected. The signal on CFA8 remained the strongest signal (praw = 
8.99x10
-5
) after correction for this by analysing for association with a CMH meta-
analysis, although it did drop below the level of genome-wide significance (Figure 
17A). The inflation factor was reduced to less than optimal (λ < 1), suggesting an over-
correction for population stratification (λ = 0.84). The signal remained below the level 
of significance after correcting for multiple testing (pgenome = 0.148). This region on 
CFA8, nevertheless, showed the strongest signal, 10-fold greater than that observed 
anywhere else on the genome. The region extended from 63.600 to 71.732 Mb with the 
most significantly associated SNP, BICF2G630416812, at 71.732 Mb. Further 
investigation of the signal on CFA8 revealed that it was formed by two apparently 
independent and distinct signals at 63.614 Mb (BICF2P582923; praw = 1.16x10
-4
; pgenome 
= 0.197) and 71.732 Mb (BICF2G630416812; praw = 8.99x10
-5
; pgenome = 0.148) 
respectively (Figure 17C). These loci are hereafter referred to as locus 1 and locus 2 
respectively. A second analysis (section 2.3.2) using FMM to correct for population 
stratification identified two signals in the same regions (as described above) on CFA8 
(Figure 17B and C): praw = 1.82x10
-4
 at 63.614 Mb (BICF2P582923) and praw = 
1.42x10
-5
 at 71.732 Mb (BICF2G630416812). While these p-values have not been 
corrected for multiple testing they are consistent with the results observed during the 
CMH meta-analysis (Figure 17C). Using FMM to correct for population stratification 
resulted in a greatly reduced inflation factor (λ = 0.27), far below the optimum level of λ 
= 1, suggesting an over-correction for population stratification. The small sample size 
might also skew the corrected inflation factor.  
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Figure 17. Genome-wide association mapping of PRA2 in GRs 
-Log10 of p-values after correction for population stratification, using two approaches. 
The red lines indicate the Bonferroni-corrected 5% significance level, based on 103,264 
SNPs. A) The CMH meta-analysis approach shows the strongest signal on CFA8 (praw = 
8.99x10
-5
, pgenome = 0.148). B) The FMM approach also shows the strongest signal on 
CFA8 (praw = 1.42x10
-5
).   C) Two distinct signals can be seen at 63.614 Mb and 71.732 
Mb.  
  
93 
Chapter 3 – Golden Retrievers 
3.6.2 Homozygosity and Haplotype Analysis 
A haplotype at either locus 1 or locus 2 that was homozygous in all cases but not 
controls could not be identified through visual examination of SNP genotypes (Figure 
18). BICF2P582923 (pgenome = 0.197) at locus 1 is homozygous (T/T) in 6/10 cases, but 
either heterozygous (T/C) or homozygous for the alternate allele (C/C) in all the control 
samples. Similarly, BICF2G630416812 (pgenome = 0.148) at locus 2 is homozygous 
(T/T) in 6/10 cases, but either heterozygous (T/C) or homozygous for the alternate allele 
(C/C) in all the control samples. The signals at loci 1 and 2 could not be clearly defined, 
with no obvious homozygous haplotype unique to affected individuals.  However, a 437 
kb region was identified upstream of locus one on CFA8 from 62.647 to 63.084 Mb, for 
which all of the PRA cases analysed were homozygous (“Homozygous Block”, Figure 
18A). Five of the controls were also homozygous for the “affected” haplotype in this 
region. There was also a larger region, from 62.526 Mb to 63.263 Mb (“Affected 
Haplotype”, Figure 18A), over which the haplotypes of most of the cases are different 
from those of the controls at locus 1. Inferred phasing (section 2.3.2) of 21 SNP markers 
spanning this 737 kb region revealed the presence of six alleles, only one of which was 
homozygous in 8/10 cases but none of the controls (Haplotype number 1 in Figure 19). 
While it is possible this is the “PRA-2” allele, the possibility that the observed 
inheritance pattern of this haplotype is coincidental and the PRA-causing mutation is 
actually near BICF2P582923 or BICF2G630416812 could not be discounted. Therefore 
PRA critical regions were defined at these loci to ensure coverage of all of these 
elements and extend from 62.046 to 64.373 Mb and from 71.147 to 72.634 Mb, 
comprising regions of 2.327 and 1.487 Mb respectively, and 3.814 Mb in total. Critical 
region 1 contains 17 genes, 14 of which have human orthologues (Figure 18B and 
Appendix V). Spermatogenesis associated protein 7 (SPATA7) has been associated with 
juvenile aRRP and aRLCA
127
, and tetratricopeptide repeat domain 8 (TTC8) with BBS 
and aRRP
128-130
. Critical region 2 contains 11 genes, all of which have human 
orthologues. None of these 11 genes have previously been associated with ocular 
function or retinal degeneration in humans. SPATA7 and TTC8 are both within the 
“Affected Haplotype” and were therefore both excellent candidate genes for further 
investigation. Due to the identification of two loci and two candidate genes, the critical 
regions surrounding both loci were selected for further investigation, specifically by 
targeted resequencing. 
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Figure 18. Homozygosity analysis of GRs with PRA2 
A) SNP genotypes for 10 PRA cases and 16 PRA controls, over the two regions 
identified during the GWA study, encompassing loci 1and 2. BICF2P582923 (pgenome = 
0.197) is indicated with the upper arrow at locus one. BICF2G630416812 (pgenome = 
0.148) is indicated with the lower arrow at locus 2. A homozygous block from 62.647 to 
63.084 Mb and a larger homozygous “Affected Haplotype” are upstream of locus 1. 
Critical regions 1 and 2 encompass all of these elements. B) There are 17 and 11 genes 
found within critical regions 1 and 2 respectively, as annotated on CanFam2.0 (taken 
from Ensembl genome browser). SPATA7 and TTC8 were provocative candidate genes.  
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Figure 19. Haplotype analysis in GRs with PRA2.  
SNP genotypes for 10 PRA cases and 16 PRA controls, over the 737 kb “Affected 
Haplotype” identified during the GWA study. Inferred phasing of the 21 SNP markers 
revealed six unique haplotypes, each of which was assigned a colour and number. 
Haplotype number 1 (yellow) is the “Affected Haplotype”. 
3.7 Sequencing of PRA-2 Critical Regions 
3.7.1 Target Enrichment of PRA-2 Critical regions 
Custom-made RNA baits (section 2.4.2.1) were designed based on the CanFam2.0 
reference sequence covering critical regions 1 (CFA8:62,045,807-64,372,549 bp) and 2 
(CFA8:71,147,444-72,634,192 bp); regions 2.327 and 1.487 Mb in size respectively, 
and 3.814 Mb in total. As repeat masking was applied to avoid repetitive elements, baits 
were designed over 2.254 Mb, 59% of the total region with an average GC content of 
46.9%. 
Target enrichment of 10 gDNA samples (five cases, two obligate carriers and three 
controls) with the custom RNA baits was performed (section 2.4.2.2) and the captured 
libraries for each sample had concentrations ranging from 4.14 nM to 12.40 nM. 
Samples were pooled and the final library contained 27.7 μL captured DNA at a 
concentration of 7.2 nM. While this is below the 10 nM recommended by the 
manufacturer, it was not possible to repeat the target enrichment. From this study we 
now know that libraries with concentrations <10 nM are sufficient for successful 
sequencing. 
  
96 
Chapter 3 – Golden Retrievers 
3.7.2 NGS Data Analysis – Target Capture Efficiency 
More than 400 million reads were generated in total (section 2.4.2.5), across all 10 
samples sequenced. Approximately 30% of these reads were PCR duplicates and 
therefore removed from further analysis. A total of >287 million reads remained, 97% 
of which  mapped to CanFam2.0. Target capture efficiency is represented by the 
percentage of bases that map to the targeted regions, and was relatively similar between 
the 10 samples processed, with an average of 72.8% (Table 8). Approximately 74% of 
bases had >30x coverage and average read depth was 427x.   
Table 8. Capture efficiency for PRA-2 targeted NGS 
Sample 
no. 
Clinical 
Status 
Mean 
coverage of 
baited region 
Bases mapped 
to targets (%) 
Bases with 
>10X 
coverage (%) 
Bases with 
>20X 
coverage (%) 
Bases with 
>30X 
coverage (%) 
1 Affected 423x 75.30 78.65 76.01 73.84 
2 Affected 392x 72.73 77.27 74.48 72.21 
3 Affected 441x 72.95 78.07 75.57 73.55 
4 Affected 485x 74.25 77.76 75.39 73.47 
5 Affected 404x 70.38 79.18 76.59 74.55 
6 Carrier 388x 74.24 77.93 75.39 73.25 
7 Carrier 460x 70.49 79.80 77.38 75.55 
8 Unaffected 350x 74.32 77.67 74.97 72.73 
9 Unaffected 427x 73.73 78.76 76.31 74.38 
10 Unaffected 503x 70.04 79.12 76.84 75.06 
 Average 427x 72.84 78.42 75.89 73.86 
 
3.7.3 NGS Data Analysis – Variant Identification 
More than 25,000 SNPs and 2,400 indels were identified when the NGS sequence was 
compared with the CanFam2.0 reference sequence (section 2.4.2.5). Of these, 658 SNPs 
and 168 indels segregated with the phenotype, of which only two variants were 
predicted to alter a protein product. One was a non-synonymous substitution in exon 12 
of the SPATA7 gene (CFA8: 62,735,867 bp; c.A1378G), resulting in a missense variant 
(p.Thr459Ala). The other provocative variant was a single base (adenine) deletion in an 
exon of TTC8 (CFA8: 63,129,154; Figure 20). 
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Figure 20. IGV display of the 1-bp deletion in TTC8  
Each of the three samples (PRA-affected, obligate carrier and control) viewed in IGV 
are represented by two panels. The upper panel is a histogram where the height of each 
column is representative of the read depth at that location. The lower panel is a 
graphical view of a subset of the reads that align to that location. The “A” nucleotide 
indicated is absent in almost all reads in the PRA-affected sample, approximately half 
the reads in the obligate carrier sample and none of the reads in the PRA-unaffected 
(control) sample. 
3.7.4 Characterising SPATA7 and TTC8 Retinal Transcripts 
TTC8 occurs in three isoforms in humans. Two isoforms are created by alternative 
splicing of exon 5
128
, the functional implications of which are unknown. Both isoforms 
are ubiquitously expressed and only the larger isoform (containing exon 5, TTC8) was 
therefore taken as the reference sequence. A third retinal isoform containing exon 2A 
(TTC82A) has also been identified
130
. Only a single isoform of SPATA7 has been 
reported
131
. As was the case with SLC4A3 in section 3.5.1, several inconsistencies and 
possible errors were identified in the canine SPATA7 and TTC8 gene predictions 
(SPATA7: data not shown; TTC8: Figure 21).  
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All of the coding sequence of the SPATA7 and TTC8 retinal transcripts were 
successfully amplified and sequenced in a healthy dog (sections 2.2 and 2.4.1) revealing 
that both genes are transcribed in the canine retina. The presence of the SPATA7 variant, 
c.A1378G, in the retinal mRNA transcript from a healthy dog as well as limited 
conservation in 35 eutherian mammals (data not shown) suggested the variant is 
unlikely to be pathogenic and it was therefore eliminated from further investigation. A 
TTC8 isoform lacking exon 5 was not detected, however two isoforms of TTC8 were 
found to be transcribed in the canine retina and intron-exon boundaries are identical to 
those of the human and mouse (Figure 21), which is in conflict with the boundaries 
predicted by Ensembl genebuild for the canine gene. One canine TTC8 retinal isoform 
was found to contain exon 2A. Amplification of the full 5’ and 3’ UTRs was 
unsuccessful. Sequencing of the retinal mRNA transcripts of both isoforms revealed 
that canine TTC8 (Genbank accession no JQ941743) encodes 505 amino acids and 
TTC82A (Genbank accession no JQ941742) encodes 515 amino acids, with predicted 
molecular weights of 57.571 kDa and 58.247 kDa respectively. 
The exonic 1 bp deletion detected by NGS was a frame-shift variant, caused by the 
deletion of a single adenine in exon 8 (c.669delA, CFA8:63,129,154). It is predicted to 
cause a premature stop codon (p.Lys223ArgfsX15), possibly resulting in the 
degradation of mRNA by NMD or a truncated protein product (Figure 22). TTC8c.669delA 
affects both isoforms of the protein.  
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Figure 21. Graphical comparison of the intron-exon boundaries of TTC8. 
A) Mouse (Mus muscularis) TTC8. B) Human (Homo sapiens) TTC8. C) Canine (Canis 
familiaris) TTC8 as predicted by Ensembl genebuild. Thirteen of the genebuild exons 
predicted are identical to the human and mouse exons (black). Exon 2 (grey) differs at 
the 3’ intron-exon boundary. Exons 3, 8, 9 and 10 (grey) show no sequence or size 
similarity to their human or murine equivalents and are probably incorrect. D) Canine 
TTC8 exons confirmed by sequencing of the retinal mRNA transcript. Exon 2A was not 
predicted by Ensembl genebuild. The location of the sequence variant is indicated. 
 
Figure 22. Effect of TTC8c.669delA on the TTC8 protein 
A) The normal retina-specific and ubiquitous isoforms encode 515 and 505 amino acids 
respectively. The proteins differ only with the presence or absence of 10 amino acids 
unique to the retina-specific isoform (grey). The remainder of the protein is identical in 
both isoforms. B) Both isoforms are affected by the c.669delA mutation. 233 amino 
acids at the N-terminus of the retina-specific protein and 223 of the ubiquitous isoform 
are normal. However the deletion causes a shift in the reading frame of 15 amino acids, 
leading to a premature termination codon. This results in a truncated protein product, 
lacking 267 residues of the C-terminus of both isoforms. More than half of the protein is 
therefore absent. 
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3.7.5 TTC8c.669delA Variant Validation 
All 26 GR dogs (10 cases and 16 controls) that participated in the GWA study for the 
coding variant, TTC8c.669delA, were then screened (section 2.4.1) to confirm the 
association of this variant with PRA and compare it with the most associated SNP 
markers, BICF2P5829231 and BICF2G630416812, without correcting for population 
stratification. TTC8c.669delA showed significant allelic association with PRA (Praw = 
6.31x10
-7
, Pgenome = 0.019) and was more strongly associated than BICF2P582923 (Praw 
= 5.79x10
-6
, Pgenome = 0.109) or BICF2G630416812 (Praw = 1.30x10
-6
, Pgenome = 0.036). 
Eight out of ten PRA cases and none of the controls were homozygous for TTC8c.669delA. 
While the variant shows incomplete association with PRA, it has a strong likelihood of 
a deleterious effect on the protein. In addition, the nucleotide and the amino acid 
affected by TTC8c.669delA is conserved in 32 eutherian mammals (data not shown). 
Analysis of the segregation of TTC8c.669delA with PRA in a family (Figure 23) indicates 
that the form of PRA (known as PRA-2) associated with this variant is recessive and 
fully penetrant. 
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Figure 23. Segregation of PRA-2 in a GR pedigree 
The segregation of PRA-2 is consistent with an autosomal recessive mode of 
inheritance with full penetrance. The PRA-2 variant allele is represented by “-“ and the 
wildtype allele by “+”. Clinical information pertaining to and DNA samples from 
individuals 1-7 was unavailable. Samples used for the GWA study are indicated (*). 
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3.7.6 PRA-2 Phenotype Questionnaire 
Mutations in TTC8 have been associated with RP and BBS in humans
128-130
, but only 
one of the GRs in our cohort that was homozygous for TTC8c.669delA was reported to 
have clinical signs other than PRA. These were “hormonal changes and thyroid 
problems”, the precise nature of which are unknown.   
A questionnaire (Appendix VII) was sent to the owners of dogs with PRA-2 to assess 
the presence of systemic clinical signs in addition to PRA. Only two of these 
questionnaires were returned: 
1) A bitch, diagnosed with PRA at the age of 5.9 years, was reported to be in good 
health. She was small for the breed, at 30kg was overweight for her size and 
gained weight easily. She had undergone metabolism tests, and while not 
treated, the results were considered borderline. The owner also reported a 
behavioural anomaly i.e. she had never been able to catch a ball in the air, which 
is unusual for a GR. 
2) A dog, diagnosed with PRA at 2.9 years, was reported to be in good health until 
his death at 9 years, from cancer. At 52 cm tall, he was considered small for the 
breed (males typically range from 58 cm to 61 cm), but was not overweight. The 
owner also reported a behavioural anomaly i.e. he was aggressive towards 
certain people when in the home, but not outside. Interestingly, he also appeared 
to have a poor sense of smell, which is very unusual for a GR. 
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3.8 Population screening of SLC4A3c.2601_2602insC and 
TTC8c.669delA 
3.8.1 Research Sample Cohorts 
An additional 661 GR dogs were screened to confirm that the SLC4A3c.2601_2602insC 
mutation is not a commonly occurring polymorphism in this breed, making a total of 
709 GRs tested (Table 9). Of the confirmed PRA cases, 56.3% were homozygous for 
SLC4A3c.2601_2602insC (SLC4A3
-/-
) and 87.2% of obligate carriers were heterozygous 
(SLC4A3
+/-
). The majority of dogs (99.6%) known to be clinically free of PRA were 
either carriers of the mutant allele (9.2%; SLC4A3
+/-
) or homozygous for the wild type 
allele (90.4%; SLC4A3
+/+
). These GRs were from a number of different countries 
including known PRA cases from the UK, Sweden, France and the USA (data not 
shown). The mutation described here accounts for 55.6% and 76.0% of PRA cases from 
the UK and Sweden respectively. However it accounts for only a minority of PRA cases 
from France and Finland, 12.5% and 33.3% respectively, and none of the cases from the 
USA.  
Table 9. SLC4A3 genotypes and PRA clinical status for 709 GRs 
 PRA Affected PRA Carrier PRA Unaffected Unknown Total 
SLC4A3
-/-
 
45 1 2 0 48 
56.3% 2.6% 0.4% 0% 6.8% 
SLC4A3
+/-
 
8 34 47 11 100 
10.0% 87.2% 9.2% 13.9% 14.1% 
SLC4A3
+/+
 
27 4 462 68 561 
33.8% 10.3% 90.4% 86.1% 79.1% 
Total 80 39 511 79 709 
 
An additional 634 GR dogs were tested for TTC8c.669delA to confirm that the mutation is 
also not a commonly occurring polymorphism in this breed, making a total of 660 GRs 
(Table 10). Of the 35 confirmed PRA cases used in the study 22 (62.9%) were 
homozygous for TTC8c.669delA (TTC8
-/-
) and all 513 dogs known to be clinically free of 
PRA at their last eye examination, including five obligate carriers of PRA, were either 
carriers of the mutant allele (3.9%; TTC8
+/-
) or homozygous for the wild type allele 
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(96.1%; TTC8
+/+
). PRA-2 accounts for the majority of cases of PRA that are not PRA-1 
in all countries, excluding Canada (data not shown). 
Table 10. TTC8 genotypes and PRA clinical status for 660 GRs 
 PRA Affected PRA Carrier PRA Unaffected Unknown Total 
TTC8
-/-
 
22 0 0 0 22 
62.9% 0.0% 0.0% 0.0% 3.3% 
TTC8
+/-
 
1 2 18 4 25 
2.9% 40.0% 3.5% 3.6% 3.8% 
TTC8
+/+
 
12 3 490 108 613 
34.3% 60.0% 96.5% 96.4% 92.9% 
Total 35 5 508 112 660 
 
The allele frequency of PRA-1 is 0.14 based on all 709 GRs submitted to the AHT for 
the research purposes (Table 11). This is not unusually high, even for a recessive 
disease allele. The allele associated with primary lens luxation in terrier breeds has 
similar frequencies in many terrier breeds
132
. The allele frequency of PRA-2 is 0.05, 
based on all 660 GRs submitted to the AHT for the research purposes (Table 11). This 
is also not unusually high for an autosomal recessive disease allele in dogs. The GR 
cohorts screened contained samples collected for the purposes of research, including all 
available samples from dogs clinically affected with PRA, and samples from PRA-
unaffected dogs closely related to affected dogs and to one another. This cohort was 
therefore subject to considerable sampling bias. This, combined with the relatively 
small number of samples screened, has resulted in a cohort that does not conform to 
HWE (Table 11). A subset of the GR cohort that was unrelated at the parent level and 
from the UK, was selected for allele frequency estimations (n=88, Table 11, collected 
and genotyped by Bryan McLaughlin and Lou Hayward, AHT). These samples were 
collected for the purpose of estimating disease allele frequencies in the breed, and as 
such clinical history pertaining to these dogs is unknown. Analysis of PRA-1 and PRA-
2 using only this cohort resulted in reduced allele frequencies, and this cohort does 
conform to HWE (Table 11). This suggests that the high degree of relatedness between 
samples and sampling bias are a major cause of deviation from HWE.  
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Table 11. GR population screening for PRA-1 and PRA-2 
 
Observed Genotypes* HWE 1-in-__ Expected 
Breed -/- -/+ +/+ TOTAL 
Allele 
Freq 
χ2 P Affected Carrier 
Research Cohorts 
PRA-1 48 100 561 709 0.138 118.00 1.73x10
-27
 52 4 
PRA-1 UK 
(Unrelated) 
0 7 81 88 0.040 0.15 0.70 632 13 
PRA-2 22 25 613 660 0.052 251.82 1.04x10
-56
 366 10 
PRA-2 UK 
(Unrelated) 
0 2 86 88 0.011 0.01 0.91 7744 45 
AHT Genetic Services Cohorts 
PRA-1 2 83 770 855 0.051 0.02 0.88 386 10 
PRA-2 0 27 388 415 0.033 0.47 0.49 945 16 
 
* The mutant allele is represented by “-“ and the wildtype allele by “+”. 
 
To determine whether SLC4A3c.2601_2602insC is present in healthy dogs of other breeds or 
is causal for PRA in other breeds, a cohort/sample set of 273 dogs from three closely 
related breeds made up of PRA cases of unknown aetiology and unaffected dogs was 
screened: 132 LR (16 cases), 92 FCR, 49 CBR (two cases). All 273 dogs were 
homozygous wild-type (SLC4A3
+/+
).  
Similarly, to determine whether TTC8c.669delA is present in healthy dogs of other breeds 
or is causal for PRA in other breeds, a cohort/sample set of 174 dogs from three closely 
related breeds made up of PRA cases of unknown aetiology and unaffected dogs was 
screened: 70 LR (17 cases), 59 FCR, 48 CBR (two cases). One LR with PRA was 
homozygous for the variant (TTC8
-/-
). The remaining 173 dogs were homozygous wild 
type (TTC8
+/+
). 
3.8.2 AHT Genetic Services Cohorts 
The DNA test for PRA-1 was made available commercially on 15 November 2010. 
Over a period of 26 months, 855 GRs from 24 countries were genotyped by the AHT 
Genetic Services (Table 11). Overall, two were SLC4A3
-/-
 (0.2%) and 83 were 
SLC4A3
+/- 
(10%), indicating an overall allele frequency of 0.05. Similarly, the DNA test 
for PRA-2 was made available commercially on 13 August 2012. Over a period of six 
months, 415 GRs from 19 countries were genotyped by the AHT Genetic Services 
(Table 11). Overall, none were TTC8
-/-
 and 27 were TTC8
+/-
 (6.5%), indicating an 
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overall allele frequency of 0.03. These larger and more diverse AHT Genetic Services 
cohorts did conform to HWE and are therefore likely to be more representative of the 
general population than the research cohorts.  
The allele frequency of SLC4A3c.2601_2602insC in each country was calculated for those 
represented by at least 20 samples (Table 12) and range from 0.01 to 0.15. Each cohort 
represented by >20 samples conforms to HWE. The allele frequency of 0.115 in dogs 
from the USA is surprising as none of the PRA cases from the USA were found to be 
homozygous for SLC4A3c.2601_2602insC. This may be due to the relatively small number of 
samples tested (n = 26), and only time will tell if this estimate is inflated. The allele 
frequency of 0.149 in Denmark is also high, although could be explained by the 
geographical proximity to Sweden, where the allele frequency of PRA-1 is 
approximately 9.3% (personal communication, Tomas Bergström). 
Table 12. PRA-1 allele frequency breakdown by country (n>19) 
 
Observed Genotypes* HWE 1-in-__ expected 
 
Country -/- -/+ +/+ TOTAL 
Allele 
Freq 
χ2 P Affected Carrier Region† 
France 0 8 56 64 0.063 0.28 0.59 256 9 1 
Germany 0 5 80 85 0.029 0.08 0.78 1156 18 1 
Spain 0 1 47 48 0.010 0.01 0.94 N/A N/A 2 
Denmark 0 11 26 37 0.149 1.13 0.29 45 4 3 
Finland 0 4 33 37 0.054 0.12 0.73 342 10 3 
Norway 0 5 37 42 0.060 0.17 0.68 282 9 3 
UK 2 32 367 401 0.045 1.93 0.17 496 12 3 
Canada 0 2 20 22 0.045 0.05 0.82 484 12 4 
USA 0 6 20 26 0.115 0.44 0.51 75 5 4 
Total 2 74 686 762 0.051 8.63x10
-6
 1.00 382 10 
 
 
* The mutant allele is represented by “-“ and the wildtype allele by “+”. 
† 1 = Western Europe, 2 = Southern Europe, 3 = Northern Europe, 4 = North America 
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Due to the relatively short period of time for which the PRA-2 DNA test has been 
available, the numbers of dogs tested from individual countries is still small. Therefore, 
the allele frequency of TTC8c.669delA for each country was calculated for those 
represented by at least 10 samples (Table 13) and range from 0 to 0.15. Each cohort 
represented by >10 samples conforms to HWE. The allele frequency of 0.15 in dogs 
from Austria is surprising as none of the PRA cases are from Austria. This may be due 
to the relatively small number of samples tested (n = 10), and only time will tell if this 
estimate is inflated. 
Table 13. PRA-2 allele frequency breakdown by country (n>9) 
 
Observed Genotypes* HWE 1-in-__ expected 
 
Country -/- -/+ +/+ TOTAL 
Allele 
Freq 
χ2 P Affected Carrier Region† 
USA 0 1 23 24 0.021 0.01 0.92 2304 25 1 
Finland 0 1 10 11 0.045 0.02 0.87 484 12 2 
UK 0 13 275 288 0.023 0.15 0.70 1963 23 2 
Italy 0 0 17 17 0.000 N/A N/A N/A N/A 3 
Spain 0 2 10 12 0.083 0.10 0.75 144 7 3 
Austria 0 3 7 10 0.150 0.31 0.58 44 4 4 
France 0 2 13 15 0.067 0.08 0.78 225 8 4 
Total 0 22 355 377 0.029 0.34 0.56 1175 18 
 
 
* The mutant allele is represented by “-“ and the wildtype allele by “+”. 
† 1 = North America, 2 = Northern Europe, 3 = Southern Europe, 4 = Western Europe 
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3.9 Screening of SLC4A3 in humans 
3.9.1 Introduction and Background 
As discussed in Chapter 1, while 185 of the genes that contain mutations that cause 
retinal degeneration in humans have been identified, it is estimated that the genes 
involved in approximately 35% of aR retinal dystrophies remain unknown
57
. While 
PRA is widely considered to be the veterinary equivalent of RP, the limited 
characterisation of many forms of PRA at the cellular and molecular level suggests it 
may, in some cases, be the equivalent of other retinal dystrophies. Alvarez et al. 
identified SLC4A3 as a candidate gene for human vitreoretinal degenerations based on 
their findings of blindness and retinal degeneration in knockout mice
125
. However, prior 
to the identification of SLC4A3c.2601_2602insC in GRs with PRA in this study, SLC4A3 had 
not been associated with naturally occurring, spontaneous ocular disease in any species. 
The identification of the variant therefore endorses the status of SLC4A3 as a candidate 
gene for human retinal degenerations. The SLC4A3 gene was therefore screened in 
DNA from human patients with retinal degeneration of unknown aetiology in order to 
determine whether mutations in the gene cause retinal degeneration. 
3.9.2 Sample and Assay Selection 
Little is known about the phenotype associated with PRA-1 in GRs beyond 
ophthalmoscopic observations. Clinically the fundus appears identical to other forms of 
PRA and histological and detailed ERG analysis has not been reported. In addition the 
age of onset is difficult to define, although the age at which dogs with PRA-1 are 
diagnosed is approximately 6-7 years. This is suggestive of a relatively late-onset 
condition, a hypothesis consistent with the findings in the SLC4A3 knockout mouse in 
which a selective inner retina defect is followed by photoreceptor degeneration at eight 
months
125
. As six of the 10 genes already implicated in both canine and human 
progressive retinal disease are involved in RP (see Chapter 1 Table 2), SLC4A3 is a 
strong candidate for humans with RP. A cohort of 192 DNA samples from individuals 
with aRRP of unknown aetiology was therefore selected for screening.  
Eight additional human patients with various forms of retinal degeneration caused by 
unknown variants were also selected for screening. In each patient, autozygosity 
mapping previously conducted at the Institute of Ophthalmology had identified large 
regions that potentially harboured disease-causing variants (personal communication, 
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Alice Davidson).  These regions contained SLC4A3, amongst other genes (Table 14), 
and these patients were therefore prioritised and screened first. 
A number of DNA screening methods were considered as a cost-effective alternative to 
Sanger sequencing, particularly high-resolution melting (HRM) analysis. This 
commonly used technique identifies melting changes of a DNA duplex caused by 
variation in sequence. As with any screening methods, however, additional sequencing 
is required to identify and confirm specific variants. More than 5,000 variations have 
been identified in human SLC4A3, which appear to be evenly spread across the gene 
(data not shown). As a result it is likely that HRM analysis would identify variations in 
most, if not all exons that would require subsequent sequencing.  In addition, due to the 
number of exons involved (n = 25), a great deal of HRM optimisation would be 
required. Therefore screening of all exons of the gene by Sanger sequencing was 
considered the least costly and time-consuming approach. 
Table 14. Patients with mapped homozygous regions containing SLC4A3 
Patient 
ID 
Disease 
Region containing SLC4A3 Other regions identified 
Size 
(Mb) 
No of 
genes 
Retinal 
genes* 
Size 
(Mb) 
No of 
genes 
Retinal 
genes* 
1 aRRP 28.78 193 3 19.74 74 0 
2 aRRP 19.24 158 4 88.69 503 5 
3 Rod monochromasy 9.42 39 1 280.70 2218 21 
4 Recessive retinal dystrophy 22.59 182 3 222.93 2010 22 
5 aRRP 36.36 271 3 94.87 1271 20 
6 aRRP 13.91 99 1 172.98 1334 17 
7 aRRP (pseudo dominant) 14.16 93 1 369.70 1774 20 
8 cone-rod dystrophy 16.07 102 3 34.38 281 1 
 
* Genes previously associated with retinal disease in humans 
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As is the case in the dog, two main isoforms of SLC4A3 have been described in humans: 
a full-length (SLC4A3fl) isoform made up of 23 exons and a cardiac (SLC4A3c) isoform 
made up of 18 exons
133
. These differ at the N-terminus but have identical C-terminal 
regions (Figure 24). Alternative splicing of exon six of SLC4A3fl results in two “full-
length” isoforms that differ by 81 bp, or 27 amino acids. SLC4A3fl1 (Transcript ID: 
ENST00000358055; Accession no: NM_005070) is the shorter version and results in a 
protein made up of 1,232 amino acids. SLC4A3fl2 (Transcript ID: ENST00000273063; 
Accession no: NM_201574) results in a protein made up of 1,259 amino acids (Figure 
24), and this is the isoform referred to throughout the remainder of this document. In 
SLC4A3c exon C1 replaces exons one to six of the full-length transcript, resulting in a 
shorter protein product made up of 1,034 amino acids.  
 
 
 
Figure 24. Human SLC4A3 gene and protein isoforms 
A) The three isoforms of SLC3A3 are created by alternative splicing of exons 1-6 and 
C1, and by alternative splicing of exon 6 (grey). B) SLC4A3fl1 and SLC4A3fl2 proteins 
are created from alternative splicing of exon 6 and differ only with regards to the 
absence and presence respectively of 27 amino acids. SLC4A3c is created by alternative 
splicing of exon C1 and the first 72 amino acids are completely different than the full-
length isoforms (grey). All three isoforms are identical over the 962 amino acids at the 
C-terminal end. 
3.9.3 Variants identified 
Sequencing of all known exons and intron-exon boundaries of human SLC4A3 (section 
2.2 and 2.7.2) in 200 patients revealed 50 SNP variants affecting at least one individual 
when compared with the human reference sequence (hg19, data not shown). Of these, 
21 are located in exons, 23 in introns, four in the 5’-UTR and two in the 3’-UTR. The 
majority (n=39) have previously been identified and have entries in the dbSNP 
database. Variants that could be pathogenic were retained for further investigation, i.e. 
those that may affect exon splicing or result in amino acid changes that are predicted to 
be pathogenic by at least one of the SNP pathogenicity prediction tools utilised.  
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After elimination of variants unlikely to be pathogenic from the investigation five SNP 
variants remained that were predicted to affect exon splicing and/or change the amino 
acid sequence of the protein (Figure 25 and Table 15). Fourteen patients in total, all of 
which come from the panel of 192 aRRP cases, carried one of these five variants.  
SNPs_1-4 are non-synonymous SNPs that result in amino acid changes that are 
predicted to be pathogenic by at least one of the in silico prediction tools (PolyPhen, 
SIFT and PMut). SNP_4 and SNP_5 are predicted to affect exon splicing and due to 
their location in exons 22 and 18 respectively would affect all three isoforms of the 
protein. If the predictions are accurate, SNP_4 (c.G3674A, p.R1225Q) could introduce 
a new acceptor site. This would result in a 147 bp, in-frame deletion from exon 22, 
decreasing the size of the exon from 174 to 27 bp. This would, in turn, produce a 
deletion of 49 amino acids near the C-terminus of the protein, resulting in a 1,210 amino 
acid protein (Figure 26B) with the first 1,176 and last 34 amino acids identical to the 
wildtype protein. SNP_5 (c.G2865A, p.G955G) could remove an existing acceptor site, 
which would result in a 180 bp increase in the size of exon 18, from 90 to 270 bp. The 
first 949 amino acids of the resulting protein would be normal, followed by 41 different 
amino acids and a premature termination codon, resulting in a loss of 269 amino acids 
(Figure 26C). 
These five variants all have potentially pathogenic, loss-of-function effects on the 
SLC4A3 protein. Only the A allele of SNP_1 was present in the homozygous state in a 
single sample as well as in the heterozygous state in an additional four samples. 
However, the presence of this allele in the homozygous state in the 1000 genomes and 
EVS populations suggests it is highly unlikely to be disease causing. SNPs_2-5 were all 
only identified in the heterozygous state. In addition no patients carried more than one 
variant (i.e. not compound heterozygotes). 
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Figure 25. Effects of potentially pathogenic SNP variants on SLC4A3 protein 
The number of amino acids that make up each protein domain are indicated. All five 
SNP variants affect the full-length isoform of SLC4A3, with two occurring in the first 
part of the N-terminal cytoplasmic domain unique to the full-length isoform (grey). 
Only three variants affect the cardiac and full-length isoforms. 
 
 
 
Figure 26. Predicted effects of two splice-site variants on the SLC4A3 protein. 
Graphical representation of the wildtype human SLC4A3 protein and the predicted 
effects of splicing variants on the protein. The numbers of amino acids are indicated, 
and the nucleotides affected by the variants are bracketed. A) Normal full-length (1,259 
amino acids) protein. B) SNP_4 could introduce an acceptor site resulting in the 
reduction in the size of exon 22 from 174 to 27 bp. This equates to an in-frame deletion 
of 49 amino acids near the C-terminus of the protein, and a final protein 1,210 amino 
acids in size. C) SNP_5 could remove an acceptor site resulting in an increase in the 
size of exon 18 from 90 to 270 bp, which equates to an insertion of 41 amino acids 
(Ins), a premature termination codon, and the loss of 269 amino acids at the C-terminus. 
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Table 15. Potentially pathogenic SNP variants 
Variants 200 Patient Panel 
1,000 Genomes Data 
(n=1,092) 
EVS Data (n=~6,500) 
SNP 
_# 
Genomic 
Location 
A1
*
 A2
†
 
Possible effect 
on splice sites 
Codon 
change 
rs Number 
Pathogenic 
by
‡
 
A1/A1 A2/A1 A2/A2 
A2 
Freq 
A1/A1 A2/A1 A2/A2 
A2 
Freq 
A1/A1 A2/A1 A2/A2 
A2 
Freq 
1
§
 2:220494118 C A  H157P rs597306 PP 195 4 1 0.015 1013 74 5 0.038 5891 552 54 0.051 
2 2:220494940 C T  S226L rs36068948 PP 199 1 0 0.003 1084 8 0 0.004 6453 48 0 0.004 
3 2:220502366 G C  D894H rs61729101 PP, S 194 6 0 0.015 1079 13 0 0.006 6357 146 0 0.011 
4 2:220505656 G A 
Introduction of 
acceptor site 
(0.00-0.81) 
R1225Q rs150952379 PP, S, PM 199 1 0 0.003 1091 1 0 0.000 6496 7 0 0.001 
5 2:220502903 G A 
Loss of acceptor 
site  
(0.45-0.00) 
G955G   199 1 0 0.003         
 
* Allele 1 = Reference allele 
† Allele 2 = Minor/variant allele 
‡ PP = PolyPhen; S = SIFT; PM = PMut 
§ Allele 2 (A) is actually the reference allele, while allele 1 (C) is the ancestral allele 
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3.10 Discussion 
3.10.1 PRA-1 and SLC4A3 
Using a GWA mapping approach, a novel locus on chromosome 37 that is statistically 
associated with PRA in the GR breed (pgenome = 1.0x10
-5
) has been identified. A critical 
region of 644 kb, formed by two overlapping homozygous blocks, was defined through 
homozygosity analysis using the SNP genotypes. Most of the cases (23/27) and none of 
the controls were homozygous for one of the homozygous blocks. 
SLC4A3 was identified as a strong candidate causal locus within the PRA-critical region 
as it encodes the anion exchanger 3 (AE3) protein, which mediates Cl
-
/HCO3
-
 exchange 
across cellular membranes
134
 and is expressed in various tissues including the Müller 
and horizontal cells of the retina
124
.  Interestingly, the effect of AE3-deficiency has been 
described in a knockout mouse model showing that a selective inner retina defect is 
followed by photoreceptor degeneration
125
, similar to the retinal degeneration seen in 
many forms of PRA and RP. 
SLC4A3 occurs in two main isoforms, SLC4A3fl and SLC4A3c, which have identical 
transmembrane and C-terminal regions while the N-terminal amino acids differ (Figure 
15)
124,126
. SLC4A3fl is expressed predominantly in the brain, but it is also found in the 
gut, kidney, heart and Müller cells of the retina
124,133-136
. The cardiac isoform is 
expressed predominantly in the heart and also in the horizontal neurons of the 
retina
124,134,136
. 
Sequencing of SLC4A3 transcripts from healthy retinal mRNA served three purposes. 
Firstly it confirmed the presence of “cardiac” and “full-length” mRNA transcripts in the 
normal canine retina. Secondly it revealed that the intron-exon boundaries predicted by 
genebuild for the dog were incorrect for five of the first eight exons. They are instead 
identical to the human and mouse boundaries.  Thirdly it revealed exons orthologous to 
part or all of human exons 1, 2, 3 and 8, that were absent from the Ensembl canine 
predictions (Figure 14). Two large gaps in the reference sequence were found upstream 
of canine exons 2 and 8, and it is very likely that the missing exons lie within these 
gaps. As is the case in humans and mice, canine SLC4A3fl is alternatively spliced to 
produce two “full length” isoforms (SLC4A3fl1 and SLC4A3fl2). The functional 
implication of the difference between these isoforms is currently unknown. 
The two exonic and nonsynonymous variants identified in this study (SLC4A3c.A44C and 
SLC4A3c.2601_2602insC) are in tight linkage disequilibrium for the 25 dogs screened. In two 
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dogs (one case and one control) however, variant alleles are not inherited together. 
SLC4A3c.2601_2602insC is more strongly associated with PRA than SLC4A3c.A44C or 
BICF2G630131493, and it appears to be fully penetrant.  
In order to further test the validity of the insertion mutation, 709 GRs were screened for 
the insertion (Table 9). The majority, 56.3%, of the PRA cases, 87.2% of the obligate 
PRA carriers and 99.6% of clinically unaffected dogs (which could be clear of the 
mutation or carry a single copy) had SLC4A3 genotypes that are concordant with their 
clinical status. There were two groups of dogs with genotypes discordant with their 
phenotypes. The first comprises three PRA-unaffected dogs that were SLC4A3
-/-
 (one of 
which is an obligate carrier). All three dogs were examined by a veterinary 
ophthalmologist at 4-5 years of age and as average age of onset is approximately seven 
years they would not necessarily have been displaying clinical signs at the time of their 
examination. Thus 93.8% of dogs (45/48) homozygous for the mutation (SLC4A3
-/-
) 
have developed PRA, suggesting that the mutation is fully penetrant, or nearly so. The 
inheritance observed in a pedigree of 32 dogs (18 cases) is supportive of a recessive 
mode (Figure 16). The second group of discordant dogs comprised 35 PRA-affected 
dogs that were not homozygous for SLC4A3c.2601_2602insC and four obligate carriers that 
did not carry SLC4A3c.2601_2602insC. It is formally possible that the mutation has a 
dominant mode of inheritance with incomplete penetrance, or complex trait or 
compound heterozygote effects. However, the PRA cases discordant with 
SLC4A3c.2601_2602insC segregation (SLC4A3
+/+
 and SLC4A3
+/-
) tended to develop PRA at 
an earlier age, with an average age at diagnosis of 5.27 years (data not shown), which is 
consistent with the segregation of a third form of PRA in the GR breed (PRA-2). It is 
becoming increasingly apparent that even in breeds with small effective population 
sizes, mendelian conditions may be genetically heterogeneous. For example day 
blindness in the Alaskan Malamute breed is caused by two or more mutations, only one 
of which is currently known
137
. These discordant cases were therefore used to undertake 
a subsequent study (sections 3.6 and 3.7) in which a third locus and mutation were 
identified. Due to the limited knowledge regarding the specific clinical pathology of the 
PRA form associated with SLC4A3c.2601_2602insC it was termed PRA-1. None of the 
affected GR dogs are known to have any cardiac or neurological abnormalities. This is 
consistent with previous findings that loss of AE3 alone is insufficient to cause cardiac 
or neurological disease in mice
138,139
. 
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The AE3 protein is part of a group of Na
+
-independent anion exchangers and it 
exchanges chloride for bicarbonate
134,140
. Little is known about the structure of the 
protein, but it is thought to be similar to family member SLC4A1 (AE1). SLC4 proteins 
are made up of three structural domains (Figure 15). At the N-terminus there is a 
hydrophilic, cytoplasmic domain of between 400 and 700 amino acids, followed by a 
hydrophobic, polytopic transmembrane domain of approximately 500 amino acids, 
comprising up to 14 transmembrane spans, and lastly a cytoplasmic domain of between 
30 and 100 amino acids at the C-terminal end
133,135
. 
The mutation, c.2601_2602insC (p.E868RfsX104) in SLC4A3fl and c.1981_1982insC 
(p.E661RfsX104) in SLC4A3c, occurs in the transmembrane region and as a result is 
likely to affect both full length and cardiac isoforms of the protein (Figure 15). The shift 
in the reading frame results in an incorrect sequence of 104 amino acids and the loss of 
266 residues at the C-terminal end of the protein. These residues constitute a large 
portion of the transmembrane region and the complete C-terminal cytoplasmic region. 
Retinal tissue from a dog affected with PRA was not available and SLC4A3 mRNA 
could not be isolated from available tissues (blood or buccal cells); therefore 
confirmation of whether the protein is expressed in a truncated form or not expressed at 
all due to NMD of the mRNA transcript has not been possible. In the event of truncated 
protein expression, functionally important residues are lost. 
Glycosylphosphatidylinositol-linked carbonic anhydrase IV (CAIV)
141
 and 
transmembrane carbonic anhydrase IX (CAIX) interact with exofacial portions of the 
transmembrane domains of AE3
142
; the C-terminal tail of the SLC4 polypeptides 
contains acidic motifs that may serve as cytoplasmic carbonic anhydrase II (CAII) 
binding sites
143,144
. Coexpression of each of the CA proteins with AE3 results in 
increased HCO3
-
 transport activity. A number of possible functions for SLC4A3fl in 
Müller cells have been proposed:  
1) Intracellular CO2 released by photoreceptors is converted into HCO3
-
 and H
+
 by 
carbonic anhydrases. It is thought that removal of these products into the blood or 
vitreous is facilitated by transporters such as SLC4A3 in the Müller cell end 
feet
145
.  
2) SLC4A3fl may facilitate the exchange of intracellular HCO3
-
 for extracellular Cl
-
, 
thereby contributing to pH maintenance
124
 and a lack of bicarbonate in the retina 
results in loss of retinal function
146
.  
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3) Finally it may play a role in Cl- level maintenance which potentially affects Cl--
dependent transporter activity e.g. transporters of γ-Aminobutyric acid (GABA) 
and taurine
147
.  
Horizontal cells also express various carbonic anhydrases, which could in turn create 
significant levels of intracellular HCO3
-
. By exchanging this HCO3
- 
with extracellular 
Cl
-
, SLC4A3c may contribute to pHi homeostasis
124
. 
PRA caused by the mutation described here has an average age at diagnosis of 6.67 
years and this is indicative of a late age of onset (data not shown). Two affected 
individuals that were diagnosed at the relatively young age of four years (individuals 31 
and 32 in Figure 16) were examined at the same time as a number of relatives including 
their mother. In these two dogs the disease was at an early stage. The late age at 
diagnosis corresponds to the late-onset findings of Alvarez et al. where SLC4A3 
knockout mice appeared completely normal at four months of age
125
. However on closer 
investigation the mice were observed to be affected by an inner retinal defect from birth, 
which led to a failure of phototransduction at four months, followed by pathological 
signs of photoreceptor degeneration at eight months and eventually complete blindness. 
Pathological signs included defects in retinal blood vessels, the optic nerve head and rod 
bipolar cells, as well as reduced a-wave ERG amplitudes and b-wave depression
125
, 
consistent with most forms of PRA. SLC4A3 deficiency also resulted in increased 
expression of CAII and CAXIV enzymes as well as the Na
+
/HCO3
-
 co-transporter, 
NBC1, in the horizontal and Müller cells. The authors hypothesised that while these 
changes possibly compensated for the loss of SLC4A3 to some extent, the ability of the 
cells to maintain acid-base balance is still compromised, leading to late-onset 
photoreceptor cell death
125
.  
3.10.2 PRA-2 and TTC8 
Using a GWA mapping approach, a novel locus on chromosome 8 that is associated, 
albeit not with genome wide significance, with PRA in the GR breed (pgenome = 0.148) 
was identified. An “Affected Haplotype” of 737 kb was defined through homozygosity 
and haplotype analysis using the SNP genotypes. Most of the cases (8/10) and none of 
the controls were homozygous for the “Affected Haplotype”. 
SPATA7 and TTC8 were identified as candidate causal genes due to their position within 
the PRA critical region, their expression in the retina and their association with human 
retinal disease. SPATA7 was first identified in human spermatocytes and is thought to 
be involved in chromatin preparation for the initiation of meiotic recombination
131
. In 
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addition the protein is expressed in the retina and shows a uniform distribution in the 
inner segment cytoplasm. Nonsense and loss-of-function variants have been identified 
in patients with juvenile recessive RP and LCA from distinct ethnic groups
127
. TTC8 
(a.k.a. BBS8) is one of a number of BBS proteins that likely function in membrane 
trafficking to the primary cilium
148
. Homozygous and heterozygous variants have been 
identified in a small number of BBS families
128,129
 and a homozygous variant in the 
splice acceptor site of a retina-specific exon has been found to cause aRRP
130
. 
Sequencing of SPATA7 and TTC8 transcripts from healthy retinal mRNA served four 
purposes. Firstly, it confirmed the presence of both mRNA transcripts in the normal 
canine retina. Secondly, the presence of the SPATA7c.A1378G variant in mRNA from a 
healthy dog allowed the elimination of this variant from further investigation. Thirdly, it 
revealed that the intron-exon boundaries predicted by genebuild for TTC8 in the dog 
were incorrect for five exons. They are instead identical to the human and mouse 
boundaries.  Finally, it revealed an exon orthologous to human exon 2A, that is absent 
from the Ensembl canine prediction (Figure 21). As is the case in humans and mice, 
canine TTC8 is alternatively spliced to produce two isoforms (TTC8 and TTC82A). The 
precise functional difference between the two isoforms is unknown, but it is thought 
TTC82A plays in important role in the function of the protein in the photoreceptor cell-
containing outer nuclear layer of the retina
130
.  
In order to further test the validity of the deletion mutation, TTC8c.669delA, 660 GRs were 
screened for the mutation (Table 10). This analysis revealed that 62.9% of the PRA 
cases, 40% of the obligate PRA carriers and 100% of clinically unaffected dogs (which 
could be clear of the variant or carry a single copy) have TTC8 genotypes that are 
concordant with their clinical status. All 22 dogs homozygous for the mutation i.e. 
TTC8
-/-
, have developed PRA, suggesting that the mutation is fully penetrant. The 
inheritance observed in a family of eight dogs (three cases) is supportive of a recessive 
mode (Figure 23). There was a group of dogs with genotypes discordant with their 
phenotypes, comprising 13 PRA-affected dogs that are not homozygous for 
TTC8c.669delA and three obligate carriers do not carry TTC8c.669delA. It is formally possible 
that the mutation has a dominant mode of inheritance with incomplete penetrance, or 
complex trait or compound heterozygote effects. However, given that three distinct loci 
have now been implicated in PRA in the breed, it is more likely that still more loci are 
responsible for the discordant cases. PRA caused by the mutation described here has an 
average age at diagnosis of 4.51 years and this is indicative of a late age of onset (data 
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not shown). The discordant GR PRA cases i.e. TTC8
+/+
 and TTC8
+/-
 tended to develop 
PRA at a later age, with an average age at diagnosis of 6.38 years (data not shown), 
which is consistent with the segregation of a fourth form of PRA in the GR breed.  
TTC8 encodes the protein tetratricopeptide repeat (TPR) domain 8 and was recognised 
as a candidate gene due to its previous implication in BBS and aRRP in humans
128-130
. 
Human TTC8 is made up of 14 exons and alternative splicing of the fifth exon results in 
two isoforms that are widely expressed in ciliated tissue
128
. In addition a retina-specific 
isoform, expressed exclusively in the retina and primarily in photoreceptors, is created 
by the alternative splicing of exon 2A
130
. The gene is comprised of 12.5 TPR motifs, 
which represent a protein-protein interaction module found in functionally diverse 
proteins that facilitates specific interactions between partner proteins
128,149,150
. Part of 
the gene is also similar to the prokaryotic domain pilF, which is involved in twitching 
mobility and type IV pilus assembly
128,151,152
. TTC8 is one of seven highly conserved 
BBS proteins that form a stable complex known as the BBSome, which functions 
primarily at the ciliary membrane and is thought to play a role in ciliogenesis
148,149
. The 
structural elements of the proteins that make up the BBSome resemble those of coat 
protein (COP) complexes involved in intracellular transport (COPI, COPII). BBS 
proteins, while not required for ciliogenesis per se, are thought to transport a specific set 
of transmembrane proteins to the cilia
148,149
.  
BBS is a pleiotropic disease and characteristic symptoms include obesity, retinal 
degeneration, kidney malformation, hypogonadism, polydactyly and learning 
disabilities. While the syndrome is usually inherited in an autosomal recessive manner, 
triallelic inheritance has also been observed
64
. While most mutations that significantly 
alter the structure of the TTC8 protein cause BBS, those that result in skipping of the 10 
amino acids encoded by exon 2A cause non-syndromic RP (Figure 27). The 
TTC8c.669delA mutation in the GR is predicted to have a significant effect on the structure 
of the protein, including the loss of tetratricopeptide repeats and the pilF-like domain 
near the carboxyl terminus
128
.  
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Figure 27. Comparison of human and canine retinal disease mutations 
In humans, only mutations in exon 2A cause RP (orange
130
), while mutations elsewhere 
have been associated with BBS (yellow
128
 and blue
129
). TTC82Ac.699delA (purple) is 
associated with PRA in GRs. 
Most of the affected dogs, however, presented with typical PRA and no additional 
clinical signs. It is possible that other clinical signs in the dog have simply not been 
reported to, or by, the examining ophthalmologists. One dog with PRA-2 was reported 
to have “hormonal changes and thyroid problems”, the precise nature of which are 
unknown. Attempts to gain further information pertaining to this dog have thus far been 
unsuccessful. Signs seen in two other dogs (small stature, obesity, aberrant metabolism 
and olfaction, and unusual behaviour), as reported by their owners, suggest there may 
be more to the phenotype of PRA-2 than solely PRA. As the signs reported are 
subjective, an objective, clinical investigation is warranted. Attempts to conduct a 
clinical examination of one of these dogs have been unsuccessful. Nevertheless, it is 
clear there are phenotypic differences between human BBS and canine PRA-2. It is 
unclear whether these phenotypic differences are purely due to species differences or 
some other as yet unknown mechanism, such as the effect of modifier genes. The TTC8 
protein is clearly critical to ensure efficient function of ciliated tissue in humans, as 
demonstrated by the BBS phenotype. In contrast, it may be that the TTC8 protein is 
critical for photoreceptor function in dogs, but less so in other tissues, which would 
explain a retina-specific or possibly less severe systemic phenotype in dogs. 
Alternatively, there may be other proteins that compensate for the loss of TTC8 in dogs 
more than in humans. While PRA is widely considered to be the veterinary equivalent 
of RP, the limited characterisation of PRA at a cellular level is insufficient to fully 
justify this comparison. Further investigations are required to understand the cellular 
processes involved in this form of PRA, including whether the rod or cone 
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photoreceptor cells are affected first and whether other signs indicative of a syndrome 
are present in affected dogs. 
3.10.3 Prevalence of PRA-1 and PRA-2 in GR populations 
The absence of the SLC4A3c.2601_2602insC allele from non-GR breeds tested, including 
some dogs affected with PRA, indicates that the mutation is rare and probably confined 
to GRs. In contrast, identification of a LR (with clinically apparent PRA) homozygous 
for the TTC8c.669delA allele suggests it may be present in the LR breed. However, as only 
1/17 LR PRA cases in our sample set, is caused by this mutation, it may be only a minor 
cause of PRA in the breed. The absence of the mutation from the other 69 LRs could be 
attributed to the small number of samples tested. The absence of TTC8c.669delA from FCR 
and CBR dogs tested, including some dogs affected with PRA, indicates that the 
mutation is rare and is probably confined to the GR and LR breeds. 
The mutant allele frequencies of SLC4A3c.2601_2602insC and TTC8c.669delA (4% and 1.1% 
respectively) within the samples collected for research purposes (n = 88, Table 11) 
would indicate that 1 in 632 and 1 in 7,744 GRs in the UK is affected with PRA-1 and 
PRA-2 respectively. These samples were unrelated at the parent level and were 
collected specifically to estimate the allele frequency in the breed. However this could 
still be an over-estimate as any sample cohort collected for research is unlikely to be 
representative of the wider GR population as not all dog owners will be aware of the 
research to begin with. In addition, the cohort size is also relatively small, thereby 
reducing the accuracy of population statistics and predictions.  
In contrast, sample cohorts collected through AHT Genetic Services are larger and more 
diverse, as they were not recruited for any particular study, and therefore more 
representative of the wider population. However, the SLC4A3c.2601_2602insC allele 
frequency of 4.5% in the UK fraction of this cohort was actually slightly higher than the 
unrelated research cohort (4%). Similarly, the TTC8c.669delA allele frequency of 2.3% in 
the UK fraction of the AHT Genetic Services cohort was also slightly higher than the 
unrelated research cohort (1.1%) This suggests the strategy of collecting unrelated 
samples specifically for the purposes of estimating allele frequencies may be sufficient, 
assuming sufficient numbers are available, and the resulting data presents reliable 
evidence on which to base advice offered to breeders.  
The presence of both mutations in GR dogs from all over the world (Table 12 and Table 
13) suggests the mutations may have arisen prior to the geographic dispersion of the 
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breed. The SLC4A3c.2601_2602insC allele frequency of 5.1% indicates that 1 in 386 GRs 
worldwide will develop PRA-1, and 1 in 10 is expected to carry it. Similarly, the 
TTC8c.669delA allele frequency of 3.3% indicates that only one in 945 GRs worldwide 
will develop PRA-2, although 1 in 16 is expected to carry it. 
3.10.4 SLC4A3 in Humans 
While SLC4A3 has not been directly linked with disease in humans, the p.Ala867Asp 
variant confers susceptibility to idiopathic generalised epilepsy (IGE)
153
. Hentschke et 
al. described a SLC4A3 knockout mouse that appeared healthy, but had a reduced 
seizure threshold and increased seizure-induced mortality
138
. In addition, AE3c has a 
key role in myocardial pHi recovery from alkaline loads
154
. While the loss of AE3 alone 
has no known adverse effects on the heart the combined loss of AE3 and 
sodium/potassium/chloride transporter 1 (NKCC1, aka SLC12A2) impairs cardiac 
function
139
. Similarly, loss of AE3 in the TM180 transgenic mouse (with a Glu180Gly 
substitution in the α-tropomyosin gene) led to more rapid decompensation and heart 
failure than the TM180 mouse alone
155
. 
The identification of a frameshift insertion in SLC4A3 in GR dogs with PRA endorses 
the status of this gene as a candidate for human retinal degenerations. Screening of the 
exons of SLC4A3 in DNA samples from 200 patients with retinal degeneration resulted 
in the identification of five SNP variants that may be pathogenic. Fourteen individuals 
with aRRP carry one (n = 13) or two (n = 1) copies of the minor allele at one of these 
loci. None of the heterozygous individuals carry more than one pathogenic variant and 
do not therefore appear to be compound heterozygotes. SNPs_1-3 are unlikely to cause 
RP due to their frequency in the 1000 Genomes and EVS populations (Table 15). The 
two remaining variants (SNP_4 and SNP_5) are each found in one individual and could 
have large effects on exon splicing (Figure 26). This could be confirmed through 
analysis of mRNA transcripts if they could be detected in easily accessible tissue such 
as blood or buccal cells. However, as canine SLC4A3 mRNA is undetectable in blood or 
buccal cells, human SLC4A3 mRNA is also likely to be undetectable and this was not 
pursued. In addition, the individuals affected by these variants carry only a single copy 
and the variants therefore remain insufficient to cause aRRP on their own. 
While it appears that the variants in SLC4A3 identified in this study are unlikely to 
cause aRRP in the cohort screened, at least on their own, this is insufficient evidence to 
exclude the gene as a candidate for retinal degeneration. There are a number of 
scenarios in which SLC4A3 could be involved in retinal degeneration:  
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1) Intronic mutations or upstream elements controlling transcription that cannot be 
identified by sequencing exons could be pathogenic by affecting exon splicing or 
regulation of gene expression.  
2) It is possible disease-causing mutations in this gene are rare and affected 
individuals have yet to be screened. For example, mutations in the C2ORF71 gene 
have been associated with RP
156,157
. However, in a study screening the gene in 
DNA from 286 individuals affected with LCA (n=95) or aRRP (n=191), a biallelic 
variant responsible for retinal degeneration could not be identified
158
.  
3) It is also possible that mutant SLC4A3 actually causes retinal degeneration other 
than RP. Given the late onset of clinical signs in the dog and mouse models, early 
onset degenerations such as LCA are unlikely to be caused by variants in SLC4A3. 
Alvarez et al. concluded that their results in the knockout mouse linked aberrant 
SLC4A3 to vitreoretinal degeneration
125
. While there are similarities to vitreoretinal 
disorders, the data presented for the mouse phenotype is not pathognomonic of a 
particular human phenotype (personal communication, Michel Michaelides). In 
addition, vitreoretinal disorders are rare and DNA samples may be difficult to 
obtain. The other abnormalities reported by Alvarez et al., altered ERG and 
abnormal retinal vessels, are shared by many vitreoretinal and retinal degenerations. 
Currently there is no evidence to suggest a human phenotype more likely to be 
caused by variants in SLC4A3 than aRRP and screening of patients with other 
phenotypes was therefore not undertaken.  
NGS is now commonly performed in patients with retinal dystrophies by many groups 
world-wide, so it is possible that human SLC4A3 mutations may be identified through 
these efforts. 
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3.11 Conclusion  
Several forms of PRA segregate in the GR, including prcd, but this form of PRA does 
not account for the majority of cases, particularly in Europe. Using a GWA analysis 
approach, two novel candidate mutations were identified that are likely to represent 
major susceptibility loci for PRA in the GR. SLC4A3c.2601_2602insC (p.E868RfsX104) 
accounts for the majority of cases in our sample cohort (56%) and TTC8c.669delA 
(p.Lys233ArgfsX15) accounts for a further 28% (Figure 28). While these variants do 
not explain all cases of PRA in this study, suggesting that there are additional loci 
causing PRA in this breed, they do appear to be fully penetrant and together cause the 
majority of PRA cases in the breed.  These findings therefore indicate that PRA is 
caused by at least four variants in this breed. 
These findings also comprise the first report of an association between aberrant SLC4A3 
and retinal degeneration in a spontaneous animal model. As a result, SLC4A3 has 
become a provocative candidate gene for human retinal degenerations. All of the 
variants identified through the screening of SLC4A3 in human patients with retinal 
degeneration were eliminated from further investigation due to insufficient evidence of 
pathogenicity. However, the absence of possible causal variants in ~200 human aRRP 
patients is insufficient evidence to exclude the gene as a candidate entirely. It may be 
associated with disease in a very small number of patients, or even patients with a 
different disease type altogether. 
In conclusion, the findings presented here established PRA-1 as a model for human 
retinal disease and PRA-2 as a model for human RP, and potentially BBS. Both forms 
of PRA in the GR may prove to be a valuable models for further studies to enhance our 
understanding of visual pathways and gene therapy investigations. It is unknown 
whether the remaining cases are caused by variants in one or more genes, and this, 
along with the relatively few samples available, will make identification of further 
variants in the breed challenging (discussed further in Chapter 6).   
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Figure 28. Geographical distribution of GR PRA variants 
More than half (56%; 45/80; blue) of the PRA cases tested are the PRA-1 form of the 
disease, while 28% (22/80; red) are PRA-2 and the remaining 16% (13/80; green) have 
PRA of unknown aetiology. 
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Chapter 4  Gordon Setters 
4.1 Introduction and background 
GoSs are a healthy breed and are reported to be predisposed to only a handful of 
hereditary conditions. These include lethal astrocytosis, canine juvenile cellulitis, hip 
and elbow dyplasia and cerebellar degeneration
121
. GoSs were originally known as 
Black and Tan Setters and were popular in the Midland counties of the United Kingdom 
in the 17
th
 century
122
. The first ever documented description of PRA was in a GoS over 
100 years ago, described by Magnusson as stated by Barnett
159,160
. However, since that 
time there have been few reports of the condition until the 21
st
 century, when a number 
of dogs were diagnosed with a late-onset PRA
161
. Irish Setters (IrS) and Irish Red and 
White Setters (IRWS) are two distinct breeds that are thought to have originated from 
common founders, and both are known to be predisposed to PRA. It is unclear how 
closely related GoSs are to IrSs, but anecdotal evidence suggests they have been 
interbred in the past. In addition there are currently breeding kennels that breed with 
both; it is therefore possible that interbreeding is still occurring. IrSs are known to be 
affected by an early-onset form of PRA, rod-cone degeneration 1 (rcd1)
162
. However, in 
recent years in particular, a number of older dogs that are homozygous for the wildtype 
allele at the rcd1 locus have been diagnosed with PRA. Evidence therefore suggests 
there is at least one other form of PRA, with a later age of onset, segregating in this 
breed in addition to rcd1
163
. Anecdotal evidence suggests that PRA in the IRWS is also 
a late-onset form of the disease. In light of this it is possible that the GoS, IrS and IRWS 
breeds share the late onset form of PRA, caused by an identical mutation. 
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4.2 Diagnoses and Clinical Findings 
PRA in the GoS is clinically indistinguishable from PRA in other breeds. Dogs typically 
present with tapetal hyper-reflectivity, optic nerve atrophy and attenuated vessels 
(Figure 29). Dogs in which clinical signs are present also display an absence of retinal 
function as detected by ERG (Figure 30). The mode of inheritance is consistent with an 
autosomal recessive trait. The age at diagnosis (which is indicative of age of onset) was 
reported for 16 dogs in our sample cohort. The average was 8.91, but ranged from 3 to 
12 years of age with only four younger than eight years of age.  
 
Figure 29. Fundus changes observed in a GoS with PRA. 
A) The fundus of a healthy dog. B-D) The fundus of a Gordon Setter, age 11 years, 
displaying signs typical of PRA in most breeds: Hyper-reflective tapetum (B), 
pigmentary changes in the non-tapetal fundus (C) and vascular attenuation (D). 
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Figure 30. Retinal function measured in a GoS with PRA. 
Scotopic ERGs conducted without sedation, showing the average of up to 12 tests. A) 
Control ERG of a dog with normal vision. The characteristic a-wave and b-wave are 
evident. B) ERG of a Gordon Setter affected with PRA. The flat line is indicative of no 
retinal function. 
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4.3 SNP Genotyping 
4.3.1 Genome-Wide Association Mapping 
GWA analysis of 38 GoS dogs, 16 PRA cases and 22 controls over the age of 8 when 
last examined, which were genotyped with 107,982 SNPs (section 2.3) revealed a 
genome-wide significant association with PRA on chromosome 17 (CFA17; praw = 
2.76x10
-10
, pgenome = 1x10
-5
). Additional genome-wide significant associations were 
seen on chromosomes 10 (praw = 7.47x10
-7
, pgenome = 0.02), 21 (praw = 6.1x10
-7
, pgenome = 
0.02) and 28 (praw = 3.2x10
-7
, pgenome = 0.01) (data not shown). IBS clustering confirmed 
the presence of substantial population stratification, with an inflation factor > 1 (λ = 
2.44, based on median χ2). MDS analysis revealed an uneven distribution of cases and 
controls (Appendix I), suggesting that many of the cases were more closely related to 
one another than to the controls, and vice versa.  The signal on CFA17 remained strong 
(praw = 2.22x10
-8
) and the inflation factor was reduced (λ = 1.56) when corrected for 
population stratification with a CMH meta-analysis (Figure 31A). This signal remained 
significant after correction for multiple testing (pgenome = 2x10
-5
)
 
while all other signals 
fell below the level of genome-wide significance (data not shown). The statistically 
associated region on CFA17, defined as the region encompassing statistically associated 
SNPs, spanned 1.64 Mb from 25.825 to 27.466 Mb with the most statistically associated 
SNP markers (BICF2S23023516 , BICF2P960008, BICF2S23914151 and 
BICF2S23419454) at 25.83, 25.84, 26.06, and 27.19 Mb (Figure 31B). Alternative 
analysis of the data using FMM to correct for population stratification revealed similar 
results with the only statistically significant association on CFA17 (praw = 3.96x10
-9
), 
although the most statistically associated SNP (BICF2P91126) was at 27.47 Mb (data 
not shown). However, the greatly reduced inflation factor (λ = 0.34) suggests an over-
correction for population stratification. 
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Figure 31. Genome-wide association mapping of PRA in GoSs 
-Log10 of p-values after correction for population stratification. The red lines indicate 
the Bonferroni-corrected 5% significance level based on 107,982 SNPs. A) Results 
show a strong statistical signal on CFA17 (praw = 2.22x10
-8, 
pgenome = 2.00x10
-5
). B) 
Statistically associated SNPs span a 1.64 Mb region from 25.825 Mb to 27.466 Mb on 
CFA17.  
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4.3.2 Homozygosity Analysis 
A haplotype of 3.221 Mb, extending from 24.629 to 27.851 Mb, was identified through 
homozygosity analysis for which 15 of 16 cases and only 1 of 22 controls were 
homozygous (Figure 32). Although PRA in the GoS is likely to be inherited as an aR 
trait, and all affected dogs would therefore be expected to be homozygous for the 
disease-associated haplotype as well as the causal mutation, it is also possible that more 
than one form of PRA is segregating in the breed. The case that is not homozygous for 
the region was diagnosed at 4.5 years of age and this is younger than expected for the 
GoS breed. For this reason this disease-associated region was not excluded from further 
investigation on the basis of the single discordant case that was not homozygous as it 
may have been suffering from a genetically distinct form of PRA. There are 27 genes 
within the PRA critical region, 22 of which have human orthologues (Figure 32B and 
Appendix IV). One of the genes, chromosome 2 open reading frame 71 (C2ORF71), has 
been associated with RP in humans, is expressed in the retina and is thought to play a 
role in retinal function, although its exact role remains unknown
156-158,164
. None of the 
other 26 genes are known to have an ocular or retinal function, or have been associated 
with vision loss. C2ORF71 alone was therefore identified as the most provocative 
candidate gene for further investigation. 
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Figure 32. Homozygosity analysis of Gordon Setters with PRA 
A) SNP genotypes for 16 PRA cases and 22 PRA controls, over the 1.6 Mb region 
identified during the GWA study. Fifteen of the cases share a homozygous haplotype of 
147 SNPS (Homozygous Block), defining the critical region of 3.221 Mb between 
24.629 Mb and 27.851 Mb on CFA17. One of the cases does not share this haplotype 
with the other 15 cases, while one of the controls does. The five most significantly 
associated SNPs are indicated by arrows (↓; CMH-corrected in black, FMM-corrected 
in red). B) The critical region contains 27 genes, as annotated on CanFam2.0 (taken 
from the Ensembl genome browser), of which C2ORF71 is the most provocative 
candidate gene. 
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4.4 Sequencing of Candidate Gene C2ORF71 
4.4.1 Characterising C2ORF71 Retinal Transcript 
Alignment of canine, human and mouse genomic and coding sequences revealed several 
inconsistencies and possible errors in the prediction of intron-exon boundaries of canine 
C2ORF71 (Figure 33). All of the coding sequence of the C2ORF71 retinal mRNA 
transcript was successfully amplified and sequenced (sections 2.2 and 2.4.1) in a healthy 
dog, confirming that the gene is transcribed in the canine retina. In addition, intron-exon 
boundaries were identical to those of the human and mouse, which is in conflict with 
the boundaries predicted by Ensembl genebuild for the canine gene (Figure 33). All 
attempts at sequencing the full 5’ and 3’ UTRs were unsuccessful. Sequencing of the 
retinal mRNA transcript revealed that the canine C2ORF71 protein (Genbank accession 
no JN390834) contains 1,308 amino acids with a predicted molecular weight of 139 
kDa. 
4.4.2 Sanger Sequencing of C2ORF71 
Primers for the sequencing of gDNA were designed to ensure coverage of the known 
exons as well as probable 5’- and 3’-UTRs. The C2ORF71 gene contains only two 
exons, both of which were sequenced (sections 2.2 and 2.4.1) by Sanger sequencing in 
two PRA affected and four PRA unaffected GoSs, as well as one Miniature Long Hair 
Dachshund and one Flat Coat Retriever. Comparison of the sequence data with the 
canine reference genome sequence (CanFam2.0) revealed 31 sequence variants. Only 
one of the sequence variants segregated consistently with PRA within the eight samples 
sequenced, was exonic and potentially pathogenic (Figure 33D). This variant was an 
inserted cytosine in exon 1 (c.3149_3150insC; CFA17:26,010,485). It is predicted to 
shift the reading frame and cause a premature stop codon (p.C1051VfsX90) potentially 
resulting in degradation of the mRNA by NMD or a truncated protein product (Figure 
34). While the position of the variant is not particularly well conserved at the nucleotide 
or amino acid level between 31 eutherian mammals (data not shown), the predicted 
effect of the variant is severe and it therefore remains significant.  
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Figure 33. Graphical comparison of the intron-exon boundaries of C2ORF71. 
A) Mouse (Mus muscularis) C2ORF71. B) Human (Homo sapiens) C2ORF71. C) 
Canine (Canis familiaris) C2ORF71 as predicted by Ensembl genebuild. Both exons 
predicted (grey) show sequence similarity with human and mouse exon 1, although the 
5’- and 3’-boundaries are inconsistent. D) Canine C2ORF71 exons confirmed by 
sequencing the retinal transcript. The location of the fully-segregating sequence variant 
is indicated, and is exonic and nonsynonymous. 
 
 
 
Figure 34. Effect of variant C2ORF71c.3149_3150insC on the C2ORF71 protein. 
A) The wildtype canine C2ORF71 protein contains 1308 amino acids. B) The effect of 
the insertion on the protein is significant. 1047 amino acids at the N-terminus of the 
protein are normal. However the insertion causes a shift in the reading frame that results 
in 90 aberrant amino acids and leads to a premature termination codon. This is predicted 
to result in a truncated protein product, lacking 171 residues of the C-terminus. 
Therefore a large part of the protein is absent. 
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4.4.3 C2ORF71c.3149_3150insC Variant Validation 
All 38 GoSs (16 cases and 22 controls) that participated in the GWA study were 
screened (section 2.4.1) by Sanger sequencing for the coding variant, 
C2ORF71c.3149_3150insC, to confirm the association of this mutation with PRA and 
compare it with the most highly associated SNPs, BICF2S23023516, BICF2P960008, 
BICF2S23914151 and BICF2S23419454. The genotypes of the mutation and all four 
SNPs were perfectly concordant in all dogs i.e. homozygous for the reference allele 
(C2ORF71
+/+
), heterozygous (C2ORF71
+/-
) or homozygous for the mutant allele 
(C2ORF71
-/-
). C2ORF71c.3149_3150insC, along with all four markers showed significant 
and equal allelic association with PRA (praw = 2.758x10
-10
). It also showed almost 
complete segregation with PRA (15/16 cases) and is highly likely to have a deleterious 
effect on the protein. Seven GoSs were carriers of the mutation but all were clinically 
free of PRA at their last eye examination (average age 12yo, range 10-14yo) which 
substantiates the hypothesis that PRA in the GoS has an aR mode of inheritance. 
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4.5 C2ORF71c.3149_3150insC Population Screening 
4.5.1 Research Sample Cohorts 
Eighty-eight additional GoSs, (seven clinically affected with PRA and 81 unaffected 
dogs of any age) were screened (section 2.6.1.1), making a total of 126 GoSs tested for 
C2ORF71c.3149_3150insC (Table 16) to confirm that the mutation was not a commonly 
occurring polymorphism in this breed.  Of the 22 PRA cases used in the study 19 
(86.4%) were homozygous for the mutation (C2ORF71
-/-
) and 84/104 (80.8%) dogs 
known to be clinically free of PRA were either carriers of the mutant allele (44.2%; 
C2ORF71
+/-
) or homozygous for the wildtype allele (36.5%; C2ORF71
+/+
). For 12/20 
clinically unaffected dogs that were homozygous for the mutation, their age when they 
were last examined was reported (average = 9 years). Interestingly, seven were at least 
10 years old and three subsequently underwent follow-up ophthalmoscopic examination 
at the AHT (sections 2.1.1.2 and 4.5.3). Anecdotal evidence from owners suggests that 
affected GoSs often present with nyctalopia (night-blindness) initially, prior to more 
extensive visual impairment, indicating that this form of PRA may be a rod-cone 
degeneration (RCD), known hereafter as RCD4 to distinguish it from forms of RCD 
described previously. 
Table 16. C2ORF71 genotypes and PRA clinical status for 126 GoSs 
Genotype PRA Affected PRA Unaffected Total 
C2ORF71
-/-
 
19 20 39 
86.4% 19.2% 31.0% 
C2ORF71
+/-
 
1 46 47 
4.5% 44.2% 37.3% 
C2ORF71
+/+
 
2 38 40 
9.1% 36.5% 31.7% 
Total 22 104 126 
 
To determine whether RCD4 accounts for PRA in other breeds, a further 91 dogs were 
screened from two closely related breeds. These were 19 IRWSs and 72 IrSs, including 
three and 10 respectively clinically affected with PRA. All 19 IRWS dogs, including 
three PRA cases, were homozygous for the wild-type allele (C2ORF71
+/+
). Of the 10 
IrSs with PRA, seven were homozygous for the mutation (C2ORF71
-/-
), while the 
remaining three PRA cases were either carriers (C2ORF71
+/-
; n=2) or homozygous 
wildtype (n=1). In addition a further five IrS dogs that had not been diagnosed with 
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PRA were also homozygous for the mutation (Table 17). Only one of these dogs had 
previously had an eye examination, at the age of six years, and was free of PRA at the 
time. Another subsequently underwent follow-up ophthalmoscopic examination at the 
AHT (sections 2.1.1.2 and  4.5.3). 
Table 17. C2ORF71 genotypes and PRA clinical status for 72 IrSs 
In addition to these setter breeds, C2ORF71c.3149_3150insC has been identified in Standard 
Poodles (SP) Tibetan Terriers (TT) and English Setters (ES) (Table 18). Six out of nine 
C2ORF71
-/-
 ESs had been clinically diagnosed with PRA. Interestingly in this breed, the 
C2ORF71c.3149_3150insC allele was found exclusively in dogs from Norway. Out of three 
SPs and six TTs that were C2ORF71
-/-
, one and three respectively had been diagnosed 
with PRA. The five dogs without a PRA diagnosis were sampled for different studies 
and therefore were too young to show signs of RCD4 and/or were not 
ophthalmoscopically examined.  
The allele frequency of C2ORF71c.3149_3150insC in the GoS, IrS, ES and TT breeds is 
extremely high for an autosomal recessive disease allele. The cohorts screened 
contained samples collected for the purposes of research, including all available samples 
from dogs clinically affected with PRA, and samples from PRA-unaffected dogs closely 
related to affected dogs and to one another. These cohorts were therefore subject to 
considerable sampling bias. This combined with the relatively small number of samples 
screened has resulted in cohorts that do not conform to HWE, with the exception of IrSs 
(Table 18). Analyses using only 36 dogs with unique sires and dams resulted in a 
reduced disease allele frequency, and this cohort does conform to HWE (Table 18). This 
suggests that the high degree of relatedness between samples is a major cause of 
deviation from HWE, and must be considered when making disease frequency 
predictions and subsequent breeding recommendations.  
Genotype PRA Affected PRA Unaffected Total 
C2ORF71
-/-
 
7 5 12 
70.0% 8.1% 16.7% 
C2ORF71
+/-
 
2 25 27 
20.0% 40.3% 37.5% 
C2ORF71
+/+
 
1 32 33 
10.0% 51.6% 45.8% 
Total 10 62 72 
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Table 18. Population screening for RCD4 
 Observed Genotypes* HWE 1-in-__ Expected 
Breed -/- -/+ +/+ TOTAL 
Allele 
Freq 
χ2 P Affected Carrier 
Research Cohort 
Gordon 
Setters 
39 47 40 126 0.50 8.12 4.00x10
-3
 4 2 
Gordon 
Setters 
Unrelated 
6 14 16 36 0.36 0.89 0.35 8 2 
Irish 
Setters 
12 27 33 72 0.35 2.34 0.13 8 2 
English 
Setters 
9 7 40 56 0.22 22.90 1.70x10
-6
 20 3 
Standard 
Poodle 
3 3 86 92 0.05 38.81 4.66x10
-10
 418 11 
Tibetan 
Terrier 
6 11 81 98 0.12 20.57 5.75x10
-6
 73 5 
AHT Genetic Services Cohort 
Gordon 
Setters 
208 747 833 1788 0.33 4.14 0.04 9 2 
Irish 
Setters 
158 824 1267 2249 0.25 2.28 0.13 16 3 
Tibetan 
Terrier 
1 24 35 60 0.22 1.91 0.17 21 3 
 
* The mutant allele is represented by “-“ and the wildtype allele by “+”. 
 
4.5.2 AHT Genetic Services Cohort 
The DNA test for RCD4 was made available commercially on 21 March 2011, initially 
only for GoSs and later for IrSs and TTs also. Over a period of 24 months 1,788 GoSs 
from 28 countries were genotyped by AHT Genetics Services (Table 18). Overall, 208 
(12%) were C2ORF71
-/-
 and 747 (42%) were C2ORF71
+/-
, indicating an overall allele 
frequency of 0.325. Similarly over a period of 18 months 2,249 IrSs from 31 countries 
were genotyped for C2ORF71c.3149_3150insC (Table 18). Overall, 158 (7%) were 
C2ORF71
-/-
 and 824 (37%) were C2ORF71
+/-
, equal to an overall allele frequency of 
0.253. TTs have recently been added to the breeds tested, and over a period of three 
months 60 TTs from two countries were genotyped for C2ORF71c.3149_3150insC (Table 
18). Overall, only one (2%) was C2ORF71
-/-
 and 24 (40%) were C2ORF71
+/-
, equal to 
an overall allele frequency of 0.217. The larger number of samples resulted in a 
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distribution of genotypes closer to HWE than research samples; only the GoS cohort did 
not conform to HWE. The Genetic Services cohorts are therefore likely to be more 
representative of the general population than the research cohorts.  
The allele frequency for each country was calculated for those represented by at least 20 
samples (Table 19) and range from 0.16 to 0.5 in GoSs and 0.003 to 0.33 in IrSs. The 
allele frequency in TTs in the UK is 0.22. Interestingly, each cohort represented by >20 
samples, with the exception of the Finnish GoS cohort, conforms to HWE. Additionally, 
the frequency of C2ORF71c.3149_3150insC is higher than expected for the recessive disease 
trait in most cohorts. 
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Table 19. GoS RCD4 breakdown by country (n>19) 
 
Observed C2ORF71 Genotypes* HWE 1-in-__ expected 
 
Country -/- -/+ +/+ TOTAL 
Allele 
Freq 
χ2 P Affected Carrier Region† 
Gordon Setters 
Australia 10 37 42 89 0.320 0.18 0.67 10 2 1 
Canada 0 11 22 33 0.167 1.32 0.25 36 4 2 
USA 11 102 189 302 0.205 0.37 0.54 24 3 2 
Poland 7 30 19 56 0.393 0.85 0.36 6 2 3 
Russia 5 19 14 38 0.382 0.13 0.71 7 2 3 
Norway 2 17 45 64 0.164 0.06 0.80 37 4 4 
Sweden 5 18 24 47 0.298 0.33 0.56 11 2 4 
Finland 1 28 22 51 0.294 5.30 0.02 12 2 4 
Italy 5 16 9 30 0.433 0.22 0.64 5 2 5 
UK 70 203 182 455 0.377 1.14 0.28 7 2 6 
Austria 0 12 11 23 0.261 2.87 0.09 15 3 6 
Switzerland 2 20 19 41 0.293 1.30 0.25 12 2 6 
Germany 42 158 153 353 0.343 0.02 0.90 9 2 6 
Netherlands 14 29 34 77 0.370 2.85 0.09 7 2 6 
Belgium 11 20 11 42 0.500 0.10 0.76 4 2 6 
Total 185 720 796 1701 0.320 1.34 0.25 10 2 
 
Irish Setters 
Australia 3 14 22 39 0.256 0.13 0.71 15 3 1 
USA 0 1 195 196 0.003 0.00 0.97 153,664 197 2 
Poland 1 10 22 33 0.182 0.01 0.92 30 3 3 
Hungary 1 9 14 24 0.229 0.09 0.76 19 3 3 
Norway 0 7 30 37 0.095 0.40 0.53 112 6 4 
Sweden 4 39 72 115 0.204 0.21 0.65 24 3 4 
Finland 11 55 89 155 0.248 0.38 0.54 16 3 4 
UK 81 410 482 973 0.294 0.22 0.64 12 2 6 
Belgium 10 61 77 148 0.274 0.20 0.65 13 3 6 
Germany 25 111 133 269 0.299 0.07 0.79 11 2 6 
Netherlands 10 59 52 121 0.326 1.43 0.23 9 2 6 
Total 146 776 1188 2110 0.253 1.56 0.21 16 3 
 
Tibetan Terriers 
UK 1 24 34 59 0.220 2.00 0.16 21 3 6 
Total 1 24 34 59 0.220 2.00 0.16 21 3 
 
 
* The mutant allele is represented by “-“ and the wildtype allele by “+”. 
† 1 = Australasia; 2 = North America; 3 = Eastern Europe; 4 = Northern Europe; 5 = Southern Europe; 6 = Western 
Europe 
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4.5.3 Ophthalmoscopic Follow-Up 
Three of the GoSs and one of the IrSs not previously diagnosed with PRA but identified 
as homozygous for the C2ORF71c.3149_3150insC allele during the screening of research 
samples described above were subsequently examined by an ophthalmologist (section 
2.1.1.2; Table 20). The three older dogs (GoS#1, GoS#2 and IrS#2) displayed clinical 
signs consistent with PRA and this was confirmed by flat ERG traces in two of them 
(data not shown). GoS#3 did not display any clinical signs associated with PRA, but did 
have a reduced ERG response (data not shown). 
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Table 20. Ophthalmoscopic examination and ERG analysis of C2ORF71
-/-
 dogs 
ID Age (years) Ophthalmoscopic examination ERG Method ERG Result Information from owner 
GoS#1 11 
 Poor pupillary light reflexes   No sedation  
Flat traces 
Nyctalopia i.e. tentative and 
nervous in dark 
 Bilateral cataracts   Darkened room, without dark adaptation 
 Tapetal hyper-reflectivity   Average of 12 flashes 
 Mild/moderate blood vessel attenuation 
 
GoS#2 11 
 Subtle changes in tapetum  Dark adapted 
Flat traces 
Retains enough vision to run an 
agility course 
 Mild vessel attenuation  Under anesthesia 
 
 Average of 8 flashes 
Gos#3 6.5 
 Normal retina   Dark adapted 
Diminished responses 
 
 Incipient cataracts  Under anesthesia 
 
 Average of 8 flashes 
IrS#1 13 
 Nuclear sclerosis 
 None None 
Completely blind for 2 years at 
time of examination 
 Senile cataract formation 
 Areas of tapetal hyper-reflectivity 
 Mild vascular attenuation. 
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4.5.4 RCD4 Haplotype Comparison 
Only two informative microsatellite markers could be identified within 50 kb of the 
C2ORF71c.3149_3150insC mutation; CFA17_25.99 at 25.99 Mb is 20,486 bp upstream of 
the mutation, and CFA17_26 at 26.01 Mb is 794 bp upstream. These markers were 
genotyped (section 2.2 and 2.3.3) in dogs (from the five affected breeds) that were 
C2ORF71
-/-
, C2ORF71
+/- 
and C2ORF71
+/+
 (Figure 35). The results indicate that 
C2ORF71
-/- 
dogs all share a single allele at both marker loci (315 at CFA17_25.99 and 
295 at CFA17_26), while C2ORF71
+/-
 dogs all have at least one copy of the ‘315 295’ 
haplotype. This suggests that the C2ORF71c.3149_3150insC mutation is ancestral to these 
breeds. The presence of this haplotype in normal dogs from the IrS and ES breeds 
suggests the haplotype is relatively common in these breeds, but not in the three 
remaining breeds, GoS, SP and TT.  
 
Figure 35. Haplotypes comparison in five RCD4-affected breeds 
Genotypes of two markers in close proximity to the C2ORF71c.3149_3150insC variant in 
RCD4-affected, -carrier and –normal dogs from 5 different breeds. a=affected, 
c=carrier, n=normal at RCD4 locus.  
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4.6 Discussion 
Using a GWA mapping approach, a novel locus on chromosome 17 that is significantly 
associated with PRA in the GoS breed (pgenome = 2.00x10
-5
) has been identified. A 
critical region of 3.221 Mb was defined through homozygosity mapping using the SNP 
genotypes. Most of the cases (15/16) and one control (1/22) were homozygous for the 
same haplotype across the critical region. C2ORF71 was identified as a strong candidate 
causal locus within the PRA-critical region as it has been implicated in human retinitis 
pigmentosa
156,157,164
. C2ORF71 is highly expressed in the eye in humans, and is 
localised to the photoreceptors, specifically the outer segment or connecting cilium
157
. 
The phenotypes of individuals affected with mutations in C2ORF71 vary in that while 
RP is usually diagnosed as an adult, individuals with a more severe and early-onset 
retinal dystrophy have also been described
157
. The human protein contains no known 
functional domains. However, a proline-rich region near the C-terminal end of the 
protein is annotated on the Ensembl GRCh37 assembly (Figure 34). While the 
functional significance of this domain in C2ORF71 is unknown, proline-rich domains in 
other proteins have been implicated in protein interactions
165
. In addition, evidence 
indicates that residues G2 and C3 are highly conserved and undergo post-translational 
lipid modification
157
. Finally, Collin et al. also show that C2ORF71 plays an important 
role in the mature retina, and may also be required in the developing retina
156
. A novel 
candidate mutation in the C2ORF71 gene was identified that is likely to represent a 
major causal mutation for PRA in the GoS. This mutation was a frame-shifting insertion 
that is predicted to result in a truncated protein product (c.3149_3150insC, 
p.C1051VfsX90). 
Sequencing of C2ORF71 from healthy retinal mRNA served three purposes. Firstly it 
confirmed the presence of the C2ORF71 mRNA transcript in the normal canine retina. 
Secondly it revealed that the intron-exon boundaries predicted by Genebuild for the dog 
are incorrect. They are instead identical to the human and mouse boundaries. Thirdly it 
revealed an exon orthologous to human exon 2, that is absent from the Ensembl canine 
predictions (Figure 33). No alternative isoforms of C2ORF71 were observed, and none 
have been reported for the mouse or human gene.  
In order to further test the validity of the insertion mutation, 126 GoSs were screened 
for the mutation (Table 16). Most 19/22 (86.4%) of the PRA cases and 80.8% of 
clinically unaffected dogs (which could be clear of the mutation or carry a single copy) 
have C2ORF71 genotypes that are concordant with their clinical status. There are two 
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groups of dogs with genotypes discordant with their phenotypes. The first comprises 20 
PRA-clear dogs that are C2ORF71
-/-
. Three of these dogs had cataracts and as a result a 
comprehensive fundus exam was impossible, and an ERG was not conducted. It is 
possible the cataracts in these dogs may be secondary to undiagnosed PRA. A further 
four dogs, while not officially diagnosed with PRA, were described to have abnormal 
blood vessels (narrow or atretic). These signs are consistent with the very early stages of 
PRA. We were unable to obtain clinical information pertaining to seven of the dogs, and 
the remaining six dogs were examined between the ages of 2 and 11 years. The age of 
diagnosis of RCD4 is highly variable, ranging from 5-12 years, with an average of 9.8 
years in our cohort, and as such these eight discordant dogs could have been examined 
prior to the onset of their clinical signs. Of the 20 discordant dogs, three were 
subsequently re-examined (Table 20). GoS#1 and GoS#2, both 11 years old, displayed 
clinical signs and a flat ERG trace (indicative of limited or no retinal function) 
consistent with PRA. GoS#3, at only 6.5 years old had a normal retina, but a reduced 
ERG trace (indicative of reduced retinal function), suggestive of very early sub-clinical 
PRA. This dog also had incipient cataracts which could be secondary to PRA. This 
suggests the onset of retinal degeneration in middle-age and slow progression, a 
hypothesis that may be confirmed by following the progress of this dog in coming 
years. Thus eight of the 20 discordant dogs showed signs of early PRA and if these are 
considered to be affected with PRA, 69.2% of dogs (27/39) homozygous for the 
mutation (C2ORF71
-/-
), have developed PRA, suggesting that the mutation is highly, if 
not fully penetrant, assuming the dogs live long enough to develop the disease. The 
observation that only one of the 47 RCD4 heterozygotes has been diagnosed with PRA, 
including 21 dogs ranging from 9-14 years of age when examined, and the analysis of 
pedigrees (Figure 36) is supportive of a recessive mode of inheritance. The RCD4 
heterozygote is included in the second group of discordant dogs which comprises three 
PRA-affected dogs that are not C2ORF71
-/-
. Interestingly these dogs have a younger age 
at diagnosis (less than 4.5 years) than the average of 9.8 for all other cases. This 
suggests a locus other than C2ORF71 may be associated with PRA in these dogs. 
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Figure 36. Segregation of RCD4 in a GoS pedigree 
The segregation of RCD4 is consistent with an autosomal recessive mode of 
inheritance. A single dog (#21) is homozygous for RCD4 but has not been diagnosed 
with PRA. This dog does have cataracts which prevented fundus examination and could 
be secondary to undiagnosed PRA. The RCD4 mutant allele is represented by “-“ and 
the wildtype allele by “+”. 
IrSs and IRWSs are now distinct breeds, although they share ancestors and were once 
considered coat colour variants of a single breed. They are therefore closely related to 
one another, and to GoSs, and as a result are the breeds most likely to share the 
C2ORF71c.1349_1350insC mutation. Screening of 72 IrS and 19 IRWS dogs, including ten 
and three late-onset, non-rcd1, PRA cases respectively, revealed that the mutation is 
present in IrSs, but is absent from IRWSs. C2ORF71 genotypes of 70.0% of the IrS 
PRA cases and 91.9% of clinically unaffected dogs (which could be clear of the 
mutation or carry a single copy) were concordant with their clinical status. The 
discordant dogs could be explained with similar arguments to the GoS above. Four of 
the five PRA-unaffected dogs genetically affected with RCD4 (C2ORF71
-/-
), were not 
examined beyond their sixth birthdays, and would therefore probably not yet have 
developed PRA. Subsequent to these findings the fifth dog was examined 
ophthalmoscopically at the age of 13 (IrS#1,Table 20), by which time she had been 
clinically blind for 2 years. None of the changes observed were sufficient to cause 
complete blindness, and were also insufficient to be diagnosed as PRA. However, due 
to the restricted view of the fundus it is possible that further PRA-associated changes 
were missed. In addition a confirmatory ERG was not available. 
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As the ES breed is part of the Setter family, along with the GoS and IrS breeds, the 
detection of RCD4 in this breed was anticipated. RCD4 was only detected in ESs from 
Norway. However, the 36 ESs that make up the remainder or the cohort are all from 
related UK breeding lines with only seven unique sires and ten unique dams between 
them, and none were clinically affected with PRA. These samples therefore provide 
insufficient evidence to infer the absence of RCD4 from the UK ES population.  
The detection of RCD4 in TTs and SPs was surprising considering these breeds are 
relatively distantly related to one another and to the Setters
24
. However, this is not an 
unprecedented scenario in dogs as prcd has been detected in many diverse breeds
47
. One 
hypothesis to explain the detection of RCD4 in diverse breeds is the presence of a 
mutation hotspot, in which the same effective mutation, the insertion of a C somewhere 
in a poly(C) tract, arose more than once as independent events. The detection of the 
same alleles, 315 and 295 of markers CFA17_25.99 and CFA17_26 respectively, 
inherited with C2ORF71c.1349_1350insC mutation in all five breeds (Figure 35) is in conflict 
with this hypothesis. Rather the evidence indicates a single mutation event occurred on 
a chromosome containing alleles 315 and 295, prior to individual breed formation. One 
hypothesis is that the “315 295” haplotype was common in the population when the 
C2ORF71c.1349_1350insC variant arose, resulting in copies of this haplotype that do not 
carry the mutation. This is demonstrated in the IrS and ES dogs genotyped, and suggests 
that the mutation may have originated in ancestors of the IrS and ES breeds, prior to 
dispersal to other breeds.  
The mutation allele frequency in four of the five breeds screened is unusually high for a 
recessive disease allele (Table 18). These frequencies are likely over-estimates, as 
research sample cohorts are subject to sampling bias and therefore are unlikely to be 
representative of the wider population. This hypothesis is supported by the observation 
that only the IrS and unrelated GoS cohorts conform to HWE. Nevertheless these data 
suggest the mutation is common in all four breeds.  
The data obtained from the AHT Genetics Services cohorts (Table 18), while also 
unlikely to be completely representative of breed populations, is arguably more so than 
research cohorts, particularly as a larger dataset is available. The mutation allele 
frequency in GoSs of 0.33, much lower than that of the research cohort, indicated that 1-
in-9 GoSs worldwide are genetically affected with RCD4 and almost half (0.44) carry 
the mutation. The mutant allele frequency in IrSs of 0.25 indicated that 1-in-16 IrSs 
worldwide are genetically affected with RCD4 and more than one third (0.38) carry the 
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mutation. In addition the GoS allele frequencies observed in 15 different countries are 
similar, ranging from 0.16-0.5. IrS allele frequencies observed in 10 different countries 
(excluding the USA) range from 0.01-0.33. Interestingly for both breeds the highest 
allele frequencies are observed in European countries, followed by Australasia and 
North America. The presence of the mutation in TTs (with an allele frequency of 0.22 in 
the UK), SPs and setter breeds, as well as the results of microsatellite marker 
genotyping, suggests it may have arisen early in, if not prior to the development of the 
breeds, before geographically distinct populations were formed. This could also explain 
the low frequency of C2ORF71c.3149_3150insC in IrSs from the USA: the US population 
may have been founded with a small cohort of dogs in which the mutant allele was 
absent or very rare. However the apparent absence of C2ORF71c.1349_1350insC from the 
IRWS breed is surprising. While the mutation has not been found in the population, and 
does not account for the three late-onset PRA cases tested (with an average age of 
diagnosis of 10 years), the possibility that RCD4 may be present in the IRWS 
population cannot be ruled out as the number of cases tested was very small. 
Alternatively the RCD4 allele may have been lost when the breed underwent a severe 
bottleneck towards the end of the 19
th
 century, reaching the brink of extinction. The 
extraordinarily high mutant allele frequency in most breeds could be a result of a lack of 
selection against the disease as dogs would only begin to show clinical signs well after 
the normal breeding age. The late age of onset may also account for the diverse range of 
breeds affected. It is possible, if not highly likely, that many older dogs go blind due to 
late-onset PRA, potentially RCD4, but a diagnosis is not sought as the loss of sight is 
attributed to old age. It is also possible that RCD4 segregates in additional breeds but 
has thus far gone undetected. 
Interestingly, this mutation still does not account for all cases of PRA in the GoS or 
non-rcd1 PRA in the IrS breeds, indicating the presence of at least one additional 
mutation for PRA in each breed that remains to be identified. This additional variant 
may be extremely rare in GoS and IrS dogs and as such it will be difficult to collect a 
sufficient number of cases to conduct a GWA study and alternative approaches need to 
be considered (discussed in Chapter 6). 
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4.7 Conclusion 
PRA in the GoS has not previously been associated with any genetic mutations. Using a 
GWA analysis approach, a novel candidate mutation, c.3149_3150insC, was identified 
in the C2ORF71 gene that is likely to represent a causal mutation for PRA in the GoS 
and IrS. While this mutation does not account for all cases of PRA in this study, 
suggesting that there are additional loci causing PRA in these breeds, it does appear to 
be highly penetrant and a major cause of PRA in these breeds. Given that RCD4 is also 
present in at least three other breeds it is possible, if not probable, that more breeds are 
affected. Screening of dogs from as many breeds as possible for RCD4 is therefore 
warranted. The development and availability of a DNA test will enable breeders to 
eventually eliminate RCD4 from the breeds affected entirely.  
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Chapter 5  Tibetan Spaniels 
 
5.1 Introduction and Background 
Tibetan Spaniels are fairly healthy as a breed, and in general are currently predisposed 
to only a few hereditary conditions including PRA, cataracts and entropion
121
. The 
origin of the breed, along with the Lhasa Apso (LA) and Tibetan Terrier (TT) breeds 
(which are also predisposed to PRA) can be traced back to ancient Tibetan 
monasteries
122
. Apart from the small number of clinically affected TTs that are 
homozygous for the RCD4 mutation that have been identified during this study as  (as 
described in Chapter 4), the mutations responsible for PRA in any of these Tibetan 
breeds have yet to be identified. While initial investigations will focus on TSs, due to 
their similar origins it is possible all three breeds share an ancestral mutation causing 
PRA. 
5.2 Diagnoses and Clinical Signs 
Typical ophthalmoscopic signs observed in TSs with PRA include tapetal hyper-
reflectivity, attenuated blood vessels and optic nerve atrophy. The average age at 
diagnosis in our sample cohort, which is indicative of age of onset, is 4.69, but ranges 
from 1 to 11 years of age. The wide range of ages-at-diagnosis could be due to a cohort 
comprising genetically different forms of PRA or a single form of PRA with a variable 
phenotype. 
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5.3 SNP Genotyping 
5.3.1 Genome-Wide Association Mapping 
GWA analysis (section 2.3.2) of genotyping data from 32 TS dogs (22 cases and 10 
controls over the age of four when last examined) genotyped with 15,674 SNPs (section 
2.3.1)  revealed a genome-wide significant association on chromosome 10 (CFA10; praw 
= 1.77x10
-7
, pgenome = 0.004). Two SNP markers 1.86 Mb apart (BICF2P729624 at 62.0 
Mb and BICF2S23250878 at 63.86 Mb) were equally the most associated with PRA. 
IBS clustering using genome-wide SNP marker data confirmed the presence of 
population stratification with a genomic inflation factor > 1 (λ = 1.69 based on the 
median χ2) and MDS revealed an even distribution of cases and controls (Appendix I). 
The inflation factor was reduced to an acceptable level (λ = 1.06) after correcting for 
population stratification with a CMH meta-analysis. While the signal on CFA10 (praw = 
2.01x10
-5
, Figure 37A) dropped below the level of Bonferroni-corrected significance, 
the permutation-corrected signal remained statistically associated (pgenome = 0.014). 
Alternative analysis of the data using FMM to correct for population stratification 
revealed similar results, with the strongest signal on CFA10 (praw = 5.67x10
-5
, Figure 
37B) and a reduced inflation factor (λ = 1.27). Using both CMH and FMM corrections 
the most associated SNP was BICF2S23422025 at 66.74 Mb. The signal on CFA10 was 
at least 10-fold stronger than a number of signals seen on other chromosomes including 
1, 8 and 38. While only a single SNP (BICF2S23422025 at 66.74 Mb) was statistically 
significantly associated, the signal on CFA10 extended from 62 to 67.37 Mb (Figure 
37C). The use of only ten controls would have reduced the power of the GWA analysis. 
Additional controls would therefore probably have resulted in a stronger statistical 
signal.  
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Figure 37. Genome-wide association mapping of PRA in Tibetan Spaniels 
-Log10 of p-values after correction for population stratification. The red lines indicate 
the Bonferroni-corrected 5% significance level based on 15,674 SNPs. A) The CMH 
meta-analysis approach shows the strongest signal on CFA10 (praw = 2.01x10
-5
, pgenome 
= 0.014). B) The FMM approach also shows a prominent signal on CFA10 (praw = 
5.67x10
-6
). C) The signal spans a region of 5.37 Mb from 62 to 67.37 Mb on CFA10. 
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5.3.2 Homozygosity Analysis and Microsatellite Finemapping 
A haplotype homozygous in cases, but not in controls, could not be easily identified 
through homozygosity analysis (data not shown). The most highly-associated SNP in 
CMH and FMM analyses, BICF2S23422025 (pgenome = 0.014) is homozygous (A/A) in 
most of the cases (19/22), but also in 3/10 controls. The SNP20 BeadChip contains a 
relatively small number of SNPs resulting in a low genotyping resolution – one  SNP 
approximately every 114 kb if all SNPs are informative. In the case of the TS cohort, 
only 15,674 SNPs were informative, resulting in 1 SNP approximately every 159 kb on 
average. This made it difficult to identify homozygous haplotypes from the SNP data 
alone so additional microsatellite markers from the region were genotyped to provide 
additional haplotype information (Figure 38). Due to sample availability constraints 
(low DNA quantity) only 18 of the original 22 cases and five of the original ten controls 
(one of which is an obligate carrier) used in the GWA study were used in the 
microsatellite marker genotyping study. Even with the increased resolution it was not 
possible to define a haplotype that was homozygous in all cases. A number of factors 
may contribute to this: there may be more than one form of PRA in the breed and the 
cases are therefore heterogeneous; alternatively the causal mutation may be within a 
haplotype too small to be easily identified at the current marker resolution. Due to the 
uncertainty of the precise boundaries, a broad critical region of 3.794 Mb, from 63.935 
Mb to 67.729 Mb on CFA10 was identified. This region is almost completely 
homozygous in most of the cases (12/18) and none of the controls, but heterozygous in 
the obligate carrier. This region contains 31 genes, 29 of which have human orthologues 
(Figure 38B and Appendix IV).  
At the time this work was undertaken, none of the genes in the region could be 
identified as strong functional candidates. However RP28 had been mapped to a locus 
in humans (2p14-15)
166,167
, and part of the genomic region in dogs syntenic to the RP28 
locus overlapped with the PRA critical region identified here. Due to the lack of 
identifiable candidate genes, sequencing of the whole critical region with next 
generation sequencing was chosen for further investigation of the TS_PRA locus. 
Subsequently, mutations in FAM161A have been associated with RP28 in humans and 
this gene was therefore identified as an excellent candidate gene for further 
investigation
168,169
. None of the other genes in the region are known to be involved in 
ocular or retinal function or are associated with vision loss in any species. 
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Figure 38. Homozygosity analysis of TSs with PRA 
A) Microsatellite and SNP marker genotypes for 18 PRA cases and five controls (made 
up of one obligate carrier and four normal dogs) over the region identified during the 
GWA study. It is not possible to define a narrow region for which all of the cases are 
homozygous, however, it is possible to define a broad region for which most of the 
cases (12/18) are homozygous, from 63.935 to 67.729 Mb. The most associated SNP 
markers are indicated with arrows (→) B) The critical region contains 31 genes, as 
annotated on CanFam2.0 (taken from Ensembl). 
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5.4 Sequencing of the TS_PRA locus on CFA10 
5.4.1 Target Enrichment of the TS_PRA Critical Region 
Custom-made RNA baits were designed based on the CanFam2.0 reference sequence 
(section 2.4.2.1), to cover the 3.794 Mb critical region (CFA10:63-68 Mb). As repeat 
masking was applied to avoid repeat-rich regions, baits were designed over 2.723 Mb, 
54% of the total region with an average GC content of 41.0%. 
Target enrichment of 10 gDNA samples (four cases, two obligate carriers and four 
controls) with the custom RNA baits was performed (section 2.4.2.2) and the captured 
libraries for each sample had concentrations ranging from 1.71 nM to 13.22 nM. 
Samples were pooled and the final library contained 54.5 μL captured DNA at a 
concentration of 3.7 nM. While this is less than the 10 nM recommended by the 
manufacturer, it proved to be sufficient for successful sequencing. 
5.4.2 NGS Data Analysis – Target Capture Efficiency 
More than 280 million reads were generated in total (section 2.4.2.5), for all 10 sample 
sequences combined. Approximately 30% of these reads were PCR duplicates and 
therefore removed from further analysis. A total of >190 million reads remained, 96% 
of which mapped to CanFam2.0. Approximately 72% of bases mapped to the targeted 
regions, and almost 65% of all reads had >30x coverage (Table 21).  Target capture 
efficiency is represented by the percentage of bases that map to the targeted regions, and 
was relatively similar between the 10 samples processed, with an average of 71.8%. 
Baited regions also had an average read depth of 236 reads. 
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Table 21. Capture efficiency for TS_PRA targeted NGS 
5.4.3 NGS Data Analysis – Variant Identification 
More than 19,000 SNPs and 3,700 indels were identified when the sequence was 
compared with the CanFam2.0 reference sequence (section 2.4.2.5). Of these, 194 SNPs 
and 81 indels segregated with the phenotype, but none of these variants were predicted 
to alter the protein product. Visual analysis of sequence data in IGV revealed 16 
additional variants (larger insertion and deletions not identified using the NGS analysis 
pipeline), of which seven segregated with the phenotype. One of these variants is an 
insertion flanked by a 14 bp repeat motif (Figure 39). This repeat is visualised in IGV as 
an increase in the read depth. The length of the inserted sequence is longer than the 
length of the NGS reads (>50 bp) and the precise sequence of the insertion could 
therefore be only partly determined (Figure 39B). Only this variant, which was 
predicted to be located near a splice acceptor site of the FAM161A gene (CFA8: 
64,974,130; Figure 39), could potentially alter the protein product, by interfering with 
exon splicing.  
 
 
Sample 
no. 
Clinical 
Status 
Mean coverage 
of baited region 
(X) 
Bases mapped 
to targets (%) 
Bases with 
>10X 
coverage (%) 
Bases with 
>20X 
coverage (%) 
Bases with 
>30X 
coverage (%) 
1 Affected 289 74.68 72.54 69.06 66.33 
2 Affected 273 73.68 72.16 68.59 65.82 
3 Affected 248 74.42 71.82 68.24 65.39 
4 Affected 253 74.76 71.98 68.38 65.61 
5 Carrier 201 72.31 71.49 67.39 64.10 
6 Carrier 248 73.90 70.43 66.68 63.83 
7 Normal 169 69.98 69.85 65.31 61.75 
8 Normal 238 71.93 73.36 69.37 66.25 
9 Normal 275 72.33 72.15 68.63 65.97 
10 Normal 168 59.66 70.10 65.65 62.08 
 Average 236 71.77 71.59 67.73 64.71 
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Figure 39. IGV display of the >50 bp insertion in FAM161A  
A) Each of the three samples (PRA-affected, obligate carrier and control) viewed in 
IGV are represented by two panels. The upper panel is a histogram where the height of 
each column is representative of the read depth at that location. The increased read 
depth in the affected panel is characteristic of a duplication, caused by the repeat motif 
flanking the insertion. The lower panel is a graphical view of a subset of the reads that 
align to that location. The sudden termination of reads and the insertion symbol (I) 
either side of the duplicated sequence is also characteristic of an insertion flanked by the 
duplicated sequence. The inserted sequence is present in all reads in the PRA-affected 
sample, approximately half the reads in the obligate carrier and none of the reads in the 
PRA-unaffected (control) sample. B) Inserted sequence (blue and green) as determined 
from NGS data, flanked by 14 bp repeats (orange). 
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5.4.3.1 Sanger Sequencing of FAM161A Insertion 
The full sequence of the insertion was determined by Sanger sequencing (sections 
2.4.1.3-2.4.1.8) using primers flanking exon 5 of FAM161A, including the insertion site 
in gDNA from 80 TS dogs (29 affected with PRA, 10 obligate carriers and 41 
unaffected). Using agarose gel electrophoresis, a single band of the expected size (720 
bp) was visible for 40 unaffected samples, while a band approximately 230 bp larger 
(~950 bp) was visible for 17 of the PRA affected samples and none of the carrier or 
unaffected samples (data not shown). Carriers of the insertion were more difficult to 
identify from gel electrophoresis alone (the larger band was not as bright as the smaller 
band, and sometimes not visible at all), presumably due to preferential amplification of 
the shorter DNA fragment lacking the insertion. However, carriers were identifiable by  
Sanger sequencing. Sequencing of the ~230 bp insertion revealed that it contains a 132 
bp short interspersed nuclear element (SINE), a retroposon that is distributed widely 
throughout the canine genome
170
. As is characteristic, the SINE is followed at the 3’ end 
by a dinucleotide repeat, (CT)8, and a poly(A) tract (interrupted by the occasional T) at 
least 45 bp in length. The nucleotides at the 3’-end of the poly(A) tract are duplicated at 
the 5’-end of the SINE (Figure 40). The number of adenine nucleotides that comprise a 
portion of the poly(A) tract (underlined in Figure 40A) could not be determined 
accurately due to difficulties amplifying homopolymers with synthetic taq polymerases, 
specifically polymerase slippage along the poly(A) tract. However, based on the 
sequence traces, there appear to be 35-50 adenine nucleotides.  
 
 
Figure 40. Sequence of SINE insertion 
A) The sequence and B) graphical representation of the SINE insertion. The precise 
number of nucleotides that comprise the underlined portion of the poly(A) tract remains 
unclear, but is approximately 35-50. 
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5.4.3.2 Poly(A) Tract Length 
An AFLP assay (section 2.2) using primers flanking the SINE insertion was used to 
further define the length of the insertion and therefore the poly(A) tract. As a result of 
Taq polymerase slippage on the poly(A) tract, amplification of the SINE insertion 
resulted in multiple products varying in size, creating a “hedgehog” effect (Figure 41). 
The SINE insertion was amplified from 21 dogs that were either homozygous (n = 14) 
or heterozygous (n = 7) for the SINE insertion, as determined by sequencing (Section 
5.4.3.1). For most dogs (15/21), the highest peak was at 391 bp (Figure 41A). The size 
of the wildtype amplicon is 153 bp, and this suggests the SINE insertion is 238 bp in 
size. Therefore, the poly(A) tract (represented by the underlined text in Figure 40A) is 
44 nucleotides in length. In 5/21 samples assayed the highest peak was at 396 bp 
(Figure 41B), suggesting a poly(A) tract five nucleotides longer i.e. 49 nucleotides. One 
dog carried a single copy each of the 391 and 396 bp alleles (Figure 41C). The age at 
diagnosis was known for 12 of the dogs assayed that were clinically affected with PRA 
(Figure 41). The age at diagnosis of PRA in dogs with only the 391 bp allele ranges 
from 2.9 to 10.2, but there is insufficient data for the 396 bp allele. These data are 
consistent with the length of the poly(A) tract having no effect on the age at diagnosis. 
 
Figure 41. AFLP assay of SINE insertion 
Amplification of the SINE insertion resulted in multiple products. A) The highest peak 
was at 391 bp in most dogs, and the age at diagnosis ranged from 2.9 to 10.2 years. B) 
In some dogs the highest peak was at 396 bp. One of these dogs was diagnosed at 3.3 
years of age. C) A single dog carried both allele 391 and allele 396, and was diagnosed 
at 4.2 years of age.  
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5.4.4 Characterising FAM161A Retinal Transcripts 
In humans FAM161A occurs in two main isoforms, full-length (FAM161Afl) and short 
(FAM161Ash), formed by alternative splicing of exon 4 (Figure 42)
168,169
. Four 
incomplete canine FAM161A isoforms were predicted by Ensembl, but alignment with 
human and mouse genomic and coding sequences (section 2.4.1.1) revealed several 
inconsistencies and possible errors in the prediction of canine intron-exon boundaries 
(Figure 42A-C). Most of the coding sequence of the FAM161A retinal transcripts 
(section 2.1.2.2), from both the main isoforms (FAM161Afl and FAM161ash), was 
successfully sequenced (sections 2.4.1.2-2.4.1.8) in a healthy dog, excluding the first 46 
nucleotides of the coding sequence (Figure 42D and E). Sequencing revealed that both 
isoforms are transcribed in the canine retina. In addition, intron-exon boundaries are 
identical to those of the human and mouse, which is in conflict with the boundaries 
predicted by Ensembl genebuild for the canine gene. Canine retinal mRNA sequence 
differed from CanFam2.0 reference sequence in exon 1, and two variants were 
identified: the first was a SNP (CA) that changes an alanine residue to an aspartic 
acid residue; the second was a 6 bp insertion resulting in the in-frame insertion of two 
alanine residues (Figure 42E). To assess the prevalence of these variants, gDNA from 
43 TSs and 76 dogs comprising 31 breeds were sequenced.  The SNP variant was 
present in the homozygous and heterozygous state in both cohorts (i.e. TSs and multiple 
breeds). Eight dogs from five breeds, excluding TSs, were heterozygous for the 
insertion variant and none were homozygous. It is unclear what effect, if any, these 
variants have on the protein, but these data suggest they are unlikely to be pathogenic. 
Sequencing of the full 5’- and 3’-UTRs and the beginning of exon 1 was unsuccessful, 
probably due to high GC content. Sequencing revealed that canine FAM161Afl contains 
716 amino acids and FAM161Ash contains 660 amino acids, with predicted molecular 
weights of  83kDA and 76kDa respectively. The SINE insertion occurs near the 
acceptor splice site of intron 4 i.e. near the boundary of intron 4 and exon 5 
(FAM161Afl: c.1758-15_1758-16ins238; FAM161Ash: c.1590-15_1590-16ins238) 
(Figure 42D). 
  
Chapter 5 – Tibetan Spaniels 
161 
  
Figure 42. Graphical comparison of the intron-exon boundaries of FAM161A. 
A) Mouse (Mus muscularis) FAM161A. B) Human (Homo sapiens) FAM161A. C) 
Canine (Canis familiaris) FAM161A as predicted by Ensembl genebuild. Six genebuild 
exons (black) are identical to the mouse and human exons, while the intron-exon 
boundaries for five exons (grey) are inconsistent and four exons (white) bear little or no 
resemblance to human and mouse exons. D) Canine FAM161A exons confirmed by 
sequencing the retinal mRNA transcript. Exon 1 (red) was only partially sequenced. The 
location of the splice site insertion is indicated. E) Only the 3’-end of exon 1 (black) 
was successfully sequenced. Two alternative alleles were identified in retinal mRNA 
that differed from the CanFam2.0 reference sequence. 
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5.4.5 FAM161Ac.1758-15_1758-16ins238 Variant Validation 
5.4.5.1 AFLP Genotyping Assay 
The straightforward AFLP assay used in section 5.4.3.2 (i.e. amplification of the region 
surrounding the SINE insertion with a pair of flanking primers, and comparison of 
amplicon lengths to determine the presence or absence of the SINE; Figure 43A) proved 
inefficient as a genotyping assay. Specifically, carriers of FAM161Ac.1758-15_1758-16ins238 in 
particular, but also homozygous dogs, could not always be identified with confidence, 
for two reasons (Figure 43B): 
1) The length of the wildtype and mutant amplicons differed by the length of the 
SINE insertion (~238 bp). As a result, preferential amplification of the smaller 
amplicon resulted in a far stronger fluorescence signal for the wildtype allele 
than for the mutant allele. 
2) As discussed in section 5.4.3.2, these primers generate multiple products due to 
Taq polymerase slippage, resulting in a “hedgehog” effect. This further diluted 
the fluorescence emitted by the mutant allele, which often could not be 
distinguished with confidence from background fluorescence levels. 
To create the most efficient and accurate assay possible three primers were used instead 
of two (Figure 43C; sections 2.2 and 2.6): A single, fluorescently-labelled forward 
primer, a wildtype-specific reverse primer and a mutant-specific reverse primer. These 
primers do not flank the poly(A) tract and result in amplicons of similar size (135 bp 
and 137 bp), thereby generating wildtype and mutant amplicons that emit roughly equal 
fluorescence (Figure 43D). These primers were used for all subsequent FAM161A 
genotyping. 
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Figure 43. FAM161Ac.1758-15_1758-16ins238 genotyping assay 
A) A straightforward AFLP assay using flanking primers (red arrows) proved 
inefficient. B) The fluorescence signal emitted by the mutant amplicon (approximately 
391 bp) was always far lower than that emitted by the wildtype amplicon (153 bp). C) 
The use of allele-specific reverse primers (wildtype = Rwt, mutant = Rmt) resulted in 
amplicons of similar length (135 bp and 137 bp respectively). D) The wildtype and 
mutant amplicons also emitted roughly equal fluorescence. Therefore dogs homozygous 
for the wildtype allele (135 bp, FAM161A
+/+
), heterozygous (FAM161A
+/-
) and 
homozygous for FAM161Ac.1758-15_1758-16ins238 (137 bp, FAM161A
-/-
) could be reliably 
identified. 
  
  
Chapter 5 – Tibetan Spaniels 
164 
5.4.5.2 FAM161Ac.1758-15_1758-16ins238 Genotyping 
All 32 TS dogs (22 cases and 10 controls) that participated in the GWA study were 
screened for the SINE insertion, FAM161Ac.1758-15_1758-16ins238, to confirm the association 
of this variant with PRA and compare it with two of the most highly associated SNP 
markers, BICF2S23422025 and BICF2S23250878. FAM161Ac.1758-15_1758-16ins238 showed 
significant allelic association with PRA (praw = 5.03x10
-7
). The SNP markers also 
showed significant allelic association, although BICF2S23422025 was less associated 
(praw = 6.28x10
-7
). However, BICF2S23250878 was more highly associated (praw = 
1.77x10
-7
) than FAM161Ac.1758-15_1758-16ins238, but this can be attributed to two PRA cases 
that are heterozygous for the SNP (i.e. carry the minor allele) but homozygous for the 
wildtype FAM161A allele. Fifteen out of 22 PRA cases and none of the controls were 
homozygous for FAM161Ac.1758-15_1758-16ins238. Analysis of the segregation of 
FAM161Ac.1758-15_1758-16ins238 with PRA (Figure 44) indicates that the form of PRA 
associated with this variant is recessive and fully penetrant. The form of PRA that is 
associated with FAM161Ac.1758-15_1758-16ins238 is known hereafter as PRA-3. 
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Figure 44. Segregation of PRA-3 in a TS pedigree 
The segregation of PRA-3 is consistent with an autosomal recessive mode of 
inheritance. The PRA-3 mutation (FAM161Ac.1758-15_1758-16ins238) allele is represented by 
“-“ and the wildtype allele by “+”. Clinical information pertaining to and DNA samples 
from 26 individuals was not available. Clinical information about a single dog (#21) 
that was homozygous for FAM161Ac.1758-15_1758-16ins238 was unavailable. 
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5.4.5.3 Sanger Sequencing of Blood and Retinal mRNA Transcripts 
The location of the SINE insertion near the splice acceptor site of exon 5 suggests exon 
splicing may be affected, possibly resulting in the skipping of exon 5. To assess this 
hypothesis, mRNA transcripts were compared between a TS dog homozygous for the 
SINE insertion and two dogs of unknown breed. In the absence of suitable retinal tissue, 
RNA was purified from the blood (section 2.1.3.4) of the affected and one of the 
unaffected dogs, while retinal tissue was available from the other unaffected dog. 
Primers in exons 3 and 6 were used to amplify across exons 4 and 5 (Figure 45A; 
sections 2.2 and 2.4.1.2-2.4.1.8). A number of products were produced for all three 
samples, each of which was individually sequenced (Figure 45B):  
1) Bands 6 and 9 comprise the 421 bp amplicon (FAM161Afl), and bands 8 and 12 
comprise the 253 bp amplicon (FAM161Ash). Both of these isoforms are 
detectable in normal blood and retina, but not affected blood. 
2) Bands 3 and 11 comprise the 321 bp amplicon (FAM161Afl-5) and bands 4 and 
13 comprise the 153 bp amplicon (FAM161Ash-5). Both of these amplicons are 
detectable in affected blood. Interestingly these bands are also detectable in 
normal retina, albeit at lower levels than FAM161Afl and FAM161Ash, but not 
unaffected blood. 
3) Bands 7 and 10 comprise FAM161Afl-FAM161Ash hybrid amplicons i.e. 
sequence consistent with both isoforms was detectable in these bands. These 
could be attributed to depletion of PCR reagents in the latter stages of thermal 
cycling, resulting in annealing of the two isoforms with one another instead of 
with primers. These bands were absent from PCR experiments utilising a 
reduction in the number or cycles or a 30% increase in the reaction volume, and 
therefore in the reagents present (data not shown). A high number of cycles (n = 
40) were necessary in order to visualise PCR amplicons generated from the 
affected blood.  
4) Band 1 comprises an amplicon containing FAM161Afl-5 and intron 3, which 
could be a result of gDNA contamination. Band 2 comprises an amplicon 
containing FAM161Ash-5 and part of intron 5, while band 5 comprises an 
amplicon containing FAM161Afl and two separate parts of intron 5. These two 
amplicons could be a result of incomplete or inaccurate exon splicing. 
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These results suggest that the difference between FAM161A in PRA-3 affected and 
normal blood is the absence and presence respectively of exon 5, supporting the exon-
skipping hypothesis.  
5.4.5.4 Quantitative PCR of FAM161A mRNA Transcripts 
To further compare the levels of the four possible transcripts present in blood from an 
affected dog and from a normal dog, relative qPCR was undertaken using SYBR
®
 green 
chemistry and isoform-specific primers (Figure 45A; section 2.5). Expression levels of 
targets were normalised against two housekeeping genes, TBP and ACTP, and 
compared by relative quantification. Exons 2 and 3 are not known to be affected by any 
alternative splicing, nor are they expected to be affected by the SINE insertion, and it is 
therefore reasonable to assume that all FAM161A isoforms will contain these exons. 
Expression levels of these exons therefore constitute 100% of FAM161A transcripts 
present (FAM161Atotal).  
The coefficient of correlation (R
2
) and amplification efficiency (E) of PCR using each 
primer pair was ascertained from standard curves generated for each isoform target 
(Table 22), which in turn was used to determine expression levels in the blood. R
2
 is an 
indication of how well the data points lie on a single line, or the linearity of the standard 
curve, and should be > 0.985. E is the percentage of template that is amplified during 
each cycle, and should be between 90% and 110%. Many of the PCR reactions have 
suboptimal R
2
 and/or E values, suggesting these assays and subsequent results are 
potentially unreliable. R
2
 < 0.95 is indicative of pipetting error or the presence of 
inhibitory elements. As the only difference between each of the reactions was the 
primers used, and not all of the assays have poor R
2
 values, the presence of inhibitory 
elements is unlikely. In this instance it is likely the suboptimal R
2
 values can be 
attributed to the low reaction volumes used (6 μl) in each assay. Due to sample 
availability constraints, and the need to use the same thermal cycling parameters for 
each assay, the assays could not be individually optimised. These results are therefore 
preliminary and future investigations using fluorescent probes instead of SYBR
®
 green 
should be undertaken. These probes, whilst more costly, are more reliable than SYBR
®
 
green.   
  
Chapter 5 – Tibetan Spaniels 
168 
Table 22. Standard curves of qPCR targets 
While bearing in mind the shortcomings of the qPCR results, they do support the 
sequencing results discussed above (section 5.4.5.3) and aberrant splicing hypothesis 
(Figure 45). The similar levels of FAM161Atotal between affected and normal blood 
indicate that mutated FAM161A is not subjected to NMD. FAM161Afl and FAM161Ash 
are more highly expressed in the normal blood than FAM161Afl-5 and FAM161Ash-5, 
while in the affected blood the reverse is true (Figure 45C). Taken together, FAM161A 
in affected blood comprises predominantly mutant transcripts lacking exon 5 
(FAM161Amt = FAM161Afl-5 + FAM161Ash-5 = 84%), while FAM161A in normal blood 
comprises predominantly wildtype transcripts (FAM161Awt = FAM161Afl + FAM161Ash 
= 71%). This supports the hypothesis that the SINE insertion results in skipping of exon 
5 during pre-mRNA splicing. 
Target Slope R
2
 Efficiency (%) 
TBP -3.512 0.985 92.630 
ACTP -3.375 0.637 97.837 
FAM161Atotal -3.563 0.985 90.823 
FAM161Afl -3.551 0.982 91.256 
FAM161Afl-5 -5.569 0.791 51.209 
FAM161Ash -3.405 0.828 96.665 
FAM161Ash-5 -3.121 0.528 109.132 
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Figure 45. Comparison of FAM161A mRNA isoforms  
PCR and qPCR to compare expression levels of FAM161A isoforms in blood from an 
affected dog and an unaffected dog. A) Primers in exons 3 and 6 (red arrows) were used 
to amplify FAM161A isoforms created by alternative splicing of exons 4 and 5, 
resulting in four possible amplicons expected (fl, fl-5, sh, sh-5; sizes indicated). Primers 
pairs for qPCR (blue arrows) were designed to be specific for each isoform. B) Agarose 
gel electrophoresis of PCR amplicons. C) Relative expression of each target, determined 
by qPCR. Error bars represent standard deviation. 
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5.4.5.5 FAM161Ac.1758-15_1758-16ins238 Effect on Protein 
The data presented in sections 5.4.5.3 and 5.4.5.4 support the hypothesis that the SINE 
insertion near the splice acceptor site of exon 5 of FAM161A results in aberrant splicing 
i.e. the skipping of exon 5 (Figure 46A). It is predicted to shift the reading frame and 
cause a premature stop codon (p.S588MfsX13) possibly resulting in a truncated protein 
product (Figure 46C) or degradation of the mRNA by NMD, although experimental 
evidence for either hypothesis is required. 
 
  
Figure 46. Effect of FAM161Ac.1758-15_1758-16ins238 on the protein product 
A) FAM161Ac.1758-15_1758-16ins238 results in aberrant splicing i.e. the skipping of exon 5. 
B) The normal full-length and short FAM161A proteins differ only by the presence and 
absence respectively of exon 4-generated residues (grey). Domain UPF0564 in humans 
is critical to the correct functioning of the protein. C) Skipping of exon 5 results in a 
shift in the reading frame (FS) and a premature termination codon. The number of 
amino acids comprising each section are indicated. 
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5.5 FAM161Ac.1758-15_1758-16ins238 (PRA-3) Population 
Screening 
5.5.1 Research Sample Cohorts 
To confirm that the variant is not a commonly occurring polymorphism in this breed, 
we screened 215 additional TS dogs (section 2.6), resulting in a total of 247 TSs tested 
for FAM161Ac.1758-15_1758-16ins238 (Table 23). Of the 35 PRA cases used in the study 22 
(62.9%) were homozygous for FAM161Ac.1758-15_1758-16ins238 (FAM161A
-/-
) and all 116 
dogs known to be clinically free of PRA at their last eye examination, including 16 
obligate carriers of PRA, were either carriers of the mutant allele (14.7%; FAM161A
+/-
) 
or homozygous for the wild type allele (85.3%; FAM161A
+/+
). PRA-3 therefore 
accounts for the majority of cases of PRA in our TS cohort.  
Table 23. FAM161A genotypes and PRA clinical status for 247 TSs 
To determine whether FAM161Ac.1758-15_1758-16ins238 is associated with PRA in related 
breeds we screened a further 99 dogs from two closely related breeds most likely to 
share polymorphisms with the TS breed. These were 23 LAs and 76 TTs (Table 24), 
including nine LAs and 12 TTs affected with PRA. All 23 LA dogs, including nine PRA 
cases, were homozygous for the wild-type allele (FAM161A
+/+
). PRA-3 is therefore 
absent from this LA cohort, but as the number of dogs tested was small, it cannot be 
eliminated entirely as a form of PRA in the breed. Of the 12 TTs with PRA, four were 
homozygous for FAM161Ac.1758-15_1758-16ins238 (FAM161A
-/-
), while the remaining eight 
PRA cases were either carriers (FAM161A
+/-
; n=1) or homozygous wildtype (n=7). In 
addition, all TTs known to be free of PRA (n = 10) were homozygous for the wildtype 
allele (79.7%). PRA-3 is therefore present in the TT breed.  
  
Genotype PRA Affected PRA Carrier PRA Unaffected Unknown Total 
FAM161A
-/-
 
22 0 0 2 24 
62.9% 0.0% 0.0% 2.1% 9.7% 
FAM161A
+/-
 
2 9 8 22 41 
5.7% 56.3% 8.0% 22.9% 16.6% 
FAM161A
+/+
 
11 7 92 72 182 
31.4% 43.8% 92.0% 75.0% 73.7% 
Total 35 16 100 96 247 
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Table 24. FAM161A genotypes and PRA clinical status for 76 TTs 
The frequency of the PRA-3 allele is 0.18 in TSs, based on all 247 research samples 
tested (Table 25). This is not unusually high for an aR disease allele in dogs. However, 
the cohort screened contained samples collected for the purposes of research (as in 
Chapters 3 and 4) and was therefore subject to considerable sampling bias. This 
combined with the relatively small number of samples screened has resulted in 
populations that do not conform to HWE (Table 25). Analysis of 120 dogs that had 
unique sires and dams resulted in a reduced allele frequency, but this cohort also does 
not conform to HWE (Table 25). This suggests that the high degree of relatedness 
between samples is only one cause of deviation from HWE, and sampling bias is still 
significant.  
Table 25. Population screening for PRA-3. 
 Observed Genotypes* HWE 1-in-__ Expected 
Breed -/- -/+ +/+ TOTAL 
Allele 
Freq 
χ2 P Affected Carrier 
Research Cohort 
Tibetan 
Spaniels 
24 41 182 247 0.180 47.41 5.77x10
-12
 31 3 
Tibetan 
Spaniels 
Unrelated 
10 16 94 120 0.150 27.32 1.73x10
-7
 44 4 
Tibetan 
Terriers 
4 14 58 76 0.145 4.98 0.03 48 4 
 
* The mutant allele is represented by “-“ and the wildtype allele by “+”. 
   
Genotype PRA Affected PRA Unaffected Unknown Total 
FAM161A
-/-
 
4 0 0 4 
33.3% 0.0% 0.0% 5.3% 
FAM161A
+/-
 
1 0 13 14 
8.3% 0.0% 24.1% 18.4% 
FAM161A
+/+
 
7 10 41 58 
58.3% 100.0% 75.9% 76.3% 
Total 12 10 54 76 
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5.6 Discussion 
Using a GWA mapping and homozygosity analysis approach, a novel 3.794 Mb locus 
on chromosome 10 that is associated with PRA in the TS was identified. This region 
overlapped with part of the region syntenic to the human RP28 locus
166
. The entire 
critical region was sequenced and a single provocative variant was identified in the 
FAM161A gene. FAM161A was subsequently identified as a strong candidate causal 
locus due to the identification of FAM161A mutations in humans with RP and the 
localisation of FAM161A to the photoreceptors of the retina
168,169
. 
Sequencing of FAM161A from healthy retinal mRNA served three purposes: Firstly, it 
confirmed the presence of FAM161A mRNA transcripts in the normal canine retina. 
Secondly, it revealed that the intron-exon boundaries predicted by genebuild for 
FAM161A in the dog are incorrect for three exons. They are instead identical to the 
human and mouse boundaries. Thirdly, as is the case in humans, canine FAM161A is 
alternatively spliced to produce two isoforms, one containing and one lacking exon 4 
(FAM161Afl and FAM161Ash respectively).  
Sanger sequencing and preliminary qPCR results indicate that FAM161A mRNA 
transcripts in retinal tissue and blood from dogs not affected with PRA comprise 
predominantly the wildtype FAM161A isoforms (FAM161Afl and FAM161Ash). 
Conversely, FAM161A mRNA transcripts in blood from a dog affected with PRA-3 (i.e. 
homozygous for FAM161Ac.1758-15_1758-16ins238) comprise predominantly the aberrant 
FAM161A isoforms lacking exon 5 (FAM161Afl-5 and FAM161Ash-5). This supports the 
hypothesis that the SINE insertion results in skipping of exon 5 during pre-mRNA 
splicing in blood. While it is likely that FAM161Ac.1758-15_1758-16ins238 has the same effect 
of aberrant splicing in other tissues, the possibly that tissue-specific splicing negates this 
effect in the retina cannot be excluded. Further investigation using retinal tissue from a 
FAM161A
-/-
 dog is necessary to substantiate the hypothesis of alternative splicing. 
Interestingly, aberrant FAM161A isoforms (FAM161Afl-5 and FAM161Ash-5) were also 
present in retinal tissue from a dog not affected with PRA, albeit at much lower levels 
than the wildtype isoforms. These are most likely a result of naturally-occurring 
alternative splicing, which is a common occurrence. At least 74% of human multi-exon 
genes are alternatively spliced
171
 and up to 30% of alternative transcripts contain 
premature termination codons
172
. These are usually targets of NMD, although Lewis et 
al. observed that 4.3% of RefSeq mRNAs (i.e. experimentally identified mRNAs that 
have not been degraded) are truncated by >50 amino acids
172
. While these aberrant 
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proteins may well be expressed in healthy retinal tissue, it is clear from the 
PCR/electrophoresis and qPCR data presented here that they are a minor product 
compared with the normal, functional protein. 
Similar instances of aberrant splicing due to SINE insertions that are associated with 
canine traits have been reported: An insertion 35 bp upstream of an accepter site of the 
HCRTR2 (hypocretin (orexin) receptor 2) gene has been associated with canine 
narcolepsy in the Doberman breed
173
, and an insertion nine bp upstream of an acceptor 
site of the SILV (a.k.a PMEL; premelanosome protein) gene has been associated with 
the merle pigmentation pattern in multiple dog breeds
174
. The authors of both studies 
hypothesised that the intronic SINE insertion near a splice acceptor site displaced a 
putative lariat branch point sequence (BPS), resulting in skipping of the adjacent exon 
during mRNA splicing. Lin et al. presented data in support of this hypothesis: HCRTR2 
cDNA from dogs homozygous for the SINE insertion associated with canine narcolepsy 
lacked the sequence corresponding to the entire fourth exon
173
. The pre-mRNA splicing 
mechanism requires at least three consensus intronic sequences for optimal function. 
One of these is the 3’ consensus sequence 6PyNCAG (where Py is a pyrimidine base 
and N is any base) of the acceptor site and another, the BPS, is the site of lariat 
formation
175
. In eukaryotes the latter is typically, but not always, 20 to 50 nucleotides 
upstream of the splice junction. The consensus sequence of the BPS, to which the U2 
component of the spliceosome binds, is also variable (PyNPyTPuAPy, where Pu is a 
purine base), although the adenine base is of primary importance for lariat 
formation
176,177
. There is no sequence within 50 nucleotides of the FAM161A intron 4-
exon 5 splice site that corresponds to the BPS consensus sequence. However, a putative 
BPS located 76 nucleotides from the splice site, does correspond to the consensus 
sequence (Figure 47). While the SINE insertion does not affect the AG sequence of the 
acceptor site it will push the BPS beyond its optimal range from the acceptor site, which 
is likely to be the cause of aberrant splicing of exon 5 in affected dogs. 
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Figure 47. FAM161Ac.1758-15_1758-16ins238 effect on pre-mRNA splicing 
Wildtype and FAM161A
-/-
 sequence, with exon 5 (red), intron 4 (grey) and SINE 
insertion c.1758-15_1758-16ins238 (black) indicated. In the wildtype sequence, the 
putative BPS (blue, with the critical A underlined) is 76 bp upstream of the intron-exon 
boundary, while in the affected sequence it is >300 bp upstream of the boundary. 
A SINE insertion associated with retinal degeneration in dogs has previously been 
reported. A 44 bp insertion, comprising a poly(A)29 tract flanked by a 15 bp duplication, 
in exon 3 of RPGRIP1 was associated with cone rod degeneration (cord1) in the 
Miniature Long Hair Dachshund (MLHD)
30
. The authors predicted that this SINE 
insertion caused a shift in the reading frame leading to a premature termination codon. 
However, Kutzetsova et al. reported that the SINE insertion resulted in skipping of exon 
3, which they predicted led to an almost identical, albeit 5’-truncated, protein product178. 
The phenotype associated with the RPGRIP1 SINE insertion is highly variable, and 
significant phenotype-genotype discordance has been observed
30,178,179
. The age of onset 
of clinical signs ranged from 0.3 to 15 years, and some dogs homozygous for the 
insertion (RPGRIP1
-/-
) did not show clinical signs of retinal degeneration, although 
ERG data suggested reduced or absent photoreceptor function
179
. Conflicting 
hypotheses have been presented to account for this discordance, one of which is that the 
SINE insertion may be a benign polymorphism that is in LD with the causal 
mutation
178
. Another hypothesis suggests that phenotypic variability in the MLHD 
could be explained by retinal degeneration that is oligogenic
178,180
. Miyadera et al. 
conducted a GWA study comparing RPGRIP1
-/-
 dogs with early onset retinal 
degeneration (<3.5 years) with RPGRIP1
-/-
 dogs with late onset retinal degeneration (>4 
years) or without clinical signs of retinal degeneration. They reported that a second 1.49 
Mb locus, approximately 35 Mb away from RPGRIP1 on chromosome 15 (CFA15), 
was statistically significantly associated with the early onset form of the disease
181
. 
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While a causal mutation was not identified, the authors suggested that this second locus 
on CFA15 could be a modifier of RPGRIP1
-/-
, or it could be the second allele of a 
digenic condition
181
. A third hypothesis was that variations in the length of the poly(A) 
tract could account for phenotypic differences
180
. Longer poly(A) tracts in human L1 
LINEs (long interspersed nuclear elements) have been associated with disease in 
humans
182
 and the longer SINE in the SILV gene results in the merle phenotype in dogs, 
while the shorter SINE does not
174
. However, Miyadera et al. reported that variable 
poly(A) tract length in the RPGRIP1 SINE insertion did not correlate with variable 
phenotype
180
. While the precise length of the poly(A) tract in the FAM161A SINE 
insertion is unknown, data presented suggests the length of the poly(A) tract does vary, 
with two alleles identified (A44 and A49). However, as the predominant allele (A44) 
segregates in dogs that were diagnosed with PRA at between two and 10 years of age, it 
is unlikely that the poly(A) tract length variation has much effect on the PRA phenotype 
or severity.  
In order to further test the validity of the insertion mutation, FAM161Ac.1758-15_1758-
16ins238, we screened 247 TSs for the mutation (Table 23). We found that 62.9% of the 
PRA cases, 56.3% of the obligate PRA carriers and 100% of clinically unaffected dogs 
(which could be clear of the mutation or carry a single copy) have FAM161A genotypes 
that are concordant with their clinical status. There are two groups of dogs with 
genotypes discordant with their phenotypes. The first comprises two dogs that are 
homozygous for the mutation and have not been diagnosed with PRA. Clinical 
information pertaining to one of these dogs was unavailable, although it is known to 
have had at least one PRA-affected sibling. The other dog had not been seen by an 
ophthalmologist, but its owner reported no significant loss of sight by the time it died. 
However, it had lost one eye in an accident and developed a cataract in the other eye 
around nine years of age, which could have been secondary to PRA. The observation 
that 91.7% (22/24) of dogs homozygous for FAM161Ac.1758-15_1758-16ins238 (FAM161A
-/-
) 
have developed PRA suggests the mutation is fully penetrant, or nearly so. The 
inheritance observed in a family of 49 dogs (seven cases) is supportive of a recessive 
mode (Figure 44). The second group of discordant dogs comprises 13 PRA-affected 
dogs that are not homozygous for FAM161Ac.1758-15_1758-16ins238 and seven obligate 
carriers do not carry FAM161Ac.1758-15_1758-16ins238. It is formally possible that the 
mutation has a dominant mode of inheritance with incomplete penetrance, or complex 
trait or compound heterozygote effects. However, as is the case with PRA in GRs and 
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GoSs (Chapter 3 and Chapter 4 respectively) it is more likely that additional loci are 
responsible for the discordant cases.  
Anecdotal evidence of their shared origins in Tibetan monasteries suggests that TTs and 
LAs are the most closely related breeds to the TS, and as a result these are the breeds 
most likely to share the PRA-3 variant. Screening of 76 TT and 23 LA dogs, including 
12 and nine PRA cases respectively, revealed that the mutation is present in TTs, but is 
absent from the LAs screened. FAM161A genotypes of 33.3% of the TT PRA cases and 
100% of clinically unaffected dogs (which could be clear of the mutation or carry a 
single copy) were concordant with their clinical status. Interestingly, two of the eight 
PRA-affected TTs that were not homozygous for FAM161Ac.1758-15_1758-16ins238 (i.e. 
FAM161A
+/-
 or FAM161A
+/+
), were in fact homozygous for the mutation associated with 
RCD4 (Chapter 4). It is therefore likely that PRA in the remaining six cases in the breed 
is caused by a third unknown mutation. 
The allele frequency of FAM161Ac.1758-15_1758-16ins238 in both breeds is not unusually high, 
even for a recessive disease allele, as discussed in section 3.8.1 (Table 25). Estimates 
for both breeds indicate that up to one in 31 TS dogs and one in 48 TT dogs are affected 
with this form of PRA. However, these frequencies are likely to be inflated, as samples 
collected for research are unlikely to be representative of the wider population. This 
hypothesis is supported by the high Hardy Weinberg χ2 values for the TS breed. 
Nevertheless these data suggest FAM161Ac.1758-15_1758-16ins238 is a major cause of PRA in 
both breeds. A DNA test for PRA-3 is expected to be made commercially available 
from the AHT Genetic Services department in 2013, and screening of the wider 
population for the mutation or a sample cohort collected specifically for allele frequency 
estimations will give a more representative indication of the mutant allele frequency.  
FAM161A encodes the family with sequence similarity 161, member A protein and was 
recognised as an appealing candidate gene due to its involvement in RP in 
humans
168,169
. The gene occurs in two main isoforms, that differ by the presence or 
absence of exon 4 (FAM161Afl and FAM161Ash respectively)
168
. Both isoforms are 
expressed in multiple tissues including the retina and testes, and at lower levels in the 
heart, liver, kidney, brain, muscle, lung and thyroid gland
169
. Specifically, the protein 
has been localised to the connecting cilium and basal body in the IS of rod and cone 
photoreceptor cells, and to the basal body and centrosome of ciliated cells of different 
origins
183,184
. FAM161A has been shown to interact with the CRX (Cone-rod 
homeobox-containing) transcription factor
169
 and Lebercilin
183
, both of which have also 
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been implicated in retinal degeneration in humans
185,186
. Only a single evolutionary 
conserved domain (UPF0564) has been identified, which is vital for binding to and 
stabilising microtubules
168,184
. This region is also required for homotypic FAM161A 
interactions, as well as heterotypic interactions with paralog FAM161B (family with 
sequence similarity 161, member B)
184
. FAM161B interacts with TACC3 
(transforming, acidic coiled-coil containing protein 3), which in turn is involved in 
centrosome-dependent microtubule assembly, kinetochore attachment, chromosome 
alignment  and mitotic exit
187
. FAM161A could therefore be involved in maintenance of 
the microtubule axoneme along the connecting cilium or protein transport between the 
IS and OS
183,184
. 
FAM161Ac.1758-15_1758-16ins238 affects splicing of exon 5 of the gene, resulting in a 
truncated protein, including the loss of approximately 44 amino acids of the UPF0564 
conserved domain. However, Bandah-Rozenfeld et al. reported that the N-terminus of 
the UPF0564 domain is sufficient for homotypic and heterotypic interaction with 
FAM161B
168
. The truncated protein product is therefore expected to be functional in 
this regard. As the discovery of FAM161A involvement in retinal disease was relatively 
recent, very little is known about the structure and function of the protein in visual and 
other pathways. Further investigations are required to elucidate the precise pathways in 
which FAM161A is involved, which may lead to the identification of novel functional 
domains in the C-terminus of the protein. To this end, the canine model described here 
could be particularly useful, as no other animal models have been reported.  
The presence of FAM161A mutant mRNA transcripts in the blood of an affected dog, 
and the similar expression levels of FAM161Atotal in affected and normal blood, imply 
that the truncated transcript is not subjected to NMD. A truncated protein may therefore 
be expressed, although this would need to be confirmed by comparing FAM161A 
protein levels in FAM161A
-/-
 dogs with protein levels in FAM161A
+/+
 dogs. If this is the 
case, the truncated protein product must be sufficient to cause retinal degeneration. It is 
possible the truncated protein is toxic and therefore actively causes retinal decay. While 
none of the PRA-3 carriers (FAM161A
+/-
) have developed PRA, they may have signs of 
degeneration that are not typical of PRA and therefore easily missed (or even ignored) 
by ophthalmologists. Alternatively, the truncated protein may cause subclinical 
degeneration in carrier dogs. More likely, the truncated protein is insufficient to 
maintain normal retinal function, resulting in retinal degeneration.  
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PRA caused by the variant described here has an average age at diagnosis of 4.89  years 
and this is indicative of a late age of onset (data not shown) and consistent with 
observations in human patients in which the age of onset was in the 2
nd
 or 3
rd
 decade
169
. 
Given that FAM161A is expressed in multiple tissues, it would be interesting to 
determine whether a more severe change to the protein, such as a knock-out, would 
result in a more severe retinal or even systemic phenotype. 
The discordant TS PRA cases i.e. FAM161A
+/+
 and FAM161A
+/-
 tended to develop PRA 
at a later age, with an average age at diagnosis of 7.01 years (data not shown), which is 
consistent with the segregation of a second form of PRA in the TS breed.  
5.7 Conclusion 
PRA in the TS has not previously been associated with any genetic mutations. Using a 
GWA mapping approach, a novel candidate mutation, FAM161Ac.1758-15_1758-16ins238, was 
identified that is likely to represent a major causal mutation for PRA in the TS. While 
this mutation does not account for all cases of PRA in this study, suggesting that there 
are additional loci causing PRA in this breed, it does appear to be highly penetrant and a 
major cause of PRA in this breed. While the PRA-3 mutation is also present in TTs, as 
they are closely related and it has not been found in any other breeds, the mutation 
appears to be confined to these two breeds. The development and availability of a DNA 
test will enable breeders to eventually eliminate PRA-3 from the breeds affected 
entirely. 
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Chapter 6  General Discussion 
 
6.1 Aims of The Current Project 
PRA has been identified in more than 100 dog breeds, but in most cases the underlying 
molecular basis has yet to be elucidated. This study was conceived with three main aims 
for each of three breeds (GR, GoS and TS): 
1) Investigate the molecular basis underlying PRA.  
2) Establish a diagnostic DNA test to be commercially and available to the public. 
3) Assess the relevance of findings to human retinal degenerations. 
All three aims have been achieved, to some extent, as summarised in Table 26. 
6.1.1 Aim 1: Underlying Molecular Basis 
Four mutations were identified that were associated with PRA in three principal breeds: 
SLC4A3c.2601_2602insC and TTC8c.669delA in GRs, C2ORF71c.3149_3150insC in GoSs and 
FAM161Ac.1758-15_1758-16ins238 in TSs. These mutations were hypothesised to cause aR 
PRA in homozygous dogs. The segregation of these mutations with PRA in their 
respective breeds as well as the predicted effect of each on their respective proteins, as 
presented in previous chapters, supports this hypothesis. The function of the genes, 
particularly FAM161A and C2ORF71, is not yet well understood and the effects 
aberrant proteins i.e. gain or loss of function, cannot be precisely predicted. However, as 
inheritance of all four PRAs is consistent with an aR mode and dogs that carry the 
variants (heterozygotes) do not usually develop PRA, the variants are likely to result in 
loss of function.  
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All four mutations identified are predicted to result in truncated protein products, which 
could function inefficiently or be degraded through nonsense mediated decay (NMD). 
At least 74% of multi-exon genes in humans undergo alternative splicing
171
. It is 
estimated that 35% of these alternative gene isoforms contain premature termination 
codons
172
 and expression of these transcripts could result in harmful proteins. NMD, 
therefore, is a cellular safeguard against the expression of harmful proteins from 
incorrectly spliced mRNAs. However, in the case of a homozygous mutation that 
affects the only or major functional isoform, NMD effectively removes all mRNA 
transcripts and no functional protein will be expressed. One way to test for NMD is to 
compare the levels of mRNA between dogs with the variant and those without. Retinal 
tissue was preferable for this study (see section 6.2 for further discussion), but the same 
principle applies to any tissue in which the gene is expressed, including blood. Retinal 
tissue from dogs homozygous for any of the four mutations identified was unavailable, 
and mRNA of three of the genes (SLC4A3, TTC8 and C2ORF71) was undetectable in 
blood. It therefore remains unclear whether or not these genes are subjected to NMD. 
Evidence against NMD of aberrant FAM161A mRNA is presented in Chapter 5, but this 
would need to be confirmed by comparing protein expression levels in retinal tissue. 
The four mutations identified are all likely to result in loss of protein function. 
However, experimental evidence demonstrating the detrimental effect of the variants on 
their respective proteins, and subsequently on the biological pathways in which they are 
involved, was not obtained. The primary reason for this was the difficulty of obtaining 
the appropriate tissue from an affected dog (as discussed in section 6.2). The possibility 
that the variants are not causal themselves cannot be excluded. They could instead be in 
LD with unidentified mutations that are causal. DNA in the PRA-associated regions and 
retinal mRNA remains unsequenced, including the 5’- and 3’-UTRs of all four genes. 
These regions are often difficult to sequence, and numerous attempts using varying 
primer combinations, altered thermal cycling protocols, multiple Taq polymerases and 
RACE (Rapid Amplification of cDNA Ends) kits failed to yield positive results. 
Nevertheless, all four variants remain provocative candidate causal mutations. 
6.1.2 Aim 2: Diagnostic DNA Test 
A DNA test for each mutation has been developed and is (or will be) available to the 
public from AHT Genetic Services. The availability of diagnostic DNA tests will enable 
breeders to make sensible breeding decisions with the long term goal of eliminating 
PRA from the breed entirely whilst not adversely affecting the genetic health of the 
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breed. Breeders may be tempted to avoid breeding with dogs that are heterozygous or 
homozygous for any of the mutations. However, this reduces the effective population 
size (Ne; the number of individuals that contribute offspring to the next generation) and 
genetic diversity of the breeds, and may bring about the emergence of other recessive 
diseases. Whilst risky, breeding with a carrier dog (for example) can be made safe in a 
two ways. Firstly, the dog should only mated to a bitch that is homozygous for the 
wildtype allele. Secondly, the puppies produced should be endorsed i.e. they cannot be 
bred from themselves until they have been tested genetically. Ideally, breeding advice 
would be tailored to each individual breed and will take into consideration factors such 
as effective population size and coefficient of inbreeding (F; the probability that two 
alleles in an individual are identical by descent). However, as this usually not possible, 
the AHT generally advises breeders to continue breeding with dogs that carry a 
mutation until the frequency of the mutation is <0.01. This is particularly critical in the 
case of RCD4 as, due to the extremely high prevalence of the mutant allele in affected 
breeds, elimination of individuals heterozygous or homozygous for the mutation would 
drastically reduce the effective population size of the breed, which could in turn be 
highly detrimental to the overall health of the breed.  
6.1.3 Aim 3: Relevance to Humans 
The molecular characterisation of four new forms of PRA have resulted in the 
identification of a large animal model for at least three human retinal degenerations. 
Dogs homozygous or heterozygous for a variant could be used to establish colonies, 
which in turn could be used to undertake further molecular investigations. This could be 
particularly beneficial as a mouse model (knock-out) has only been reported for one of 
the four genes (SLC4A3). Interestingly, this is the only gene (of the four identified) that 
has not yet been implicated in retinal degeneration in humans, but remains a provocative 
candidate gene. The development of mouse models for the other three genes (TTC8, 
C2ORF71 and FAM161A) would be useful to understand the associated retinal 
degenerations better. Further molecular investigations could reveal more about the 
function of each protein, and contribute to further understanding of the networks and 
pathways involved in retinal function. In addition, several canine models have been 
used to test the proof of principal and the safety of novel therapeutic strategies, such as 
corrective gene therapies, neuroprotective agents and retinal prostheses, as reviewed by 
Beltran
188
. Further investigations could therefore also elucidate the potential use of 
these dog models in the development of therapeutic strategies.  
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Table 26. Summary of results 
Experimental 
work 
Cohort Golden Retriever PRA1 Golden Retriever PRA2 Gordon Setter PRA Tibetan Spaniel PRA 
GWA critical region CFA37, 644 kb CFA8, 3.814 Mb CFA17, 3.221 Mb CFA10, 2.352 Mb 
Variant identification 
(Sequencing) 
Sanger, Candidate Gene Targeted NGS Sanger, Candidate Gene Targeted NGS 
Disease-associated variant SLC4A3c.2601_2602insC TTC8c.669delA C2ORF71c.3149_3150insC FAM161Ac.1758-15_1758-16ins238 
Effect on protein p.E868RfsX104 p.K233RfsX15 p.C1051VfsX90 p.S588MfsX13, splicing 
AHT Genetics Services 
(Commercial DNA Test)* 
855 GRs; AF = 0.05 415 GRs; AF = 0.03 
1788 GoSs; AF = 0.33  
2249 IrSs; AF = 0.25  
60 TTs; AF = 0.22 
Test developed, launch TCB 
Canine PRA 
Disease name/identifier PRA-1 PRA-2 RCD4 PRA-3 
Phenotype Typical PRA 
Typical PRA, potentially other 
systemic clinical signs 
Typical PRA Typical PRA 
Age-at-diagnosis (years) 6.7 4.5 9.8 4.9 
Human 
Disease 
Disease association 
Idiopathic generalised epilepsy.153 
Not associated with retinal disease.  
BBS128,129, arRP130 arRP156,157,164 arRP168,169 
Gene 
Gene name 
Solute carrier family 4, anion 
exchanger 3 
Tetratricopeptide repeat domain 8 
Chromosome 2 open reading frame 
71 
Family with sequence similarity 161, 
member A 
Gene function 
Cl-/HCO3
- exchanger; pH 
regulation, Cl- level maintenance124 
Part of BBSome,  
role in ciliogenesis148 
Physiological function unknown, 
important for retinal development 
and photoreceptor function156 
Involved in developing & adult retina. 
Possibly maintenance of microtubule 
axoneme or protein transport.183,184 
Isoforms Full length (fl) and Cardiac (c)
124  
Full length (fl1 & fl2)128,  
& retina-specific (2A)130 
Full length Full length (fl) & short (sh)168 
Tissue expression Brain, heart, retina, gut, kidney
124 
Ciliated tissue (fl)128,  
2A retina specific130 
Eye157 
Retina, testes, heart, liver, kidney, 
brain, muscle, lung & thyroid gland169 
Retinal localisation 
Müller (fl) and Horizontal (c) 
cells124 
Photoreceptors, ciliary membrane OS or CC of Photoreceptors157 CC & BB of photoreceptors183,184 
Animal Models Knockout mouse
125 None reported Zebrafish157 None reported 
 
* AF = PRA-associated mutant allele frequency 
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6.2 Sample Collection 
The manner in which genetic research samples are collected by the AHT is 
simultaneously highly beneficial and highly restrictive. DNA samples are collected 
from pet dogs, by their owners, using buccal/cheek swabs. As a result, an impressive 
bank of samples has been collected over the years (> 23,000 samples from > 180 
breeds). We are therefore able to obtain, with relative ease for many studies, a sufficient 
number of samples to undertake GWA mapping studies. In addition we do not have to 
consider the costs, labour and ethical considerations associated with breeding colonies 
of dogs for the purposes of research.  
6.2.1 Tissue Availability 
However, a drawback of sourcing samples from pet dogs is that obtaining any other 
tissue is difficult. It is even difficult to obtain blood samples for the purposes of 
research, as a Home Office licence is required. As such, it is often not possible to 
conduct functional studies subsequent to the identification of mutations. This difficulty 
is compounded for PRA studies because the disease is not lethal and dogs can adapt and 
function remarkably well without sight. In contrast, dogs with severe or lethal diseases, 
such as canine Neonatal cerebellar cortical degeneration (NCCD), are usually 
euthanized and tissue can therefore be obtained for functional investigations
189
. Were 
suitable tissues available, a number of functional investigations could be undertaken. 
Protein and mRNA experiments could be undertaken to assess the effect of mutations 
on the protein, including whether or not the proteins are expressed in a truncated form 
or affect the expression levels or locations of other retinal proteins. Histological and 
immunohistochemistry experiments could be used to assess the effect of the mutations 
on retinal cells and structure. For this project it was not possible to obtain the retinal 
tissue that would have enabled further study of the mutations or diseases identified.  
6.2.2 Phenotyping 
Another drawback of sourcing samples from pet dogs is the inconsistency of disease 
phenotyping. All dogs defined as PRA cases were examined by veterinary 
ophthalmologists and therefore have robust diagnoses. However, there is variation in the 
qualifications (certificates versus diplomas) and experience of ophthalmologists as well 
as the inevitable variation introduced when multiple clinicians contribute to sample 
collection. In addition, the phenotypic information available for each case varies from 
virtually nothing to quite detailed (age at diagnosis, fundus photographs, 
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ophthalmological observations and ERG results). This makes avoiding a heterogeneous 
pool of cases all but impossible. For most dogs with PRA the only additional 
information available is the age of the dog when it was first diagnosed. This information 
was used in this project as an indication of the age of onset of each form of PRA. 
However, apart from the possible variability in the age of onset of clinical disease, the 
age at diagnosis will vary due to factors such as how observant the owners are with 
regards to changes in their dogs behaviour and how frequently the dogs eyes are 
examined. Finally, the disease progression and the presence of additional clinical signs 
cannot be easily monitored, as demonstrated in GRs with PRA-2 (Chapter 3), due to a 
number of factors. Firstly, as samples are collected over many years, many of PRA 
cases used in these studies are no longer alive, or the contact details of the owners are 
no longer accurate. Secondly, most of the dogs sampled are not in close proximity to the 
AHT. Therefore, either the owners have to travel large distances to be examined by 
AHT clinicians, or additional, willing, external clinicians need to be identified and 
involved in the study. 
6.2.3 Allele Frequency Estimations 
An estimate of the frequency of any mutant allele is required in order to properly advise 
breeders on a suitable breeding strategy that will eventually eliminate PRA from the 
breed entirely. For this estimate to be accurate, however, the sample cohort must be 
representative of the general breed population. Sampling bias will always be a factor in 
sample cohorts collected for the purposes of investigating a particular trait or condition 
(PRA in this discussion) for a number of reasons: Firstly, such a cohort will comprise a 
disproportionate number of dogs with confirmed PRA. Secondly, it will also contain a 
disproportionate number of dogs closely related to dogs with PRA, and therefore a 
disproportionate number of dogs that carry PRA mutations. Thirdly, samples will only 
be submitted by owners who are aware of the research, often only because their dog is 
related to dogs with PRA or they are members of Breed Clubs that advertise and 
promote research projects. It is likely that many pet owners will not be aware of the 
disease, much less the research project, unless they visit a veterinary ophthalmologist. 
However, many older dogs that develop PRA will not be examined by an 
ophthalmologist as the vision loss will simply be attributed to old age. Sampling bias 
can, however, be minimised, or at least reduced by changing sample collection criteria. 
For example, a cohort of GR samples used in Chapter 3 was collected specifically for 
allele frequency estimations. Samples were taken from dogs that had been selected by a 
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representative of the Golden Retriever Breed Council (Margaret Woods, Breed Health 
Co-ordinator) to meet a number of criteria: Firstly, they were of unique parentage within 
the cohort i.e. none of the dogs shared a sire or dam. Secondly, the dogs came from a 
variety of different kennels and breeding lines. Thirdly, with the aim of selecting dogs 
that represented the GR breeding population, the dogs were of breeding age (defined as 
the ages the KC allows for breeding, between one and seven years old). An alternative 
method, used by the AHT to investigate the frequency of the mutation associated with 
Neonatal cerebellar cortical degeneration (NCCD) in Beagles, involved the use of the 
Kennel Club (KC) registration database. Representatives of the KC sent buccal swab 
(sampling) kits to the owners of 500 Beagles randomly selected from the KC transfer of 
ownership database (which contains information pertaining to every single pedigree dog 
in the UK that is KC-registered, whose registration has been transferred form the 
breeder to the new owner), with the request to take a sample from their dog and return it 
to the AHT. Of the 500 kits sent out, 152 were returned to the AHT, representing a 
return rate of 30% (personal communication, Oliver Forman). This strategy is preferred 
over that used in the GR studies, as sample selection is completely random and 
objective; and dogs from pet, show and working populations are represented. It also has 
the added benefit of reaching more of the public with information about the disease 
under investigation. However, sample collection is still biased towards dogs that are KC 
registered, and it is estimated that less than 1/3 dogs in the UK is KC registered
190
.  
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6.3 GWA Population Structure 
As has been demonstrated in the literature in recent years GWA is a popular method for 
the identification of trait-associated loci in humans and other species. It is a particularly 
appropriate strategy in dogs, especially for monogenic traits, due to the inherent 
population structure present as a result of relatively recent domestication and centuries 
of selective breeding. However, unknown population structure (a.k.a stratification) has a 
confounding effect on GWA and can result in false negatives (type II errors) or 
especially false positives (type I errors). The extent of population stratification is 
represented by the inflation factor (λ), which is simply a comparison (ratio) of the 
expected and observed median χ2 values (see section 2.3.2). Population stratification 
will result in inflated χ2 values (i.e. λ > 1; χ2observed > χ
2
expected) and can be visualised with 
a Q-Q (quantile-quantile) plot.  
6.3.1 Q-Q Plots 
A Q-Q plot (Figure 48) compares the distribution of observed test statistics (χ2observed) 
with those expected under the null hypothesis (χ2expected). Deviation from the null across 
the entire distribution indicates the presence of population stratification (Figure 48B). 
Deviation from the null only at the highly significant end of the range (i.e. the highest χ2 
values) indicates a true association with the trait under investigation (Figure 48D).  
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Figure 48. Q-Q plots to assess population stratification 
Q-Q plots are generated by plotting observed against expected χ2 test statistics, and 
comparing the distribution of χ2observed (red circles) with the distribution expected under 
the null hypothesis (blue line). A) No evidence of stratification or association. B) 
Evidence of stratification only. C) Evidence of stratification and association. D) 
Evidence of association only. Image modified from McCarthy et al.
191
. 
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6.3.2 Multidimensional Scaling 
Another useful tool for visualising population structure is multidimensional scaling 
(MDS) of IBS pairwise distances (Figure 49). Ideally, the distribution of cases and 
controls should be similar, to minimise population stratification and resulting type I and 
type II errors. This allows identification and removal from further analysis of outlier 
samples that may generate spurious association results. It also allows the identification 
of possible sampling errors, such as the inclusion of samples from a different breed, that 
may also generate spurious association results. However, as with all statistical analyses, 
the larger the sample cohort is, the more accurate and useful the results will be. If the 
sample cohort is small to begin with (as were the cohorts used in this investigation), 
MDS plots are for information only, for the most part, as the removal of samples from 
further analysis will greatly reduce the power of the study.   
 
Figure 49. Multidimensional scaling plot 
MDS plots using GWA data. A) Data from four breeds separates into four distinct 
clusters, one for each breed. B) Cases and controls in a GWA study from a single breed 
should have a similar pattern of distribution. 
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6.3.3 Correction for Population Stratification 
A number of algorithms have been devised to correct for population stratification in a 
study population, and consequently reduce the number of type I and type II errors. The 
first method used during this project, meta-analysis of clusters of individuals using the 
Cochran–Mantel–Haenszel (CMH) test, is routinely used for the correction of 
population stratification in human populations. It corrects for unrecognized population 
stratification arising from remote common ancestry between individuals, and 
cryptic relatedness arising from recent common ancestry in ostensibly unrelated 
individuals, based on the proportion of alleles shared that are IBS
100,192
. Animals on the 
other hand, particularly domestic animals such as dogs, often have a third level of 
relatedness that most outbred human populations do not, family structure arising from 
familial relatedness
101
. This simply means that dogs of any given population/breed are 
expected to share large portions of the genome. As this is not the case in humans a 
CMH correction might not correct adequately for stratification, a theory supported by 
suboptimal inflation factors (λ > 1) generated after correction in 3/4 cohorts studied 
(Table 27). Mixed-model algorithms, such as fast mixed model (FMM), are routinely 
used in animal breeding applications and are efficient models for analysing complex 
kinship patterns
101
. However, 2/4 cohorts have inflation factors substantially < 1, 
suggesting this method tends to result in deflated association results (Table 27). From 
these data, it is clear that there is no single correct method for adjusting for population 
structure and it is therefore vital to use and consider the results from more than one. In 
each of the GWA studies listed in Table 27, the same signals were seen regardless of the 
analyses, and this conferred a great deal of confidence in the GWA results. 
Table 27. GWA inflation factors (λ) 
Cohort Before correction CMH correction FMM correction 
GR_PRA1 1.44 1.46 0.96 
GR_PRA2 1.32 0.84 0.27 
GoS_PRA 2.44 1.56 0.34 
TS_PRA 1.69 1.10 1.27 
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6.4 Sequencing 
Until recently the most widely used method to determine the sequence of nucleotides in 
a DNA molecule was Dye-terminator (Sanger) sequencing
193
. The method was 
employed in many ground-breaking studies including the production of human and 
canine draft sequences
23,194
 and the identification of mutations associated with disease, 
including RP and PRA
30,156,195
. While arguably still considered the gold standard for 
sequencing small fragments of DNA, the Sanger method does have limitations. It is 
labour-intensive, time-consuming and costly. The sequencing of the human genome of a 
single individual (Craig Venter) using this method required more than 340,000 runs and 
cost approximately $70 million
196,197
. Next-generation sequencing (NGS) enables cost-
effective massively paralleled sequencing of multiple samples. Around the same time as 
 enter’s genome was sequenced the newly developed Roche/454 NGS platform was 
used to sequence the genome of another individual (James Watson) and required only 
234 runs and cost $1 million
197,198
. The labour and costs have since been considerably 
reduced and it now costs less than $10,000 to sequence a human-sized genome 
(http://www.genome.gov/sequencingcosts/). A number of NGS platforms and 
technologies have been developed. The Illumina technology was selected for this 
project due to its popularity and subsequent availability at numerous service 
laboratories. The Illumina systems enable simultaneous sequencing of hundreds of 
millions of clusters of DNA fragments. The chemistry, which reads only a single base in 
each synthesis cycle, ensures highly accurate sequencing through difficult regions such 
as homopolymers and repeated sequence.  
6.4.1 Sequencing Limitations  
Sequencing, whether by the Sanger method or more recent next generation methods, is 
critical for the identification of the precise DNA mutations that cause disease. The 
Sanger method is still convenient and cost effective for determining small quantities of 
sequence. In this project it was successfully used to identify the mutations associated 
with PRA-1 in GRs and RCD4 in GoSs (SLC4A3c.2601_2602insC and C2ORF71c.3149_3150insC 
respectively). However, had the mutations associated with PRA in these breeds been 
anywhere other than in the exons of these candidate genes, they would not have been as 
easily identified. NGS, on the other hand, is becoming the method of choice for many 
studies because it allows the generation of massive amounts of sequence data. In this 
project NGS targeting specific regions was employed to identify the mutations 
associated with PRA-2 in GRs and PRA-3 in TSs (TTC8c.669delA and FAM161Ac.1758-
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15_1758-16ins238 respectively). However, had the variants associated with PRA in these 
breeds been within highly repetitive or repeat masked regions, they would have been 
more challenging to identify, as repeat masked regions were not targeted during library 
preparation. Current NGS technologies are not capable of creating reads long enough to 
be accurately aligned to highly repetitive regions of the genome. These regions i.e. 
repeat masked regions, therefore, cannot be sequenced accurately. Structural variation 
(such as large insertions and deletions) remains difficult to identify by NGS methods. 
While changes to read depth can be indicative of such variation, the target enrichment 
approach also introduces variable read depth, which is difficult to discern from 
structural variation induced read depth changes. While Pindel identifies such variations 
and was included in the NGS analysis pipeline (Chapter 2, Section 2.4.2.4), it was 
unreliable and inconsistent, due to a combination of software and hardware (i.e. 
server/processing) deficiencies. Indeed, Pindel failed to generate results for either of the 
NGS data sets analysed during this project, and as a result structural variations had to be 
identified visually where possible (section 5.4.3). 
6.4.2 NGS Challenges 
One of the biggest challenges with regards to NGS is the analysis of the extraordinary 
amount of data generated. New and improved analysis tools are made available to the 
public continuously, and it is challenging to keep abreast of the latest developments. In 
addition, there is no single package with which to undertake all of the analysis from 
start to finish, and few of the tools are designed with user-friendly interfaces. It is 
therefore becoming crucial to be proficient in the use of UNIX (the operating system in 
which most of the analysis tools run) and also programming languages such as perl, R 
and VBA (Visual Basic for Applications). 
  
  
Chapter 6 – General Discussion 
193 
6.5 Genotype-Phenotype Discordance 
While the four mutations identified account for almost 80% (108/137) of PRA cases in 
the three principal breeds investigated (GR, GoS and TS; Figure 50), a further 29 dogs 
with PRA are not homozygous for any of the variants. A number of factors could 
account for this genotype-phenotype discordance:  
Phenocopies are non-genetic retinopathies that resemble PRA, such as SARD and 
Vitamin A deficiency-induced nightblindness. It is possible that at least some of the 
“PRA cases” have been misdiagnosed as such, although this is unlikely to account 
for many of the 29 discordant cases.  
Genetic heterogeneity is a well-known confounding factor in the study of human 
retinal degenerations. While PRA within dog breeds may be less heterogeneous than 
RP or LCA in human populations, it is becoming increasingly apparent that PRA is 
not necessarily homogeneous within individual breeds, even numerically small 
breeds. Considering the number of genes that have been implicated in human retinal 
degenerations (as discussed in Chapter 1), it is hardly surprising to find that some 
breeds may have more than one form of PRA segregating with the breed. 
In addition, 20 dogs that were homozygous for the RCD4 variant (Chapter 4) and three 
that were homozygous for the PRA-1 variant (Chapter 1), had not been diagnosed with 
PRA at the time of the study. A number of factors could account for this genotype-
phenotype discordance also: 
These variants could have reduced or incomplete penetrance due to environmental 
factors or stochastic fluctuations in gene expression
199
. Age-related incomplete 
penetrance could be a significant factor in the penetrance of the RCD4 variant in 
particular. The average age at which dogs are diagnosed with RCD4 is 9 years, and 
as such, taking into consideration phenotypic heterogeneity, clinical signs of disease 
may not manifest during the dog’s lifetime. This hypothesis is supported by the 
observation that 8/18 GoSs that were homozygous for the RCD4 mutation and over 
the age of 9 years when they were examined (ranging from 9.1 to 11.8 years) were 
not diagnosed with PRA.   
While these forms of PRA appear to be monogenic, we cannot discount the 
possibility that they may in fact be complex or multifactorial traits, with multiple 
genetic contributions. The interaction of multiple genes and the environment are 
characteristic of multigenic traits, whereas the interaction of few genes is 
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characteristic of oligogenic traits. The effects of the genes are said to be modifying 
or synergistic. Heterozygous, synergistic mutations in the ROM1 and RDS genes 
result in digenic RP only when both mutations are present
200
. At least two modifiers 
manage the expression of PRPF31 mRNA to affect the penetrance of RP caused by 
this gene
201
. 
 
 
Figure 50. Mutations accounting for PRA in multiple breeds 
The mutations identified account for the majority of PRA cases in the three principal 
breeds investigated (GR, GoS and TS). A form of PRA of unknown aetiology (blue) 
still segregates in most of the breeds investigated.  
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6.6 Future prospects 
6.6.1 Identification of Remaining PRA Mutations 
The molecular characterisation of the major forms of PRA in three principal breeds also 
revealed that PRA is heterogeneous in these breeds. Indeed, PRA of unknown aetiology 
segregates in 9/11 breeds investigated (Figure 50). As only a single SP with PRA was 
tested, the possibility that other forms of PRA, in addition to RCD4, segregate in the 
breed cannot be eliminated. Due to the low numbers of samples available from dogs 
with unknown PRA, a GWA approach will not be an appropriate strategy for the 
identification of additional genetic variants. However, with the continuing development 
of NGS technologies, whole genome or whole exome sequencing could be undertaken. 
The cost of enriching canine whole exome for sequencing is still prohibitively 
expensive (approximately £250 per sample), while similar kits designed for human use 
are a fraction of the cost (<£100 per sample). In addition, as demonstrated throughout 
this project, the gene annotation of the canine genome is incomplete. While this aspect 
has been greatly improved with the recent upgrade from CanFam2.0 to CanFam3.1, it is 
still not as well annotated at the human genome, and whole exons are often missing. In 
a recent trial conducted by Oliver Forman (AHT), sequencing of canine gDNA using 
the Nextera Human Exome kit resulted in capture and sequencing of 79% of canine 
exons (personal communication, Oliver Forman). In addition, 18/19 known PRA 
mutations (including the four mutations identified in this project) are exonic, and the 
locations of 15 were captured and sequenced during this trial (personal communication, 
Sally Ricketts). Therefore, almost 80% (15/19) of known PRA mutations could, in 
theory at least, have been identified through whole exome sequencing using the human 
exome enrichment kit. Of course, the reason that most of the mutations identified to 
date have been exonic is most likely that they are the easiest mutations to find, while 
intronic or intergenic mutations are not only more difficult to identify in the first place, 
but it is also difficult to prove their pathogenicity. Exome sequencing will therefore not 
always yield positive results. 
Alternatively, an autozygosity mapping approach could be undertaken to identify 
candidate regions, genotyping PRA cases and closely related controls. Two of the GoS 
PRA cases that are not attributed to RCD4 (as discussed in Chapter 4) are closely 
related (Figure 51). Obtaining DNA samples from the close relatives that haven’t yet 
been sampled, and obtaining SNP genotypes for all of these dogs using a canine SNP 
microarray, could result in the identification of loci homozygous in both affected dogs, 
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but not in all of the controls. A recent development is the combination of exome 
sequencing and autozygosity mapping. Carr et al. demonstrated the use of whole exome 
sequence data to simultaneously identify regions of autozygosity and identify all 
possible deleterious variants in those regions
202
. 
 
Figure 51. Segregation of non-RCD4 PRA in a GoS family 
Two closely related individuals (3 and 8) are affected with a form PRA distinct from 
RCD4. DNA samples have been obtained from only three dogs (3, 7 and 8), and all 
three are homozygous for the wildtype allele at the RCD4-associated locus 
(C2ORF71
+/+
). 
6.6.2 In Vitro Functional Investigations 
In the absence of suitable (retinal) tissues from dogs in which to investigate the 
functional consequences of the mutations described, it may be possible to conduct 
investigations in vitro. Site-directed mutagenesis could be undertaken to introduce the 
desired mutations into the cDNA of the gene of interest, which could then be transfected 
into an appropriate cell line. Sun et al. investigated the expression of wildtype ABCA4 
(mutations in which have been implicated in Stargardt disease, macular degeneration, 
aRCRD and aRRP in humans, as reviewed by Koenekoop
203
) in human embryonic 
kidney (293) cells, and compared it with 37 ABCA4 mutants
204
. Their experiments 
revealed a wide variety of biochemical defects including reduced protein levels and 
defective ATP-binding. 
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6.7 Conclusions 
This study demonstrates the value of dogs from the pet population in the search for 
disease or trait mutations, as the potential sample pool is very large. However, there are 
disadvantages to be considered. Unlike dogs in research colonies it is extremely 
difficult, if not virtually impossible, to obtain consistent and detailed clinical 
information due to the variety of ophthalmologists involved, the desires of the owners 
and ethical considerations. In addition downstream investigations, such as RNA or 
functional assays, are limited by the availability of appropriate tissues. 
Nevertheless, in this study four new mutations were identified that are associated with 
PRA. To date, eight breeds have been identified that are affected by at least one of these 
mutations, and breeders can now benefit from this information by testing their dogs for 
the relevant variants and thereby improve the overall health of their breeds.  
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Figure A3. Gordon Setters (RCD4) 
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II. Primers 
Table A1. Canine Mutation Screening Primers 
Gene/Locus Mutation Method
*
 Primer Name Primer Sequence 
Amplicon Size (bp) 
Wildtype/Affected 
Tm (°C) Chr 
Amplicon 
Position (bp)
†
 
PRCD G/A SNP AD 
PRCD_F GGCCTTTCTCCTGCAGACT 
134 57 9 
7,186,629-
7,186,763 
PRCD_R GGCCTTTCTCCTGCAGACT 
PRCD_NORMAL FAM-AGCCATGTGCACCACCCTCT-BHQ 
PRCD_AFFECTED HEX-TGAGCCATGTACACCACCCTCT-BHQ 
RCD1 G/A SNP 
Sanger 
Sequencing 
RCD1_F CTTTCTTGGCTGTCGTCCTGTCCT 
157 60 3 
94,574,186-
94,574,342 RCD1_R GAGTTTTCCCGTTTCCACGAAG 
PRA-1 C ins AFLP 
GR_PRA1_F FAM-AGAGCAACCTTGTAACCCGTA 
205/206 60 37 
29,147,576-
29,147,781 GR_PRA1_R GGAAGAAGGCAATGAGAAAGG 
PRA-2 A del AFLP 
GR_PRA2_F FAM-TGCCCTTTCCACAGAGCAC 
110/109 60 8 
63,129,125-
63,129,234 GR_PRA2_R GCCATGTCTAAGCCCTTCACAA 
PRA-3v1 SINE ins AFLP 
TS_PRA_F FAM-TGTGGTAAATTGTAAGCCATGC 
153/391 57 10 
64,973,910-
64,974,062 TS_PRA_R TGTTGGTATTCTCTCATCCTTTCC 
PRA-3v2 SINE ins AFLP 
TS_PRA_AFF_F GGATCCCTTTATTTGATTTTAGAAAG 
135/137 60.5 10 
64,974,003-
64,974,139 
TS_PRA_NOR_F TCCCTTCCTTTTATTTGATTTTAGAAAG 
TS__PRA_R FAM-CAACAAACACAACCTGAGCAA 
RCD4 C ins AFLP; Q 
RCD4_F FAM-CCGAGTGCTCCCTCTGTG 
146/147 57 17 
26,010,390-
26,010,534 RCD4_R GGCTGCAGGCCTCGTC 
 
* AD = TaqMan® Allelic Discrimination; AFLP = Amplified Fragment Length Polymorphism analysis; Q=Additive Q solution used 
† CanFam2.0 
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Table A2. Microsatellite Marker Primers 
Microsatellite
*
 Position (bp)
†
 Tail-F primer Seq (5'-3')
‡
 R primer Seq (5'-3') Size (bp) Tm (°C) 
Primers for Finemapping of TS_PRA locus on CFA10 
(CA)14 61,659,255 TAGACCCAGGCAATTCAAATC TTGAGGATATCAAACCCTTCAC 193 56 
(CA)21 61,752,065 ATGGAACTGCCATATGATCCA GCATGTCCCTTGTTATGGCTA 277 56 
(GT)20 61,868,609 AGCTGGGTCCCTTTCAGTTTA CAGCCAGTACGTCTGATGCTT 236 56 
(GT)15 61,963,812 CCTTTGTGCATTCTCTGTTCC TCCCTAGGCCTACAGGATTT 234 56 
(GT)18 62,337,915 TCTGCTCTTTAAGGCCTGATG GAATGCACTTCAACCACCATT 212 56 
(GT)15 62,434,740 TCTGTTCAAGAGCTGTGTGGAT TTCTGTGGCACTGCTTCCTT 274 56 
(CA)16 62,487,468 ACTGAGGGATGCAGAAGTGAA ATATCTGAGCGCAGCATGAAG 174 56 
(CA)20 62,552,700 TTTAAGAGCCAACCACTTCCA TGCTTCTTCACCCAGATTGTT 229 56 
(GT)15 62,786,640 GCCAAATTATGCAAGTAGACCA GCATGATACCCTTTAGATTCACC 176 56 
(CA)17 62,978,760 CCTGCATGTTCTCACAAAGGT GTGGTGGTAGTTGGACAATGC 219 56 
(CT)21 63,008,220 ACCTCACTGCAGGCTCACTT TGAATGGAAGCTGTGTTTGTTC 247 56 
(CA)15 63,199,200 ATCACCTCAAATCCACCACAA TATTCCCTTGGGCAGGTTTAC 241 56 
(CA)17 63,331,680 ATGAAAGCAAAGCAGGGAGAT ATTGAAGGCTGAGGGAGCTAA 209 56 
(CA)21 63,402,960 TAGCACCAGAACCTTCCACTC GCATCACAACACTCACTCTGC 205 56 
(CA)18 63,509,760 GGAGTTTACCATAAGTAAGCTTCTCC TGCTTCTGACCATTCCACAAT 228 56 
(GT)16 63,705,840 TCCTCTCCTCCAAACACTTACC ATGCATACAGCACTTGCACAC 184 56 
(GT)17 63,820,800 CGCAGCCTTTAAATCATCCTT GCAGCTCACAATGAACCATTT 249 56 
(GT)22 63,859,200 TTCCATTCTGAAGGCCCTAAT AAGGTGTGCTGAAAGGAAAGC 244 56 
(CT)17 63,913,440 CTCCACCACTTGCTCTCTCAT GAACCCTATGAAGCAACAGCA 205 56 
(GA)16 63,934,627 CCCTACCCAAGTTCTACCCTTT TTCAGCATGACAAGGGACAC 242 56 
(GT)19 63,998,363 GCAGCACTATCAATAGCCAAA TCTACTTCATCCATGTCCTTGC 177 58 
(CA)19 64,075,600 CCCTGTATTGATTAGAGCACGA GATCACCTTGGTTTCTGGTCA 235 56 
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Microsatellite
*
 Position (bp)
†
 Tail-F primer Seq (5'-3')
‡
 R primer Seq (5'-3') Size (bp) Tm (°C) 
(AT)17 64,112,403 GCATCTGCAATCAATTTGAGG CTCCCTCTCCATTTGTCCTCT 265 58 
(GA)14 64,113,386 CATCAGTTCATCCCGTAGCAT GGCACAGTAGGAGATTAACAGCA 194 56 
(GT)14 64,186,104 ACTGCACCCATGTCTTGTTCT GGTGTTCAGTATGTGGCTATGTTC 237 56 
(GA)16 64,201,234 AAGTTCATGCCAATATCCTAGAGTC TTGTTGTTGCCTATTGGGTTC 366 56 
(CA)16 64,217,353 GCAGTTGAATAACCTGCTTGC TATCCTTTCTTCCTGCCACCT 246 56 
(TG)14 64,508,603 AGACCAGCTTTTTGCTTCAGA CTGCGATTAAATGGTCAAAGG 267 57 
(AC)11 64,572,573 CATGTTGTCATGGAATGCAAG AGTGAACCCCGACAGGTTAGT 309 57 
(TG)12 64,713,419 CCCCTAAGCCTGATCCAATAA TGAAAGGAAATGAGTAGTTTTGCT 275 57 
(AC)18 65,182,153 CAAGGGTCTAATTTCCCTTTCC TGGGTACCAAGTGGAATTTTG 127 57 
(AG)16 65,447,202 TGAACTCCTCAGACCTGCAAT CTCTGCTCCAGTCAGATTTGG 304 57 
(TG)18 65,529,249 AGCAGTTTTGAAGCATCATGG AAAAGTAGCCCAAGATCAACCA 120 57 
(TA)20 65,625,939 CAGATCTTGAGAGGGAAAGAGAA CATAGTTTCTTGCCAAGTACTGTCT 220 56 
(TC)14 65,784,034 GTTCACCTCCACTCCCATTTA GGCACAGAACAAAACATCCAT 314 57 
(TG)11(TA)10 65,931,460 CCTGTTGTGTTCAGCAAGGAT AGTTATCGCTGCCTTCTCCTC 358 57 
(GT)12 66,013,662 TGCAAAAGTGAGAGACAGATCC TGCTGTGTTATCTGCAGCTGTT 322 57 
(AT)20 66,058,427 CCGTATTCCTCCCTGTAGTCC TCCAGATTTCACAGCATGATTC 317 57 
(AC)15 66,162,019 CTCTGTGTTTATTGGCGCATT GGCGAGACCTCATTCTTTTCT 183 56 
(GT)14 66,303,329 GCAGACAGCCTTTTGTTTGAC AGTTCTACTTTGCCCGGCTAC 202 60 
(CA)11 66,379,163 GGGAAGAAAGAAACTCTTGGAA TCCCTTCTTTCCATTACCTCTG 269 57 
(TA)14 66,395,178 CCCCACACATCAACATAGGTC GCTATGCAGGCATTTATTTTGG 296 57 
(TA)18 66,448,543 GTGAAATGTATTCCGCATGGT ATGTCCTATGGCCTTTTGGTT 242 57 
(TC)14 66,509,954 GGAGAAGAGGAAGTTTTGCAG GCCAAAGTCTCAAAGGGATCT 314 56 
(AG)12 66,557,299 CACTGGCACCAGGTTAAATGT CCTATGGGGCTCTGGATAAAT 348 57 
(AC)20 66,611,818 CTCCTACTGGGAGCCAAAAAC CCACATCCTTCCTACCACTGA 212 57 
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Microsatellite
*
 Position (bp)
†
 Tail-F primer Seq (5'-3')
‡
 R primer Seq (5'-3') Size (bp) Tm (°C) 
(TC)21(TG)20 66,684,676 GCTGCATTGCTGCTTATTTTC AGGTTTAAGGCAGCACCAATC 296 57 
(TG)16 66,710,025 CCACCCTCATGTTCATCTGTT CACCATCACTCACCAATAGGG 301 57 
(CT)15 66,985,774 TTAGGATTGTGGGGTTCAGTG TCAGGTGAAAGGAAGAAGCAA 304 57 
(AC)15 67,056,476 GAAAGTGGAGGGGAAAGTGAC AACCGGGTTGAACCATTTTT 236 57 
(CA)21 67,164,626 CTGCACTGTTTCCTTCCTCTG ATCTGGGGTCTTTTTGCTGTT 270 57 
(GT)13 67,385,860 CCAGGTTTGGGGTGTATTTCT CCAGTGGTCACCTCAACAAGT 244 57 
(TC)19 67,482,874 TGAACCTCCGAAGTCACTTGT GGAAAAGTGTAAAGGGGACCA 258 57 
(GA)13 67,729,134 TGCTTCTGAGGCACGAGTATT TGCTTGCGTTGCTATTAAGTTC 302 57 
(GT)10 67,940,561 GGTTCATGCCCTCTAATAGGC ATGCCCTCACACTGAAATCAC 237 57 
(AC)20 68,043,943 CTCCGGGGACTCTCAAATTAC TCTGACTTGGGAAAGTGGTTG 263 57 
(GT)32 68,110,195 TCTAGGCTGGGCTTTGAGAAT TGTCAATTGATCCCACTCCAT 277 57 
(GT)17 68,422,023 TTTCCTTGCTCCATTGATGTC CAGAATGTGGGTGCTTTTCAT 314 57 
(TC)24 68,544,337 GTGCACCATCTGGACTACCAT ACAGTGCATTACAGGGACCAG 199 57 
(CA)15 68,607,662 AAAACCTTTCTCCTCCCCTTC ATGTAGGCCCACTTTTTGCTT 184 57 
Primers for Analysis of GoS_PRA locus on CFA17 
(AG)12 25,989,874 GGGGGTGCTAGGATAATTTTT GGAAAGGGGGATTTTTAACCT 297 57 
(GT)17 26,009,511 GGGATCAGGAAGTTTGAGCAT GCCTTCATCTGTCCCTCATTT 276 57 
 
* The number is the number of times the dinucleotide in brackets is repeated 
† Location of the F primer according to CanFam2.0 
‡ Tail= 5’-TGACCGGCAGCAAAATTG-3’ 
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Table A3. Canine Candidate Gene Sequencing Primers 
F primer Name F primer Seq (5'-3') R primer Name R primer Seq (5'-3') 
Size 
(bp) 
Tm 
(°C) 
Additive/ 
alteration
*
 
Position (bp)
†
 
Primers for PCR amplification and Sanger sequencing of SLC4A3 (CFA37) 
SLC4A3ex2_F GTCCGGGTGCCCTTGGAG SLC4A3ex2_R ACTCAAAGTCACGCTCGCT 166 56 98, Q 29,137,454 
SLC4A3ex3.1_F GGAAGGACTAGGGTGACCTTG SLC4A3ex3.1_R AGATTCCCCTTCCTCTTCCTC 347 58 ATG360, 98 29,137,955 
SLC4A3ex3.2_F TGAGGCCCTGAGCTAGAATAA SLC4A3ex3.2_R TTCAAGGGCACACCCCTAC 394 58 ATG360, 98 29,137,978 
SLC4A3ex4_F GAAAGCAAAGGTAGGGGTGTG SLC4A3ex4_R CTCTCCTCCCCTTGACAGTCT 327 54 TD, Q, 98 29,138,343 
SLC4A3ex5.1_F GTGGTTCCCCATCAAGTCC SLC4A3ex5.1_R GCTCCCGCAGGTCGTAG 132 54 98 29,140,268 
SLC4A3ex5.2_F CGAGTCGCTGGAGAGAAGAG SLC4A3ex5.2_R GAGAGCACAGAGCTTCTCCAA 257 58 98, Q 29,140,339 
SLC4A3ex1-C_F GAGGGCGTGTTTACAGACTCA SLC4A3ex1-C_R CACCACCTCCATCGAGTCAC 566 56 H7 29,141,220 
SLC4A3ex6_F GTTGTGTAGACGTGGCCTCTG SLC4A3ex6_R AGCCTCTGGGGAGGACAG 312 58 TD, Q, 98 29,141,911 
SLC4A3ex8.1_F CTCCTCCGGCCTGTTTG SLC4A3ex8.1_R AGACACGATCATGGTCTCCAC 168 56 98 29,142,901 
SLC4A3ex8.2_F TCCTGGACCTGGAGCAGAC SLC4A3ex8.2_R ATTCAGGCTGAGGCTAGAAGG 209 58 98, Q 29,143,001 
SLC4A3ex9-11_F CTGCCTTACTTGCAGCTGACT SLC4A3ex9-11_R CCGTCGAGTCTCATGTCTCAT 1831 58  29,143,418 
SLC4A3ex12-13_F GGAAGCTCCTGGAGGAATAGA SLC4A3ex12-13_R CTAAGGTCCCATGACCACAGA 897 58  29,145,430 
SLC4A3ex14-15_F GTCTGTGGTCATGGGACCTTA SLC4A3ex14-15_R GGTTGCTCTAGCACTCACCTG 1280 58  29,146,305 
SLC4A3ex16-17_F GCAGAGGGTACAAGGAAGAGG SLC4A3ex16-17_R TGAAGGTGAACAGGTTTGGAG 1270 58  29,147,228 
SLC4A3ex18_F GTTTCCTGGAACGCTGGTACT SLC4A3ex18_R GTGAGCATCACTGGGTGAGAG 487 58  29,148,499 
SLC4A3ex19-21_F TGAGAACACCACTTTGGGAAC SLC4A3ex19-21_R ACTTTTCAAAACCCTCCTCCA 1519 58  29,149,094 
SLC4A3ex22_F GGCGTTGCTGTCACTGTTACT SLC4A3ex22_R TAATGAGCTCAAAGCCTGTGC 466 58  29,150,683 
Internal primers for Sanger sequencing of SLC4A3 (CFA37) 
SLC4A3ex9_IntF CACCTCTCTCCCTAACCTGC SLC4A3ex9_IntR ATCATCCCATCCACACCTTC     
SLC4A3ex10_IntF GAAGGTGTGGATGGGATGAT SLC4A3ex10_IntR GGAGGTGAAAAGTTAACAGTCTCC     
SLC4A3ex11_IntF GGAGACTGTTAACTTTTCACCTCC SLC4A3ex12_IntR GGCTCAGTCCCTCCCATG     
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F primer Name F primer Seq (5'-3') R primer Name R primer Seq (5'-3') 
Size 
(bp) 
Tm 
(°C) 
Additive/ 
alteration
*
 
Position (bp)
†
 
SLC4A3ex13_IntF CATGGGAGGGACTGAGCC SLC4A3ex14_IntR ACAGGGGTGAGCTCCACAG     
SLC4A3ex14_IntF GAGTTGGGTCCCCAGGTC SLC4A3ex15_IntR CTTGTACCCTCTGCTCCCAAG     
SLC4A3ex15_IntF CTGTGGAGCTCACCCCTGT SLC4A3ex16_IntR TGAGCTGGTCCCTCGAAATC     
SLC4A3ex16_IntF GTTGCCTGGTCAGGTACGTG SLC4A3ex19_IntR CAGACTCAGAAGGGACCTGAG     
SLC4A3ex17_IntF GATTTCGAGGGACCAGCTCA SLC4A3ex20_IntR GGGTCACTCTGTCCGTCTC     
SLC4A3ex20_IntF CTCAGGTCCCTTCTGAGTCTG       
SLC4A3ex21_IntF GAGACGGACAGAGTGACCC       
Primers for PCR amplification and Sanger sequencing of TTC8 (CFA8) 
TTC8_ex8_F GAGGTGCTTTGAATCATTGGA TTC8_ex8_R TGAGGAAGTTTCACCCAGAAA 532 57  63,128,964 
Primers for PCR amplification and Sanger sequencing of FAM161A (CFA10) 
FAM161A_ex5_F TTCATCTCTTCAGGCCAGTGT FAM161_ex5_R ACTGCAGTAGCAGCGTGTTCT 720 57  64,973,585 
FAM161A_ex1_F CCTGTAGCGTCCCTGGTTAC FAM161A_ex1_R AAATGGAGGCTCTCCAAGAAA 570 57 98, Q 64,991,088 
Primers for PCR amplification and Sanger sequencing of C2ORF71 (CFA17) 
C2OR71_exProm_F AGGGACCAGCCTTGAGTTTTA C2OR71_exProm_R CACCCACACTCTTTGCAATTT 854 58  26,013,661 
C2OR71_ex1.1_F TCCACAAAAAGCTCTTCCAGA C2OR71_ex1.1_R CCACACCCCTCTTTGTACTCA 1483 56 35 26,012,688 
C2OR71_ex1.2_F AAAGAAAGCTGAGATGCCACA C2OR71_ex1.2_R CCTCCACGTGACTCTTCAGAC 1374 58  26,011,830 
C2OR71_ex1.3_F AGCACAGGCCCAGAAAATACT C2OR71_ex1.3_R TCCAAGGTGAGCTTTCTGGTA 1475 58  26,010,857 
C2OR71_ex1.4_F CTCTGGAAATCCTGATGGACA C2OR71_ex1.4_R CCTGAAATGAGGGACAGATGA 1363 56 Q 26,009,761 
C2OR71_ex2.1_F GGGTGAGGACCTGAGAGAATC C2OR71_ex2.1_R GGAATAAAGTTGGCCGAGAAG 1329 58  26,004,158 
C2OR71_ex2.2_F ATTTGAACAGGTGTGCCTGAC C2OR71_ex2.2_R TTTCTCCAGACCTTGGGAAGT 1477 58  26,003,225 
C2OR71_ex2.3_F CACCCCTCTATTGGGAAATGT C2OR71_ex2.3_R GTTGATGATTGCTGGACACCT 1979 58  26,001,698 
Internal primers for Sanger sequencing of C2ORF71 (CFA17) 
C2OR71_exProm_IntF GCAATTATGGCTCATTTCTC C2OR71_exProm_IntR GAGAAATGAGCCATAATTGC     
C2OR71_ex1.1_IntF1 CTGGACCAACTAGTAAGGCTG C2OR71_ex1.1_IntR1 CAGCCTTACTAGTTGGTCCAG     
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F primer Name F primer Seq (5'-3') R primer Name R primer Seq (5'-3') 
Size 
(bp) 
Tm 
(°C) 
Additive/ 
alteration
*
 
Position (bp)
†
 
C2OR71_ex1.1_IntF2 GAAAGCTGAGATGCCACACAT C2OR71_ex1.1_IntR2 ATGTGTGGCATCTCAGCTTTC     
C2OR71_ex1.2_IntF1 CTACCGCCTGCCACTTGGGAA C2OR71_ex1.2_IntR1 TTCCCAAGTGGCAGGCGGTAG     
C2OR71_ex1.2_IntF2 ATACTACTGCCAGGCCTGGAG C2OR71_ex1.2_IntR2 CTCCAGGCCTGGCAGTAGTAT     
C2OR71_ex1.3_IntF1 CTGTGAGGCAGAGAAGGTCCC C2OR71_ex1.3_IntR1 GGGACCTTCTCTGCCTCACAG     
C2OR71_ex1.3_IntF2 CAAGCCCCTGCCTCAGGAAGT C2OR71_ex1.3_IntR2 ACTTCCTGAGGCAGGGGCTTG     
C2OR71_ex1.4_IntF1 TGCAGACAGGGCCACCAGCCT C2OR71_ex1.4_IntR1 AGGCTGGTGGCCCTGTCTGCA     
C2OR71_ex1.4_IntF2 GTTTGAAGCCGCCCCACCCGG C2OR71_ex1.4_IntR2 CCGGGTGGGGCGGCTTCAAAC     
C2OR71_ex2.1_IntF1 CAGCCCCAGATTCTGGTTTGC C2OR71_ex2.1_IntR1 GCAAACCAGAATCTGGGGCTG     
C2OR71_ex2.1_IntF2 GTTGTACAAATGGTTGGAAAG C2OR71_ex2.1_IntR2 CTTTCCAACCATTTGTACAAC     
C2OR71_ex2.2_IntF1 CGGGAAGATGCACGCACTCAC C2OR71_ex2.2_IntR1 GTGAGTGCGTGCATCTTCCCG     
C2OR71_ex2.2_IntF2 CCACCAACAGGGGCCACAAGC C2OR71_ex2.2_IntR2 GCTTGTGGCCCCTGTTGGTGG     
C2OR71_ex2.3_IntF1 AGGGACGCCATTCATGAAATG C2OR71_ex2.3_IntR1 CATTTCATGAATGGCGTCCCT     
C2OR71_ex2.3_IntF2 GCCAGACTCCTGCTATATACC C2OR71_ex2.3_IntR2 GGTATATAGCAGGAGTCTGGC     
C2OR71_ex2.3_IntF3 TCCACTTCTTGAGCTCAAAGC C2OR71_ex2.3_IntR3 GCTTTGAGCTCAAGAAGTGGA     
 
* 98 = Initial denaturation at 98°C; Q = Q solution; ATG360 = AmplitaqGold 360 DNA Polymerase, 2mM Mg, 2x GC enhancer; TD = Touchdown PCR, annealing temperature decreasing from 68°C to 
54°C; H7 = Herculase Taq polymerase, with 7% DMSO; 35 = 35 amplification cycles. 
† According to CanFam2.0 
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Table A4. Canine Candidate Gene mRNA Sequencing Primers 
F primer Name F primer Seq (5'-3') R primer Name R primer Seq (5'-3') Tm (°C) Size (bp) 
Additive/ 
alteration
*
 
Primers for PCR amplification and Sanger sequencing of canine SLC4A3 mRNA 
SLC4A3exn1-2_RT-F CATGGCCAACGGAGTGAT SLC4A3exn1-2_RT-R GGATGTGTGCCGGTGAA 58 235 Q 
SLC4A3exn3_RT-F AGCTACAGCGAGCGTGACTTT SLC4A3exn3_RT-R ATCGCTGCCGATGGAGAA 58 324 Q 
SLC4A3exn4-5_RT-F GAGGAAGAGGAAGGGGAATCT SLC4A3exn4-5_RT-R CGAGACGGCTTCTTCACTAGG 58 554  
SLC4A3exn6-8_RT-F CGAGTCGCTGGAGAGAAGAG SLC4A3exn6-8_RT-R GTCCTTGTCATCATTGGGATG 58 654  
SLC4A3exn9-11_RT-F CTGCGTACCCTCCTACTGAAA SLC4A3exn9-11_RT-R GATGGAGGAATCACGATGCT 58 590  
SLC4A3exn12-13_RT-F GTTCGCTTCCTCTTTGTGATG SLC4A3exn12-13_RT-R ATCAGCCCTTCCGTCTTCTC 58 560  
SLC4A3exn14-15_RT-F CCGTGCTCTTCATCTACTTCG SLC4A3exn14-15_RT-R CAGGAAGAAGGCAATGAGAAA 58 587  
SLC4A3exn16_RT-F GCCTTCCTCATCTCGCTTATT SLC4A3exn16_RT-R GGAGTAATCCACGAGGACCAT 58 343  
SLC4A3exn17-18_RT-F CCTTTCTCATTGCCTTCTTCC SLC4A3exn17-18_RT-R GCATAACAGTCAGTGCGTTCA 58 483  
SLC4A3exn19-20_RT-F TCCTCATCCTCATCTTCATGG SLC4A3exn19-20_RT-R ACTTGACCACCCAGAGCAGT 58 534  
SLC4A3exn21-22_RT-F CAGCGTCTGTTGCTTATCCTC SLC4A3exn21-22_RT-R TAAGAATGACCAGACCGACCA 58 581  
SLC4A3exn1_C_RT-F GCTCTGGTTGAACAAAGACCA SLC4A3exn1_C_RT-R CGAGACGGCTTCTTCACTAGG 58 376 Q 
Primers for PCR amplification and Sanger sequencing of canine SPATA7 mRNA 
SPATA7_exon1-3_F CGGGAAGGTCGGAAGG SPATA7_exon1-3_R ATTTGATGCTGGCACTTATGC  298  
SPATA7_exon4-5_F CCACCTGGTCAAGAATCACAT SPATA7_exon4-5_R GGATGGAAATCCATTCACTTCT  298  
SPATA7_exon6_F ACGATGTGAAAGGGAGTTGAA SPATA7_exon6_R TTCTTGGTGTCAACTGTCTCAA  600  
SPATA7_exon7-8_F ATGGAAGCTGAAACCCAGACT SPATA7_exon7-8_R AAGCTGCAGGGAATACTGACA  243  
SPATA7_exon9-11_F ACCATGGGATGAGATCAAAGA SPATA7_exon9-11_R CTTCAGGATATGCAGCAGGTG  271  
SPATA7_exon12_F GAACGACTGTTTGAGCGACAT SPATA7_exon12_R TGGCCATTTAGGATATTTATTGATG  665  
Primers for PCR amplification and Sanger sequencing of canine TTC8 mRNA 
TTC8_mRNA_F ATGGGCTCGGAGATGGA TTC8_mRNA_R TCTGTGGGACAATCAGAGCA 57 1560  
  TTC8_mRNA_R2 GTGGAACTTGAGCAATAGCATT 57 265  
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F primer Name F primer Seq (5'-3') R primer Name R primer Seq (5'-3') Tm (°C) Size (bp) 
Additive/ 
alteration
*
 
Internal Primers for Sanger sequencing of canine TTC8 mRNA 
TTC8_mRNA_IF1 GAACTGCCTACACAGCTCG TTC8_mRNA_IR1 CGAGCTGTGTAGGCAGTTC    
TTC8_mRNA_IF2 GTTTCCAGGAGAAGTAACCC TTC8_mRNA_IR2 GGGTTACTTCTCCTGGAAAC    
TTC8_mRNA_IF3 CAACTTGGGCCACATAGCTG TTC8_mRNA_IR3 CAGCTATGTGGCCCAAGTTG    
TTC8_mRNA_IF4 CTTACGACCAGGAACCAGATC TTC8_mRNA_IR4 GATCTGGTTCCTGGTCGTAAG    
TTC8_mRNA_IF5 GTCACCTCTGGAACCAGATC TTC8_mRNA_IR5 GATCTGGTTCCAGAGGTGAC    
TTC8_mRNA_IF6 GTCTCAGGCAGCTTGGATT TTC8_mRNA_IR6 AATCCAAGCTGCCTGAGAC    
TTC8_mRNA_IF7 GTCCCCTTACGACCAGGTATTG TTC8_mRNA_IR7 CAATACCTGGTCGTAAGGGGAC    
TTC8_mRNA_IF8 CACCTCTGGCAGCTTGG TTC8_mRNA_IR8 CCAAGCTGCCAGAGGTG    
TTC8_mRNA_IF9 CCAGGCAGCTTGGATTTTA TTC8_mRNA_IR9 TAAAATCCAAGCTGCCTGG    
Primers for PCR amplification and Sanger sequencing of canine FAM161A mRNA 
FAM161A_cDNA1_F CATGGCAGCCTCGCAG FAM161A_cDNA1_R AAGTTGGGCAACTCATCTTCA 57 540 Q, 98 
FAM161A_cDNA2_F CCACTTGGAAACTATGGCAAA FAM161A_cDNA2_R TTTGCACTTGCACTTCTTCCT 57 1203  
FAM161A_cDNA3_F TTTTCCCCCTTTATCATGACC FAM161A_cDNA3_R CCAGGCTACAGATGACTTTGC 57 1423  
FAM161A_cDNA4_F ACACGGTCTTTTCTGTCTCCA FAM161A_cDNA4_R GCTTTTCTGCTGCCATTCTT 57 421 X40 
Primers for PCR amplification and Sanger sequencing of canine C2ORF71 mRNA 
C2OR71_amp1_F CTGGACCAACTAGTAAGGCTG  C2OR71_amp1_R CCACACCCCTCTTTGTACTCA  58 1048  
C2OR71_amp2_F AAAGAAAGCTGAGATGCCACA  C2OR71_amp2_R CCTCCACGTGACTCTTCAGAC  58 1374  
C2OR71_amp3_F AGCACAGGCCCAGAAAATACT  C2OR71_amp3_R TCCAAGGTGAGCTTTCTGGTA  58 1475 Q 
C2OR71_amp4_F GACCTGCTACCCAGCAAGAG C2OR71_amp4_R CTTGCACAGAGGGAGCACT 56 445 Q, 98 
C2OR71_amp5_F CACAAGAGGCTCCTGGACAC C2OR71_amp5_R GAGGGGGAACTGGCCTCT 56 243 Q, 98 
C2OR71_amp6_F GAGTGCTCCCTCTGTGCAA C2OR71_amp6_R AAGCGGTCCTTCTGATGAAA 56 479 98 
C2OR71_amp7_F CTGTGCGCGCTCAACC C2OR71_amp7_R AGTCTGATGCTTGGCTGTCTC 56 381 Q, 98 
C2OR71_amp8_F AGGCTAATCAACAGGGTGACA C2OR71_amp8_R CTGTGAGACCTCAGGCAAGAC 57 462  
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F primer Name F primer Seq (5'-3') R primer Name R primer Seq (5'-3') Tm (°C) Size (bp) 
Additive/ 
alteration
*
 
C2OR71_amp9_F CATGTTCCTGGTTTTGCAGAT C2OR71_amp9_R GAGGGCTTTGGGTCTGTACTT 57 379  
C2OR71_amp10_F CAGCATTCAAGTCACCATTGA C2OR71_amp10_R GGAATAAAGTTGGCCGAGAAG 57 393  
C2OR71_amp11_F TGCAAACAAGCAGCCTATTCT C2OR71_amp11_R CTTGTTCTCGAGCCATGATCT 57 490  
C2OR71_amp12_F CTGCTGCAAAGCTGATTTTCT C2OR71_amp12_R TTCCCACACACTTACCTCAGC 57 454  
C2OR71_amp13_F CACCCCTCTATTGGGAAATGT C2OR71_amp13_R TTTCTCCAGACCTTGGGAAGT 57 454  
C2OR71_amp14_F CAAGCAGGAGAAGAAATGCTG C2OR71_amp14_R GGTGTCCACACCTAGCTTTCA 57 364  
C2OR71_amp15_F TCTGGGAACCAGGATAGGAAT C2OR71_amp15_R ACGACATCATGTATGGGGGTA 57 469  
C2OR71_amp16_F CTGCTCCCTCCACATCTACTG C2OR71_amp16_R GTTCTCAAGGAGGGGTGAAAC 57 402  
C2OR71_amp17_F TTTTTGGCTACCATCACAACC C2OR71_amp17_R GCGTTGGGCCTATTGGTATAA 57 371  
Internal primers for Sanger sequencing of canine C2ORF71 mRNA 
C2OR71_amp1_IntF GAAAGCTGAGATGCCACACAT C2OR71_amp1_IntR ATGTGTGGCATCTCAGCTTTC    
C2OR71_amp2_IntF CTACCGCCTGCCACTTGGGAA C2OR71_amp2_IntR TTCCCAAGTGGCAGGCGGTAG    
C2OR71_amp3_IntF CAAGCCCCTGCCTCAGGAAGT C2OR71_amp3_IntR1 GGGACCTTCTCTGCCTCACAG    
  C2OR71_amp3_IntR2 ACTTCCTGAGGCAGGGGCTTG    
 
* Q = Q solution; 98 = Initial denaturation at 98°C; x40 = 40 PCR cycles 
  
A
p
p
en
d
ices 
2
2
4
 
Table A5. Primers for qPCR of FAM161A 
F primer Name F primer Seq (5'-3') R primer Name R primer Seq (5'-3') Tm (°C) Size (bp) 
FAM161Atotal_F GTGTCTCTTCCAGGTCTGAATCA FAM161Atotal_R AAGTTGGGCAACTCATCTTCA 57 130 
FAM161Ash-5_F ACACGGTCTTTTCTGTCTCCA FAM161Ash-5_R TTGCATTTTTCTTGTGGCTTG 57 135 
FAM161Ash_F ACACGGTCTTTTCTGTCTCCA FAM161Ash_R TTCACTCTTTCTTGTGGCTTG 57 135 
FAM161Afl-5_F CGGATCCTAACTAAGCAGAAGC FAM161Afl-5_R CTTGCATTTTTCTGAGAGATTTG 57 136 
FAM161Afl_F CAGAGTCAAATCTCTCAGAAAGAGTG FAM161Afl_R CTGCTGCCATTCTTGCATT 57 140 
TBP_F CATGACTCCTGGAATCCCTATC TBP_R CTCCAGAAGAGAAAGGCTGTTG 57 100 
ACTP_F CCAACCGTGAGAAGATGACC ACTP_R AGAGGCGTACAGGGACAGC 57 95 
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Table A6. Human SLC4A3 Sequencing Primers 
F primer Name F primer Seq (5'-3') R primer Name R primer Seq (5'-3') Size (bp) Tm (°C) 
Additive/ 
alteration
*
 
Position (bp)
†
 
Primers for PCR amplification and Sanger sequencing of human SLC4A3 (Chromosome 2) 
SLC4A3_ex_1.1F AGGCAAGGCTGTGGTAGAAAT SLC4A3_ex_1.1R TCTCGCAGCGCAGAGC 444 58 Q, 98 220,491,773 
SLC4A3_ex_1.2F CCCGCTCCCATTGTGC SLC4A3_ex_1.2R CCGAGACCCAGGTGAGAAG 443 58 Q, 98 220,491,773 
SLC4A3_ex_2F GGGGATTGTGGGAATATCG SLC4A3_ex_2R GGGCTACGGATCTGGAAAATA 849 58 Q, 98 220,492,089 
SLC4A3_ex_3F CAGATCCGTAGCCCTCTCTCT SLC4A3_ex_3R CACAGAGTCCAGCACAGTGTC 498 58  220,492,924 
SLC4A3_ex_4F GACTAGGGTGCCCTTGTTTG SLC4A3_ex_4R CAACACGCACTCCTCTCCTC 464 58  220,493,757 
SLC4A3_ex_5F AGGGGTACAGAGAGGAGGAGA SLC4A3_ex_5R GTCACTCTCTCCTGGGGAACT 484 58  220,494,187 
SLC4A3_ex_6F GAGAGGGTGAGGAGAAAGGTG SLC4A3_ex_6R AGAGCCTCTCCAAGGTCACTC 475 58  220,494,677 
SLC4A3_ex_6Fb ACCCTGAGAAAAGAGGAGCAG SLC4A3_ex_6Rb AGAGGACTCAGCCCTTAGCAG 660 58  220,494,523 
SLC4A3_ex_7F ATGGCCTGTTGGTGACTGTAG SLC4A3_ex_7R GTTCAGCTCCACGAACACCT 430 58  220,496,572 
SLC4A3_ex_8F ATCCTTCGCAGGAAGAAGAAG SLC4A3_ex_8R GAGAGTGTTCCTGGGAACTGA 457 58  220,496,788 
SLC4A3_ex_9F GTCAGTCAACAAATGGCTTCC SLC4A3_ex_9R CTCTGTCACTTGTGGCATTCA 489 58  220,497,353 
SLC4A3_ex_10F TGAATGCCACAAGTGACAGAG SLC4A3_ex_10R CAACCCACTCAGTGAAGTCGT 447 58  220,497,821 
SLC4A3_ex_11F TGCAGTACCTGCCTACTCTGG SLC4A3_ex_11R CAGGGGACTACGAAAGAAAGG 402 58  220,498,859 
SLC4A3_ex_12F TTCTTTGCGCAGTTTACAACC SLC4A3_ex_12R ACTGTGGACAATGAGGGACAG 373 58  220,499,378 
SLC4A3_ex_13F CCTGTAGCTCAGTGACCCAAC SLC4A3_ex_13R GATCAGGGATGCAAAGGACTC 430 58  220,499,899 
SLC4A3_ex_14F GAGAGCGTGAACAGACCAAAG SLC4A3_ex_14R ATTCCCTGATCCAGCATCTCT 620 58  220,500,755 
SLC4A3_ex_15F GTCACTCTAAGGGGCTGCTCT SLC4A3_ex_15R CAGAACTAGGTGGGGGTAGGA 499 58  220,500,908 
SLC4A3_ex_16F ATTCTCCCTCTTCCTCGGAGT SLC4A3_ex_16R CTAGAACCCCTCACTCCCAAC 430 58  220,501,301 
SLC4A3_ex_17F CACAGGTGTACTGATGACGATG SLC4A3_ex_17R AAGAAGACACCCAGGGAAGAG 466 58  220,502,227 
SLC4A3_ex_18F CTCTTCCCTGGGTGTCTTCTT SLC4A3_ex_18R TCCACTGGGAAAGTTGAGTTC 423 58  220,502,672 
SLC4A3_ex_19F TTCATTTCCCTGCCCTCTATT SLC4A3_ex_19R CCCAGCACCCTGATACTGATA 470 58  220,503,232 
SLC4A3_ex_20F TGAAAGAAGAAGCTGGCAGTC SLC4A3_ex_20R ACACAGCACATTGGGAGATTC 496 58  220,504,538 
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F primer Name F primer Seq (5'-3') R primer Name R primer Seq (5'-3') Size (bp) Tm (°C) 
Additive/ 
alteration
*
 
Position (bp)
†
 
SLC4A3_ex_21F TCCTTCTCTTGTTCAGGGTGA SLC4A3_ex_21R CCTTCATATTCATCCCATCCA 452 58  220,504,964 
SLC4A3_ex_22F TGAAGGAGAAGCTGTGACCTG SLC4A3_ex_22R GGCCTTTACCTGGACTAGCAC 499 58  220,505,410 
SLC4A3_ex_23F AGGAGGAGCTGGAGAATGG SLC4A3_ex_23R CTCAAACCTCTCCCTGGTTTT 500 58  220,506,302 
SLC4A3_ex_c1F GGGAGGGCGTGTTTACAGA SLC4A3_ex_c1R TTCGCTCCCTTCCTCCTGT 489 58  220,495,763 
Internal primers for Sanger sequencing of human SLC4A3 
SLC4A3_ex_2IntF CTGTCCCGGGCGTGGCTGGG       
 
* Q = Q solution; 98 = Initial denaturation and denaturation steps at 98°C. 
† GRCh37 
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III. PCR and Sequencing Reaction Components 
Table A7. TaqMan
®
 Allelic Discrimination 
Component Volume/reaction (µL) Final Concentration 
Genomic DNA (~20ng/µL) 2.00  
dNTPs (1.5mM) 2.93 0.2 mM 
Forward Primer (20µM) 0.44 0.4 µM 
Reverse Primer (20µM) 0.44 0.4 µM 
Fluorescent Probe 1 (20µM) 0.22 0.2 µM 
Fluorescent Probe 2 (20µM) 0.22 0.2 µM 
HST+ 10x Buffer 2.20 1X 
HotStarTaq Plus Polymerase (5 U/µL) 0.22 0.05 U/µL 
Water (MilliQ) 13.33  
Total (µL) 22.00  
 
Table A8. Amplification for AFLP Analysis 
Component Volume/reaction (Final concentration) 
 
PRA-1 PRA-2 PRA-3v1 PRA-3v2 RCD4 
Genomic DNA (~20ng/µL) 2 µL 2 µL 2 µL 2 µL 2 µL 
dNTPs (1.5mM) 
1.6 µL  
(0.2 mM) 
1.6 µL  
(0.2 mM) 
1.6 µL  
(0.2 mM) 
1.6 µL  
(0.2 mM) 
1.6 µL  
(0.2 mM) 
Forward Primer (10µM) 
0.05 µL  
(0.04 mM) 
0.05 µL  
(0.04 mM) 
0.05 µL  
(0.04 µM) 
0.1 µL  
(0.08 µM) 
0.3 µL  
(0.25 µM) 
Forward Primer 2 (10µM) 
   
0.1 µL  
(0.08 µM)  
Reverse Primer (10µM) 
0.05 µL  
(0.04 mM) 
0.05 µL  
(0.04 mM) 
0.05 µL  
(0.04 µM) 
0.1 µL  
(0.08 µM) 
0.3 µL  
(0.25 µM) 
Q Solution 0 0 0 0 2.4 µL 
10x Buffer 
1.2 µL  
(1X) 
1.2 µL  
(1X) 
1.2 µL  
(1X) 
1.2 µL  
(1X) 
1.2 µL  
(1X) 
HotStarTaq Plus Polymerase 
(5 U/µL) 
0.07 µL  
(0.03 U/µL) 
0.07 µL  
(0.03 U/µL) 
0.12 µL  
(0.05 U/µL) 
0.12 µL  
(0.05 U/µL) 
0.12 µL  
(0.05 U/µL) 
Water (MilliQ) 7.03 µL 7.03 µL 6.98 µL 6.78 µL 4.08 µL 
Total (µL) 12 µL 12 µL  12 µL  12 µL 12 µL 
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Table A9. Amplification for Sequencing (HotStarTaq Plus) 
Component Volume/reaction (µL) 
Final 
Concentration 
 
Without Q 
solution 
With Q 
solution 
 
Genomic DNA (~20ng/µL) 2 2  
dNTPs (1.5mM) 1.6 1.6 0.2 mM 
Forward Primer (20µM) 0.3 0.3 0.5 µM 
Reverse Primer (20µM) 0.3 0.3 0.5 µM 
Q Solution 0 2.4 1X 
HotStarTaq Plus 10x Buffer 1.2 1.2 1X 
HotStarTaq Plus Polymerase (5 U/µL) 0.12 0.12 0.05 U/µL 
Water (MilliQ) 6.48 4.08  
Total (µL) 12 12  
 
Table A10. Amplification for Sequencing (Amplitaq Gold 360) 
Component Volume/reaction (µL) Final Concentration 
Genomic DNA (~20ng/µL) 2  
dNTPs (1.5mM) 1.6 0.2 mM 
Mg solution (25mM) 0.96 2.0 mM 
Forward Primer (20µM) 0.6 0.2 µM 
Reverse Primer (20µM) 0.6 0.2 µM 
GC Enhancer 2  
ATG360 10x Buffer 1.2 1X 
Amplitaq Gold 360 Polymerase (5 U/µL) 0.12 0.05 U/µL 
Water (MilliQ) 2.92  
Total (µL) 12  
 
Table A11. Amplification for Sequencing (Herculase II) 
Component Volume/reaction (µL) Final Concentration 
Genomic DNA (~20ng/µL) 2  
dNTPs (1.5mM) 0.4 0.05 mM 
Forward Primer (20µM) 0.15 0.25 µM 
Reverse Primer (20µM) 0.15 0.25 µM 
DMSO  0.84 7% 
Herculase 5x Buffer 2.4 1X 
Herculase Polymerase (5 U/µL) 0.12 0.05 U/µL 
Water (MilliQ) 5.94  
Total (µL) 12  
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Table A12. Amplification for Microsatellite Genotyping 
Component Volume/reaction (µL) Final Concentration 
Genomic DNA (~20ng/µL) 2  
dNTPs (1.5mM) 1.6 0.2 mM 
Forward Primer (20µM) 0.1 0.17 µM 
Reverse Primer (20µM) 0.25 0.42 µM 
Fluorescent Primer (10µM) 0.6 0.5 µM 
Amplitaq Gold 10x Buffer 1.2 1X 
Amplitaq Gold DNA Polymerase (5 U/µL) 0.12 0.05 U/µL 
Water (MilliQ) 6.48  
Total (µL) 12  
 
Table A13. Sanger Sequencing (Canine DNA) 
Component Volume/reaction (µL) Final Concentration 
Template (PCR product) 2.00  
2.5X BigDye Ready Reaction Mix 0.50 0.2X 
10X SBDD Buffer 1.00 1.7X 
Primer (1.6µM) 1.00 0.27 µM 
Water (MilliQ) 1.50  
Total (µL) 6.00  
 
Table A14. Sanger Sequencing (Human DNA) 
Component Volume/reaction (µL) Final Concentration 
Template (PCR product) 2.00  
2.5X BigDye Ready Reaction Mix 0.50 0.125X 
5X Sequencing Buffer 2.50 1.25X 
Primer (20µM) 0.50 0.27 µM 
Water (MilliQ) 4.50  
Total (µL) 10.00  
 
Table A15. Quantitative PCR of FAM161A mRNA 
Component Volume/reaction (µL) Final Concentration 
Template (cDNA) 2.00  
2X KAPA SYBR FAST 3 1X 
Forward Primer (5 µM) 0.12 0.2 µM 
Reverse Primer (5µM) 0.12 0.2 µM 
Water (MilliQ) 0.76  
Total (µL) 6.00  
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IV. Thermal Cycling Parameters 
Table A16. TaqMan
®
 Allelic Discrimination 
 Temperature Duration Cycles 
Initial Denaturation 95°C 5 min  
Denaturation 95°C 30 s 
40 Annealing Tm
*
 30 s 
Extension 72°C 30 s 
Final Extension 72°C 10 min  
Allelic Reads 25°C 10 s  
 
* Refer to Appendix II, Table A1. 
 
Table A17. Amplification for Sequencing and AFLP 
 Temperature Duration Cycles 
Initial Denaturation 94°C 10 min  
Denaturation 94°C 1 min 
35 Annealing Tm
*
 1 min 
Extension 72°C 2 min 
Final Extension 72°C 10 min  
 
* Refer to Appendix II, Table A1, Table A3, Table A4 and Table A6.  
 
Table A18. Touchdown PCR 
 Temperature Duration Cycles 
Initial Denaturation 98°C 10 min  
Denaturation 94°C 1 min 
9 Annealing 68-55°C
*
 1 min 
Extension 72°C 1 min 
Denaturation 94°C 1 min 
26 Annealing 54°C 1 min 
Extension 72°C 1 min 
Final Extension 72°C 10 min  
 
* Starting at 68°C for the first cycle, decreasing for each subsequent cycle to 66°C, 64°C, 62°C, 60°C, 58°C, 57°C, 
56°C and 55°C. 
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Table A19. Microsatellite Genotyping 
 Temperature Duration Cycles 
Initial Denaturation 94°C 4 min  
Denaturation 94°C 1 min 
30 Annealing Tm* 1 min 
Extension 72°C 1 min 
Denaturation 94°C 1 min 
8 Annealing 50°C 1 min 
Extension 72°C 1 min 
Final Extension 72°C 30 min  
 
* Refer to Appendix II, Table A2. 
 
Table A20. Sanger Sequencing (Canine DNA) 
 Temperature Duration Cycles 
Initial Denaturation 96°C 30 s  
Denaturation 92°C 4 s 
44 Annealing 55°C 4 s 
Extension 60°C 110 s 
 
Table A21. Sanger Sequencing (Human DNA) 
  Temperature Duration Cycles 
Initial Denaturation 96°C 2 min  
Denaturation 96°C 10 s 
25 Annealing 50°C 5 s 
Extension 60°C 4 min 
 
Table A22. Quantitative PCR 
 Temperature Duration Cycles 
Initial Denaturation 95°C 10 min  
Denaturation 95°C 15 s 
40 Annealing 57°C 30 s 
Extension 72°C 30 s 
Denaturation 95°C 15 s 
1 
Melt Curve Analysis 
55°C 15 s 
95°C 15 s 
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V. Genes found in PRA-Associated Critical Regions 
Table A23. Genes Within GR_PRA1 Critical Region 
Canine Gene Position (CanFam2.0) Human homologue Full Name 
NHEJ1 37:28636730-28714886   NHEJ1   Nonhomologous end-joining factor 1 
SLC23A3 37:28720831-28727019  SLC23A3  Solute carrier family 23 (nucleobase transporters), member 3 
C2orf24 37:28729402-28732994  C2orf24  Chromosome 2 open reading frame 24 
FAM134A 37:28735172-28739313  FAM134A  Family with sequence similarity 134, member A 
ZFAND2B 37:28757195-28759520  ZFAND2B  Zinc finger, AN1-type domain 2B 
ABCB6 37:28759982-28767548  ABCB6  ATP-binding cassette, sub-family B (MDR/TAP), member 6 
ATG9A 37:28769198-28775393  ATG9A  ATG9 autophagy related 9 homolog A (S. cerevisiae) 
ANKZF1 37:28777601-28783188  ANKZF1  Ankyrin repeat and zinc finger domain containing 1 
GLB1L 37:28783030-28794586  GLB1L  Galactosidase, beta 1-like 
STK16 37:28793976-28796802  STK16  Serine/threonine kinase 16 
TUBA4A 37:28798653-28802356  TUBA4A  Tubulin, alpha 4a 
XM_848175.1 37:28815425-28818299  No homologues   
DNAJB2 37:28825498-28831692  DNAJB2  DnaJ (Hsp40) homolog, subfamily B, member 2 
Q09IV7_CANFA 37:28835626-28853430  PTPRN  Protein tyrosine phosphatase, receptor type, N 
RESP18 37:28863932-28869434  RESP18  Egulated endocrine-specific protein 18 homolog (rat) 
DNPEP 37:28897527-28908427  DNPEP  Aspartyl aminopeptidase 
DESM_CANFA 37:28933165-28939896  DES  Desmin 
SPEG 37:28947555-29004449  SPEG  SPEG complex locus 
GMPPA 37:29011301-29017577  GMPPA  GDP-mannose pyrophosphorylase A 
ACCN4 37:29024803-29047411  ACCN4  Amiloride-sensitive cation channel 4, pituitary 
CHPF 37:29048752-29052916  CHPF  Chondroitin polymerizing factor 
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Canine Gene Position (CanFam2.0) Human homologue Full Name 
TMEM198 37:29054074-29058919  TMEM198  Transmembrane protein 198 
OBSL1 37:29064807-29078905  OBSL1  Obscurin-like 1 
INHA 37:29080814-29083645  INHA  Inhibin, alpha 
ENSCAFG00000015687 37:29111682-29119204  STK11IP  Serine/threonine kinase 11 interacting protein 
SLC4A3 37:29137454-29150949  SLC4A3  Solute carrier family 4, anion exchanger, member 3 
ENSCAFG00000023993 37:29211561-29211881  No homologues   
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Table A24. Genes Within GR_PRA2 Critical Regions One and Two 
Canine Gene Position (CanFam2.0) Human homologue Full Name 
Critical Region One 
GALC_CANFA  8:62306855-62363910 GALC  Galactocerebrosidase Precursor  
GPR65  8:62387856-62391052 GPR65  Psychosine receptor  
KCNK10  8:62524243-62648292 KCNK10  Potassium channel subfamily K member 10  
SPATA7  8:62703376-62736328 SPATA7  Spermatogenesis-associated protein 7  
PTPN21  8:62758986-62821262 PTPN21  Tyrosine-protein phosphatase non-receptor type 21 
ZC3H14  8:62835738-62888899 ZC3H14  Zinc finger CCCH domain-containing protein 14 
EML5  8:62892470-63072182 EML5  Echinoderm microtubule-associated protein-like 5 
TTC8  8:63100700-63153499 TTC8  Tetratricopeptide repeat protein 8  
ENSCAFG00000024120  8:63372283-63372582 No homologues  
FOXN3  8:63585920-63586534 FOXN3  Forkhead box protein N3  
ENSCAFG00000017494  8:63856375-63857294 No homologues  
EFCAB11  8:63917901-64062130 EFCAB11  EF-hand domain-containing protein C14orf143  
ENSCAFG00000023877  8:63920525-63920698 No homologues  
TDP1  8:64069226-64148150 TDP1  Tyrosyl-DNA phosphodiesterase 1  
KCNK13  8:64167521-64262903 KCNK13  Potassium channel subfamily K member 13 
PSMC1  8:64316698-64326521 PSMC1  26S protease regulatory subunit 4 
C14orf102  8:64327945-64354840 C14orf102  UPF0614 protein C14orf102  
Critical Region Two 
EML1  8:71254961-71332255 EML1  Echinoderm microtubule associated protein like 1 
EVL  8:71426908-71499520 EVL  Enah/Vasp-like 
DEGS2  8:71501806-71521839 DEGS2  Degenerative spermatocyte homolog 2, lipid desaturase (Drosophila) 
YY1  8:71576514-71607017 YY1  YY1 transcription factor 
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Canine Gene Position (CanFam2.0) Human homologue Full Name 
SLC25A29  8:71617342-71623790 SLC25A29  Solute carrier family 25, member 29 
SLC25A47  8:71640534-71645117 SLC25A47  Hepatocellular carcinoma-downregulatedmitochondrial carrier protein 
WARS  8:71648349-71677009 WARS  Tryptophanyl-tRNA synthetase 
WDR25  8:71686511-71825757 WDR25  WD repeat domain 25 
BEGAIN  8:71833229-71840503 BEGAIN  Brain-enriched guanylate kinase-associated homolog (rat) 
DLK1  8:72005936-72012495 DLK1  Delta-like 1 homolog (Drosophila) 
RTL1  8:72145530-72147890 RTL1  Retrotransposon-like 1 
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Table A25. Genes Within TS_PRA Critical Region 
Canine Gene Position (CanFam2.0) Human homologue Full Name 
PAPOLG  10:64032104-64056830 PAPOLG  Poly(A) polymerase gamma 
REL  10:64149903-64173385 REL  V-rel reticuloendotheliosis viral oncogene homolog (avian) 
PUS10  10:64185188-64250210 PUS10  Pseudouridylate synthase 10 
PEX13  10:64255013-64279554 PEX13  Peroxisomal biogenesis factor 13 
KIAA1841  10:64295804-64345069 KIAA1841  KIAA1841 
C2orf74  10:64380504-64383662 C2orf74  Chromosome 2 open reading frame 74 
USP34  10:64418779-64623882 USP34  Ubiquitin specific peptidase 34 
XPO1  10:64693472-64740735 XPO1  Exportin 1 
FAM161A  10:64965191-64991535 FAM161A  Family with sequence similarity 161, member A 
CCT4  10:65011057-65025975 CCT4  Chaperonin containing TCP1, subunit 4 (delta) 
COMD1_CANFA  10:65037469-65210770 COMMD1  COMM domain-containing protein 1 (Protein Murr1) 
B3GNT2  10:65296758-65298488 B3GNT2  Beta-1,3-N-acetylglucosaminyltransferase 2 
TMEM17  10:65507545-65512665 TMEM17  Transmembrane protein 17 
EHBP1  10:65779934-65976775 EHBP1  EH domain binding protein 1 
OTX1  10:65984099-65987213 OTX1  Orthodenticle homeobox 1 
ENSCAFG00000024199  10:66114901-66115059 WDPCP  WD repeat containing planar cell polarity effector 
ENSCAFG00000023673  10:66187681-66187962 WDPCP  WD repeat containing planar cell polarity effector 
LOC474613  10:66290089-66428549 WDPCP  WD repeat containing planar cell polarity effector 
ENSCAFG00000003121  10:66426233-66428132 No homologues  
MDH1  10:66467514-66485173 MDH1  Malate dehydrogenase 1, NAD (soluble) 
UGP2  10:66682947-66748401 UGP2  UDP-glucose pyrophosphorylase 2 
VPS54  10:66749716-66804065 VPS54  Vacuolar protein sorting 54 homolog (S. cerevisiae) 
PELI1  10:66879734-66893812 PELI1  Pellino homolog 1 (Drosophila) 
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Canine Gene Position (CanFam2.0) Human homologue Full Name 
ENSCAFG00000023240  10:66885275-66886402 No homologues  
ENSCAFG00000003168  10:67173703-67174591 DPPA4  Developmental pluripotency associated 4 
XM_538509.2  10:67196363-67199847 AC008074.1  Galectin-related protein 
AFTPH  10:67281829-67321772 AFTPH  Aftiphilin 
SERTAD2  10:67356859-67357892 SERTAD2  SERTA domain containing 2 
SLC1A4  10:67633294-67656064 SLC1A4  Solute carrier family 1 
CEP68  10:67698865-67709087 CEP68  Centrosomal protein 68kDa 
RAB1A_CANFA  10:67714196-67726087 RAB1A  RAB1A, member RAS oncogene family 
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Table A26. Genes Within GoS_PRA Critical Region 
Canine Gene Position (CanFam2.0) Human homologue Full Name 
XM_845379.1 17:24609166-24640801 ZNF512 Zinc finger protein 512  
ENSCAFG00000024084 17:24647124-24647912 CCDC121 Coiled-coil domain containing 121  
XM_845410.1 17:24649301-24667835 No homologues GPN-loop GTPase 1 
LOC608365 17:24670387-24681479 SUPT7L Suppressor of Ty 7 (S. cerevisiae)-like  
LOC608897 17:24737529-24749996 ZNF512 Zinc finger protein 512 
LOC607762 17:24762266-24777008 No homologues  
LOC608285 17:24779556-24790704 SUPT7L Suppressor of Ty 7 (S. cerevisiae)-like 
SLC4A1AP 17:24793005-24819519 SLC4A1AP Solute carrier family 4 (anion exchanger), member 1, adaptor protein 
RBKS 17:24898729-24971223 RBKS Ribokinase 
BRE 17:24993320-25391957 BRE Brain and reproductive organ-expressed (TNFRSF1A modulator) 
Q9BGG6_CANFA 17:25444774-25464193 FOSL2 FOS-like antigen 2 
PLB1 17:25558985-25660756 PLB1 Phospholipase B1 
PP1B_CANFA 17:25783355-25803428 PPP1CB Protein phosphatase 1, catalytic subunit, beta isozyme 
TRMT61B 17:25845651-25860445 TRMT61B tRNA methyltransferase 61 homolog B (S. cerevisiae) 
WDR43 17:25872355-25915232 WDR43 WD repeat domain 43 
FAM179A 17:25954776-25995537 FAM179A Family with sequence similarity 179, member A 
C2orf71 17:26010127-26013342 C2orf71 Chromosome 2 open reading frame 71 
CLIP4 17:26024584-26102807 CLIP4 CAP-GLY domain containing linker protein family, member 4 
ALK 17:26113404-26307961 ALK Anaplastic lymphoma receptor tyrosine kinase 
ENSCAFG00000024036 17:26435738-26435941 No homologues  
ENSCAFG00000023252 17:26576350-26597037 No homologues  
ENSCAFG00000023222 17:26790612-26791325 No homologues  
YPEL5 17:26966691-26979394 YPEL5 Yippee-like 5 (Drosophila) 
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Canine Gene Position (CanFam2.0) Human homologue Full Name 
LBH 17:27046659-27069749 LBH limb bud and heart development homolog (mouse) 
LCLAT1 17:27300558-27421174 LCLAT1 Lysocardiolipin acyltransferase 1 
CAPN13 17:27496324-27548426 CAPN13 Calpain 13 
GALNT14 17:27638511-27715023 GALNT14 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 14 (GalNAc-T14) 
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VI. NGS Analysis Pipelines 
The accompanying CD contains all files and folders required for and generated by the 
NGS analysis pipeline (script written by Oliver Forman) and the target capture 
efficiency analysis pipeline (script written by Louise Downs). Only the two perl scripts, 
ngs15_3.pl and ngs_capture_v4.3.pl, were used for the analysis of data in this project. 
The input and output files described below are abridged files used for rapid 
demonstration purposes only. 
Folders and files on the CD: 
1. Input Files 
The following data files were used for the demonstration of both analysis pipelines. 
 test1.fastq  Raw sequence file (first of a pair) used in ngs_fastq.avi. 
 test2.fastq  Raw sequence file (second of a pair) used in ngs_fastq.avi. 
 test.fasta  Reference genome used in ngs_fastq.avi and ngs_bam.avi. 
 test1.bam  Binary, aligned sequence file, created from test1.fastq and test2.fastq, 
used in ngs_bam.avi and capture.avi. 
 test2.bam  Binary, aligned sequence file used in capture.avi. 
 test_baits.bed  Co-ordinates of biotinylated RNA baits, generated by the Agilent 
Technologies eArray tool and used in capture.avi. 
2. NGS Analysis 
 ngs.pdf  A PDF of the NGS analysis pipeline perl script (ngs15_3.pl). 
 ngs_fastq.avi  A video clip capturing the use of the NGS analysis pipeline using 
the test fastq files described above. The files created during this analysis are in the 
folder results_test1. 
 ngs_bam.avi  A video clip capturing the use of the NGS analysis pipeline using 
the test bam file described above. The files created during this analysis are in the 
folder results_test_bam. 
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2.1. results_test1  
All files generated are summarised in README.rtf. However, the main files used for 
subsequent analysis are: 
 best_align_test.bam  Binary, aligned sequence file, with PCR duplicates 
removed, used for loading in IGV (Integrated Genomics Viewer), along with 
best_align_test.bai, to view sequence reads graphically. A similar file, 
raw_align_test.bam, has not had PCR duplicates removed. 
 INDELS_test.bed  a list of the insertions and deletions identified. 
 SNPS_test.vcf  A list of the SNPs identified. 
2.2. results_test1_bam 
The files are similar to those described in folder results_test1. 
3. Target Capture Efficiency 
 capture.pdf  A PDF of the target capture efficiency pipeline perl script 
(ngs_capture_v4.3.pl). 
 capture.avi  A video clip capturing the use of the target capture efficiency 
analysis pipeline using the test bam files described above. The files created during 
this analysis are in the folder capture_results_test. 
3.1. capture_results_test 
Three file types are generated: 
 Log_test.rtf  A record of the analysis and user-specified parameters. 
 Text files  There are two files for each sample analysed, one with PCR duplicates 
removed and one without PCR duplicates removed. 
 Excel files  There are two files, one with PCR duplicates removed and one 
without PCR duplicates removed. Each is a summary of the results generated and is 
compiled from the individual text files. 
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VII. GR PRA-2 Questionnaire 
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